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The current regulatory framework in toxicology is expanding beyond traditional animal toxicity 
testing to include new approach methodologies (NAMs) like computational models built using rapidly 
generated dose-response information like US Environmental Protection Agency’s Toxicity Forecaster 
(ToxCast) and the interagency collaborative Tox21 initiative. These programs have provided new 
opportunities for research but also introduced challenges in application of this information to current 
regulatory needs. One such challenge is linking in vitro chemical bioactivity to adverse outcomes like 
cancer or other complex diseases. To utilize NAMs in prediction of complex disease, information from 
traditional and new sources must be interoperable for easy integration. The work presented here 
describes the development of a bioinformatic tool, a database of traditional toxicity information with 
improved interoperability, and efforts to use these new tools together to inform prediction of cancer and 
complex disease. First, a bioinformatic tool was developed to provide a ranked list of Medical Subject 
Heading (MeSH) to gene associations based on literature support, enabling connection of complex 
diseases to genes potentially involved. Second, a seminal resource of traditional toxicity information, 
Toxicity Reference Database (ToxRefDB), was redeveloped, including a controlled vocabulary for 
adverse events used to map identifiers in the Unified Medical Language System (UMLS), thus enabling a 
connection to MeSH terms. Finally, gene to MeSH associations were used to evaluate the biological 
coverage of ToxCast for cancer to understand the capacity to use ToxCast to identify chemical hazard 
potential. ToxCast covers many gene targets putatively linked to cancer; however, more information on 
pathways in cancer progression is needed to identify robust associations between chemical exposure and 




resources is necessary to leverage the large amount of data currently available to understand the role 
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Current issues in data interoperability to support computational toxicology and chemical safety 
evaluation 
Toxicology has been undergoing a period of rapid change and growth to meet the challenge of 
safety assessment for tens of thousands of chemicals with both potential environmental exposure and a 
lack of a complete dataset for hazard identification (1–4). After over a decade since the publication of the 
seminal National Research Council report, Toxicity Testing in the 21st Century: A Vision and a Strategy 
(5) calling for advancements in the field of toxicology using new approach methodologies (NAMs) (6,7), 
substantial progress has been made initially driven by the interagency collaboration for Toxicity Testing in 
the 21st Century (Tox21) (8,9) and the US Environmental Protection Agency (EPA) Toxicity Forecaster 
(ToxCast) program (10,11). These massive data generation efforts have produced dose-response 
information for chemical interactions with biological targets (2,9,12), and further motivated development of 
aggregated digital resources of legacy toxicity information (13,14) and software to access and analyze 
this information (15–20). Many fit-for-purpose applications have been developed to understand how to 
use the generated information. As a result, information is siloed, which prevents easy integration and 
exchange of data (i.e. interoperability) creating problems like inconsistent versioning, lack of provenance, 
and unnecessary duplication. Ultimately the consequence of the lack of data interoperability is that 
progress in understanding biological and toxicological effects of chemical exposures is hampered despite 
an abundance of information. To fully leverage the resulting information from NAMs for toxicology and 
public health questions, efforts must be applied to enabling connections between data sources (6). 
Overcoming the high opportunity cost of enabling interoperability of various data streams will help realize 
the following goals: rapidly and reproducibly associate NAM-based information with phenotypes and 
outcomes of interest for development of computational models (21–29), hypothesis generation aimed at 




increased mechanistic knowledge (30–35), and systematic literature reviews (36), all of which can 
support efficient and state-of-the-art screening level chemical safety evaluation (37).  
Interoperability refers to “the ability of data or tools from non-cooperating resources to integrate 
or work together with minimal effort” (38). Data interoperability can be accomplished through numerous 
means like development and adherence to controlled vocabularies (CVs) and compliance with formatting 
standards for exchange of data. Computational efforts in toxicology to generate and analyze massive 
amounts of data are relatively new, so CVs and formatting standards are not widely used and accepted. 
Of course, data interoperability challenges are not unique to toxicology and, in fact, are one of the key 
challenges facing each industry from finance to social media to public health and biomedicine (38–44). As 
an example of how interoperability promotes greater consumption of data for biological learning, platforms 
from companies like Affymetrix were developed to rapidly and affordably capture and analyze 
transcriptomic data. The application of Affymetrix platforms and other microarray technologies in a clinical 
setting was aided by standardization efforts (i.e. to support interoperability) for mass distribution of kits as 
well as standard reporting of results, which subsequently led to development of tool suites that could 
consume and analyze the information (45).  The adherence to data formatting standards allowed for 
aggregation into a single resource called Gene Expression Omnibus (GEO), which allows access to the 
research community (46,47). For toxicology, the lack of consensus on how the vast amount of 
concentration-response data collected from a myriad of in vitro platforms can be applied to regulatory 
toxicology applications has clarified the need for implementation of data management strategies that 
maximize interoperability. For instance, “big data” is being generated via whole-genome sequencing (48), 
high-content imaging (49,50), and high-throughput screening (9,11), and how they are formatted, 
processed, analyzed, stored, and accessed are dissimilar, between data types and data generators, 
which creates an additional obstacle for data integration to answer applied questions. Building consensus 
on reporting standards, both for assay design principles and observed effects, would contribute to 
progress in the use of these data for regulatory applications.  
Data interoperability is a salient and critical need to address if computational toxicology is to 
succeed in supporting modern chemical safety evaluation and research in public health and toxicology. 




develop a risk-based method for chemical prioritization and in doing so to use NAMs or the equivalent in 
lieu of traditional methods. A state has been reached in which volumes of data can be generated, but full 
utilization of these information to find creative scientific solutions absolutely necessitates taking the time 
to adopt improved data management practices in order to connect the appropriate data to a biological 
target and to understand the methodology employed. Good data management practices are embodied by 
the FAIR Data Principles or Findability, Accessibility, Interoperability, and Reusability (38). These 
principles were defined to guide existing and future endeavors in scientific research as technology 
advances and data is generated to support knowledge discovery. Without proper data interoperability, 
progress in other areas will remain limited. In support of public health research goals, these principles are 
echoed in the National Institutes of Health (NIH) Strategic Plan for Data Science, with emphasis on 
infrastructure development and support for good data management practices as a crucial effort for 
continued success (51).  One of the first steps outlined in NIH’s approach is to update the current NIH 
infrastructure by connecting related systems for increased data interoperability. The answer to the overall 
challenge of achieving interoperability is simple to describe but difficult to implement, not only due to 
mountains of legacy data trapped in antiquated or difficult to process formats, but also due to rapid data 
generation efforts with lack of standardization creating data “silos”. Clearly the NIH has identified data 
interoperability as a key measure needed to achieve near and long-term goals for health-related 
research, but the field of toxicology needs more examination and consideration of why data 
interoperability is needed and how it could be achieved (52). The objective of this chapter is to provide the 
needed introduction to the current data landscape in toxicology, including specific use case examples that 
demonstrate a need for increased data interoperability for computational toxicology. As part of this 
introduction, research needs and key questions relevant to data interoperability in the public health and 
toxicology fields are highlighted. 
 
Current state of the data landscape in toxicology 
Toxicology is a diverse and applied field where health-related information from models of animal 
and/or human toxicity are translated into actionable items for chemical safety assessment. Decisions 




have major economic implications. Thus, any changes to the existing paradigms for data collection, 
evaluation, and analysis as technology and science advances come under intense scrutiny. However, 
NAM-based data generation is proceeding, and myriad ongoing efforts continue to demonstrate how this 
information could be used to answer regulatory toxicology questions (21–23,53–58). In this section, the 
apparent lack of data interoperability for both traditional and NAM-based toxicity information are reviewed. 
Much of the available traditional toxicology data for human health safety evaluations has been 
collected through animal experimentation to identify doses that do not cause adverse health effects and 
to identify hazards. This information is captured in physical and digital text documents. Many of these 
documents are used for regulatory purposes and not computationally accessible, e.g. the data are 
available for capture in text or PDF or in database formats that are not easily integrated. The existing 
information can be found in various formats scattered across different digital systems like Integrated Risk 
Information System (IRIS) (59), PubMed (60), https://www.regulations.gov, Chemical Effects of Biological 
Systems (CEBS) (61), eChemPortal (62), Provisional Peer-Reviewed Toxicity Value (PPRTV) (63), 
Carcinogenic Potency Database (CPDB) (64), and Toxicity Reference Database (ToxRefDB) (13). This 
exemplifies lack of interoperability that promotes duplication of information and challenges in data 
provenance that culminate in a lack of data interoperability. A specific example of these issues is the 
inability to identify identical National Toxicology Program (NTP) reports in databases that collect this 
information: CEBS (61), ToxRefDB (13), and CPDB (64). These resources are databases that have 
extracted data from animal toxicity studies conducted by NTP; however, the source documents are 
available as either full reports from various online locations or broken up as separate publications that can 
be found across different scientific journals. Because of source document management that was initiated 
without understanding of the future database needs (i.e. lack of versioning and unique identifiers) due to 
the age of some of the studies, as well as differences in how entities like a “study” are defined, it’s 
extremely difficult to identify the overlap between the two resources. These issues primarily encompass 
the legacy or historical data problems the field faces, but extensive efforts are under way to increase data 
interoperability to mitigate such issues. Addressing these challenges is critical as the field is rapidly 





One of the first implementations of a public repository that integrated information on a by-
chemical basis from in vitro bioassays and in vivo toxicology data from myriad public sources was the 
Aggregated Computational Toxicology Resource, or ACToR (14) (Figure 1.1A). ACToR initially provided 
the legacy information and access to two prominent projects within NCCT, ToxCast and ToxRefDB 
through a single web application and subsequently began developing Representational State Transfer 
(RESTful) web services (65) for increased availability of the resources. ToxCast and ToxRefDB, among 
others, moved the field forward because of the massive amount of information made available to explore 
computational modeling approaches to examine chemical hazard (13,21–23,25,66,67). With the progress 
made through ToxCast and Tox21, other projects grew into defined research areas or domains like 
“Exposure” (3) and “Use” (68) that spawned the development of different databases, applications, and 
software packages to meet specific research needs (Figure 1.1B). Many of these efforts have been siloed 
endeavors that have led to duplication of information across databases and difficulty in managing this 
information with time and resources spent on “data cleaning”, version control, and quality assurance 
measures. Other centralized user interfaces for accessing both NAMs and traditional data, including the 
Comptox Chemicals Dashboard (17), NTP BioPlanet (18), National Library of Medicine (NLM) PubChem 
(69), Comparative Toxicogenomics Database (35), and NTP Interagency Center for the Evaluation of 
Alternative Toxicological Methods (NICEATM) Integrated Chemical Environment (ICE) (20), have all led 
to increased access of data. Based on the rapid growth of these user interfaces, and their capabilities, it 
is clear that tools are needed to help data stakeholders integrate and organize this information, either by 










Figure 1.1: Evolving infrastructure to support modern chemical safety evaluation 
Pictured is an abstract representation of the changing infrastructure that supports USEPA’s computational 
toxicology efforts. (A) Initially, information across relevant domains in toxicology were aggregated from 
external databases to a single database accessed through a single web application called ACToR. (B) With 
continued success in data generation projects like ToxCast, multiple products were developed. The dashed 
arrows represent indirect access to the needed information. Indirect access means that the underlying 
information was duplicated because each web application is supported by a separate database, which is 
consistent with siloing and reinforcing data inconsistency. Appendix 1 further describes each product shown 
in this figure. 
 
 
Modern chemical safety evaluation requires a framework to link relevant information 
To enable modern chemical safety evaluation, several knowledge domains must be considered 
and integrated: (1) information on chemicals or substances; (2) information on chemical bioactivity, 
phenotypes, and toxicity; and, (3) information by testing methodology, assay principle, and intended 
target. Linking chemical exposure to disease or toxicity remains a challenge in part because chemical risk 
assessment is chemical centric, and information about the development and progression of disease or 
toxicity is thus not easily examined to allow inference of which chemical exposures are linked to these 
biological outcomes. Thus, efforts to increase data interoperability for bioactivity, toxicity, or phenotype 
and testing methodology, assay principle, or intended target would enable more inferences from disease 
or toxicity back to chemical exposure. Already, there is a framework to link biological observations: the 




to complex diseases and phenotypes; this cataloguing of interrelated biological processes and actions is 
advancing efforts in toxicology to use NAMs that may be used to predict adverse outcomes. However, 
novel, hypothetical associations between chemical exposure(s) and diseases may require bioinformatic 
tools and unsupervised approaches to putatively link chemical exposures with adverse outcomes. Though 
AOPs provide organization, in consideration of the AOP framework, it is clear that computationally 
accessible databases and additional bioinformatic tools to link information to AOPs rapidly are 
increasingly needed in modern chemical safety evaluation. 
The Adverse Outcome Pathway (AOP) framework has been proposed as a method to aggregate 
relevant information together and define a set of processes contributing an adverse outcome (AO), or an 
event relevant to regulatory concern. An AOP is defined as “an analytical construct that describes a 
sequential chain of causally linked events at different levels of biological organization that lead to an 
adverse health or ecotoxicological effect” (77). An AOP is mapped as a linear progression of a series of 
key events (KEs) linked together by qualitative or quantitative key event relationships (KERs) across 
biological levels of organization, beginning with a specialized KE known as a molecular initiating event 
(MIE) and culminating with another specialized KE known as an adverse outcome (AO). As high-
throughput screening, transcriptomics, epidemiology, etc. have generated large datasets for evaluating 
the effects of chemical exposure, the field of toxicology has been evolving to create new strategies for 
linking macromolecular and cellular changes with adverse outcomes to leverage all of this new data for 
safety evaluation. Key strategies for doing this include systematic literature review and predictive 
modeling (21–23,36). Either of these can inform a network of AOPs to describe biology pertinent to 
mechanisms of disease. However, problems persist in development of AOPs: (1) how can more AOPs be 
developed via rapid linkage of MIE or KE related information from NAM-based and traditional toxicology 
screening methods? (2) How can hypotheses be generated to suggest more potential MIE to AO 
associations? To address these persistent questions, additional tools need to be developed to make the 
NAM and traditional information more accessible, and further, existing information from disparate 
resources need to be leveraged to support discovery of novel MIE to AO relationships. 
Relevant to the questions above, knowledge discovery and chemical safety evaluation for 




integration of data that were previously siloed, and these efforts are ongoing. To use NAMs, i.e. high-
throughput transcriptomics, high-throughput screening, and high-content imaging data, more effectively in 
screening level assessment, better tools to link these data to MIEs, KEs, and AOs of interest for 
regulatory toxicology are needed. However, even the traditional toxicity information could benefit from 
more standardization and computationally accessibility for linkages to be established to AOs within AOPs.   
A primary obstacle to interoperability of NAM and legacy-based information in siloed resources is 
balancing the need for domain-specific details with the need to reduce complexity to enable use of the 
data. There are several opposing drivers in balancing data complexity and simplicity, including the 
differences among data stakeholders. For instance, the needs of data scientists in terms of available tools 
and datasets may differ from the needs of the general public for data transparency and availability and 
the needs of regulatory toxicologists charged with making public health decisions. Currently, domain 
specific complexity has led to a number of standalone resources with separate databases and 
programming utilities (such as R packages to manage ToxCast or high-throughput toxicokinetic data) that 
require the user to develop a deeper understanding of how to integrate the resources.  
Increased data interoperability of traditional toxicity and NAM-based toxicity information is 
discussed further in the facets of specific use cases. One example for hypothesis generation for AOP 
development is to relate complex disease phenotypes, such as cancer, with gene information that may be 
informative. The need to associate NAM information with outcomes at higher levels of biological 
organization necessitates high quality curation and structuring of legacy toxicology information, from 
animal and human studies. The archiving and curation of legacy data supports computational model 
development to predict adverse outcomes, but this process of data management is complex. An 
additional use case for computational toxicology is the integration of both NAM and traditional data 






Example Use Cases 
Standardization and mapping of vocabularies 
As previously stated, development and adherence to formatting standards and CVs increases 
interoperability, especially for legacy information systems or new data streams without existing standards. 
The updates to Toxicity Reference Database (ToxRefDB) further described in Chapeter 3 (13) are an 
example of how legacy information can be modernized for easier integration and use to advance 
research.  ToxRefDB is the largest publicly available digital resource aggregating results from animal 
toxicity studies that was initially created for retrospective analysis and as a reference to validate both 
ToxCast bioactivities and computational models (28,29). The impetus for the recent update was to collect 
dose-response information that was not originally extracted from the studies. However, endeavors to 
increase interoperability were also undertaken. The studies in ToxRefDB span decades where the 
language for reporting adverse events is inconsistent from either subjective expert preferences or 
updates as knowledge about pathology has advanced. The terminology in ToxRefDB was standardized 
for a ToxRefDB-specific CV. The CV was mapped to concepts in Unified Medical Language System 
(UMLS), which is a resource managed by National Library of Medicine integrating over 150 biomedical 
vocabularies into a semantic network (78). By mapping to a standard that is already integrated, 
interoperability is achieved with any other resource that is also mapped to the same standard.  
A goal of this type of work will be to more easily pass information across different resources that 
could benefit from the information. For example, CEBS also captures information from animal toxicity 
studies and the adverse event reporting for histopathology results adheres to a CV called International 
Harmonization of Nomenclature and Diagnostic Criteria (INHAND) and accounted for in NTP’s 
Nonneoplastic Lesion Atlas (NLA) (79). Despite adherence to a CV, INHAND is not mapped to any other 
resources, which makes interoperability difficult. Since INHAND is not mapped to any of the UMLS 
vocabularies, interoperability between the reported adverse events in ToxRefDB and CEBS is difficult. 
However, a primary user of INHAND is the eTox consortium (80), which is a group of pharmaceutical 
companies that have compiled animal studies into a single resource. Continuing efforts of eTox include 
increased interoperability though ontology development and mapping (81). Another resource that collects 




CV is available, it does not capture the granularity needed for interoperability. Finally, another resource 
that collects information on animal toxicity studies is International Uniform Chemical Information Database 
(IUCLID) (83). Like HAWC, IUCLID has a limited CV available as a “picklist” (84) and still lacks granularity 
for adverse events that is captured in ToxRefDB. IUCLID is the primary tool used by European Chemicals 
Agency (ECHA) to collect and evaluate chemicals for regulatory applications. IUCLID is separate from the 
previously mentioned applications because it adheres to data formatting standards developed in 
conjunction with Organisation for Economic Co-operation and Development (OECD) called OECD 
Harmonised Templates (OHTs). IUCLID can consume any data formatted according to OHTs. Both 
HAWC and IUCLID have been developed for chemical-centric regulatory applications, therefore 
aggregation of information has also been primarily chemical-centric. However, moving forward with 
research endeavors investigating NAMs and to answer questions about reproducibility in animal toxicity 
studies, the adverse event reporting also must adhere to CVs and formatting standards and fully support 
interoperability. 
A massive amount of information is readily available from each of the information systems above, yet 
interoperability is still lacking primarily due to lack of CVs and data format standards. The progress made 
in ToxRefDB with CV development and mapping was a manual effort; however, automatic mapping is 
possible. Several tools like National Center for Biomedical Ontologies (NCBO) Bioportal Annotator and 
UMLS MetaMap are available map text to respective CVs using Natural Language Processing (NLP) 
techniques. Without definitions or full text input, these methods are limited to string comparisons, which 
are not always very accurate. For example, the ToxRefDB term “pathology microscopic” was manually 
mapped to the UMLS term “Histopathology Result”. When using the BioPortal Annotator, the UMLS terms 
that are mapped to “pathology microscopic” are “Pathology” and “Microscopic”, which, even together, do 
not represent “pathology microscopic” as well as “Histopathology Result”. In many cases, manually 
mapping terms may be the best option because of the accuracy, but automatic mapping pipelines can still 





Putative gene-outcome relationships for complex phenotypes  
As previously stated, one of the most prominent challenges for adopting NAMs for chemical risk 
assessment is understanding how results can be applied to current public health issues like cancer. One 
approach from Kleinsteuer et al. (2013) (25) attempted to use odds ratios between in vitro bioactivity in 
ToxCast assay and cancer-related phenotypes in rodents, as documented in ToxRefDB, to develop 
chemical cancer hazard scores. Subsequently, the biological plausibility of links between ToxCast assays 
and ToxRefDB cancer outcomes was manually assessed by a literature review. The limitations of this 
approach were made clear in Cox et al. (2016) (85) stating that small changes to the dataset dramatically 
changed the results. This model instability could be the result of false positives i.e. the chemical 
bioactivity observed in ToxCast is not related to the cancer outcome observed in ToxRefDB. The 
approach could benefit if each ToxCast assay, which are linked to gene target(s), can be established in 
cancer AOPs. Indeed, this type of approach was taken by the International Agency for Research on 
Cancer (IARC) (86,87) where each ToxCast assay was reviewed and binned into the ten key 
characteristics of carcinogens (TKCC) (88). A toxicological priority index (ToxPi) was calculated for each 
chemical based on the bioactivities of each assay in each TKCC. Further, Becker et al (2017) (89) used 
the IARC binning of ToxCast assays and cancer designations by USEPA Office of Pesticides Program 
(OPP) Cancer Assessment Review Committee (CARC) as descriptors for machine learning models to 
classify chemicals as carcinogens, and ultimately concluded that ToxCast could not classify chemicals as 
carcinogens. Associating in vitro screening data with cancer-related outcomes, and understanding 
whether this is feasible and informative with ToxCast data, is an active area of research. 
Thus, a challenge remains: the above strategies heavily rely on expert knowledge to establish 
biological links between gene targets and complex outcomes, based on previous understanding of the 
etiology and progression of these outcomes; however, expert knowledge is limited due to the reliance on 
low-throughput manual literature review, and cancer etiology, especially the role environmental chemicals 
play, is not well understood and may benefit from new information. Data-driven strategies can be 
considered as support for interoperability continues. A wealth of gene information is available that may be 
relevant to cancer etiology or other complex phenotypes that may be difficult for an expert to identify. For 




keywords in literature. This resource is called Entity MeSH Co-occurrence Network (EMCON) (32) and 
can be used to identify genes that are linked to complex disorders like breast cancer. EMCON was also 
used as a data stream in Grashow et al. (2018) (90) as part of a comprehensive gene prioritization 
framework to identify a breast cancer gene panel. The impetus for this type of approach was linking dose-
response gene expression profiles with adverse outcomes of interest. The traditional approach to analyze 
gene expression results is gene set enrichment analysis (GSEA), where pathways or other concepts are 
identified from overrepresented differentially-expressed genes in reference gene sets that are primarily 
manually curated (91). Relevant gene sets for understanding links between chemical exposures and 
complex phenotypes are not readily available. Most gene sets are available through Molecular Signatures 
Database (MSigDB) (91–93) or other resources for GSEA like Enrichr (94,95). A commonly used 
resource that links genes to disease is Online Mendelian Inheritance in Manâ (OMIM) (96), which links 
genetic variants to disease; however, variants that have been linked to complex phenotypes have 
primarily been identified in genome wide association studies (GWAS) and are not always easy to 
mechanistically characterize.  
A well-curated resource that attempts to link chemical exposures to disease is Comparative 
Toxicogenomics Database (CTD) (35). CTD curates qualified chemical-gene interactions from literature 
and integrates gene-disease relationships from primarily OMIM. The chemical-disease links are inferred 
according to the overlapping genes between chemical-gene interactions and gene-disease relationships 
(97).  CTD is a high-quality resource but dependent on manual curation, which is low-throughput. Manual 
curation efforts cannot keep pace with the rate of publication, which highlights a need for alternative 
methods for data extraction like Named Entity Recognition (NER) (98,99). A comprehensive resource of 
bioassay information is PubChem (69). Bioassay information is crowdsourced, and deposition of 
information is generalized in order to store heterogenous data in the single resource. PubChem allows 
adherence to standards, specifically Bioassay Ontology (BAO) (100,101), but is not enforced. PubChem 
is the largest single resource for chemical bioassay information, however, much of the deposited 
information does not adhere to a data formatting standard beyond what is enforced in the deposition 




still needs to be considered for increased interoperability to utilize all available information for chemical 
safety evaluation. 
To identify environmental exposures that could potentially influence susceptibility to a complex 
disease, more complex gene networks, not comprised of only variants, may be important to identify. Other 
manual curation efforts of literature continue for gene and gene function information (102); proteins 
(103,104); pathways (105–108); diseases (109); and chemicals (35,82,110). Aggregating this curated 
information with chemical dose-response information from new technologies targeting different levels of 
biological information, while also considering interoperability, could lead to rapid putative AOP 




The current regulatory framework for toxicology is becoming more flexible to keep pace with 
modern public health needs. However, a major hurdle is data interoperability. Overcoming these 
challenges will enable researchers to interrogate available data to better understand the existing 
knowledge landscape identifying gaps in our understanding of environmental toxicity and how it 
influences complex disease. Initial efforts in toxicology to promote interoperability demonstrate immense 
progress and promise, yet, for continued success, more work is needed in development and adherence to 
CVs and data formatting standards as well as implementing modern infrastructures to support the 
massive amounts of data generated and subsequent analytics.  
 
Scope of dissertation 
The focus of this dissertation is on data interoperability and how efforts to increase data 
interoperability benefit toxicology and advance our understanding of how chemical exposures affect 
complex disease. Chapter 2 highlights a use case in leveraging curated information from literature to 
extract knowledge about a complex disease, breast cancer that would not have been accessible from 
expert review alone. The data is from articles in PubMed, which is a well-known resource supporting FAIR 
data guidelines to support scientific research. The articles are manually curated by PubMed indexers to 




are a part of a CV, which is also one of the vocabularies in UMLS. With this information and the use of 
networks, a novel bioinformatic tool was built called Entity MeSH Co-occurrence Network (EMCON) that 
can be queried to identify putative genes linked to any outcome of interest that has been published within 
the curated set of literature. EMCON helps overcome issues in data interoperability between many 
sources of gene and gene-disease relationships. When considering applications within toxicology, this 
approach can be used to identify important targets of interest when screening chemicals as well as linking 
bioactivities to complex adverse events and disease. 
Chapter 3 describes a major update to Toxicity Reference Database (ToxRefDB). The most 
significant update to support interoperability is establishing a ToxRefDB-specific CV and mapping the 
terms to UMLS. This work exposes points of integration, therefore data from ToxRefDB can be consumed 
and used with other datasets.  
Finally, Chapter 4 utilizes work from the previous chapters to answer relevant questions about the 
use of ToxCast for identifying chemical hazard for cancer and complex disease. A major critique of the 
utility of ToxCast for building computational models for complex disease has been the lack of biological 
coverage within the dataset. In fact, this critique is the impetus to move forward with dose-response 
transcriptomics studies that capture many more targets. Recent efforts have attempted to use ToxCast to 
identify the cancer hazard for chemicals and a relevant question is: “does ToxCast have relevant 
biological coverage of cancer?” Because of the previous work, two data integration approaches were 
possible. One, involves the use of EMCON alone to identify ToxCast gene targets that are linked to 
cancer or cancer processes. The second uses both EMCON and ToxRefDB to identify genes linked to 
specific cancer outcomes observed in animal toxicity studies. The chapter concludes that ToxCast has 
several gene targets linked to cancer or cancer processes, but identifying what amount of biological 
coverage is necessary to identify chemical cancer hazard remains difficult. More work is needed that 








Rapid technological advances in biomedical and life sciences have led to an inundation of 
heterogeneous information across these fields. For instance, high-throughput technologies like RNA-Seq 
and other transcriptomics methods generate large amounts of gene-related data such that underlying 
biological processes can be illuminated through pathway enrichment or association (91,111). Linking 
these functional genomic data to well-characterized ubiquitous diseases such as breast cancer (112) 
could provide opportunities to derive additional etiological insight, generate new hypotheses, identify 
critical genes and pathways, and develop novel therapeutics. However, while the current volume of 
genetic, experimental, toxicological and other data presents an incredible opportunity for biomedical and 
basic science to make great knowledge gains, many challenges remain in understanding how this 
information can be best integrated and queried to produce valuable insight.  
Currently, there is no research precedent on how to link genetic and toxicological data to complex 
disease phenotypes. For example, given that breast cancer will affect one in eight U.S. women and that 
susceptibility is shaped by both genetic and environmental factors (113–118), it is worthwhile to query 
publicly available data resources to better understand how risk factors like chemical exposures initiate 
biological changes to increase disease risk (119–121). Such an approach represents a departure from 
conventional toxicological strategies, in which a single chemical exposure is investigated as the driver of 
adverse effects, rather than considering other components of risk, e.g. genetic and lifestyle factors (122). 
As an alternative, the strategy outlined in this study aligns with the Adverse Outcome Pathway (AOP) 
                                                   
 
1 This chapter previously appeared as an article in Computational Toxicology. The original citation is as follows: Watford, S., 
Grashow, R., De La Rosa, V., Rudel, R., Paul-Friedman, K., Martin, M. (2018). Novel application of normalized pointwise mutual 
information (NPMI) to mine biomedical literature for gene sets associated with disease: use case in breast carcinogenesis. 
Computational Toxicology, 7, 46-57. 
CHAPTER 2: NOVEL APPLICATION OF NORMALIZED POINTWISE MUTUAL 





conceptual framework that focuses on aggregating information on perturbed systems across levels of 
biological organization (70,123). However, development of AOPs faces the same challenges in linking 
molecular initiating events (MIE), subsequent key events (KE), and adverse outcomes (AOs) in that the 
most relevant MIEs of KEs for a given AO may not be known, and it may be difficult to link specific risk 
factors such as chemical exposures to the AO of concern. With respect to breast cancer, it is possible that 
many chemicals or mixtures contribute to risk through many mechanisms; therefore, it may be more 
pertinent to work backwards from the AO to better understand the etiology and more effectively identify 
KEs and MIEs that may lead to increased breast cancer risk (124). However, without a comprehensive 
data science resource that can integrate gene identifiers or related information on early KEs in toxicity or 
disease with AOs, the considerable amount of information already available from academic, public, and 
private sector research may not be fully leveraged for hypothesis generation regarding mechanisms of 
toxicity or disease. The goal of the work presented herein is to provide just this kind of resource that can 
provide a putative, ranked linkage between an AO of concern and a given “entity,” i.e., a gene, biological 
process, or chemical; the result of using this new tool is a ranked list of potentially relevant entities that 
can be evaluated in follow-up screening, representing a quantitative approach to literature review and 
hypothesis generation. 
Currently there are several high-profile, publicly-available efforts in toxicology developed to 
explore how chemicals perturb biological systems, including the US Environmental Protection Agency’s 
Toxicity Forecaster (ToxCast) (125) and the larger, interagency collaboration Tox21 (9). The high-
throughput bioactivity results from these research programs have been used for chemical screening 
efforts of regulatory importance, like the Endocrine Disruptor Screening Program (EDSP) (126). These 
data have also been useful in research and development of putative AOPs, wherein the chemical-target 
interactions from high-throughput screening can be used as MIEs (34). However, even with this 
considerable amount of information, linking high-throughput screening data to AOs like diseases can be 
challenging without integration with information at various levels of biological complexity that consider 
toxicity. Another effort in linking chemical exposures to disease is the Comparative Toxicogenomics 
Database (CTD). In CTD, chemical-gene interactions are manually curated from published articles and 




overlapping genes for a given chemical-gene pair where the disease-related genes are either manually 
curated from articles or pulled in from another publicly available resource, Online Mendelian Inheritance 
in Man (OMIM) (127). While these disease sources are helpful for exploring gene-disease associations for 
inherited variants, they do not consider genes involved with the initiation and progression of a disease 
from non-inherited (i.e. environmental) risk factors. Finally, massive data generation efforts for 
toxicogenomics are ongoing with applications like the Connectivity Map (CMAP) (33) and the S1500+ 
from Tox21 (128,129); in these efforts, analysis of gene expression changes resulting from chemical 
exposures are being used for drug discovery and repositioning as well as understanding chemical 
mechanisms of toxicity. With these large data generation activities underway, it is more important than 
ever that toxicologists have access to a tool that can enable ranked associations between gene identifiers 
or early KEs and possible AOs; such a tool would require integration of multiple types and sources of data 
or information. 
The most substantial source of biological and biomedical information is PubMed, a freely 
available database managed by the National Library of Medicine (NLM) that contains over 27 million 
scientific articles that are indexed by medical subject headings (MeSH terms) (130,131). MeSH terms are 
arranged in a hierarchical tree with parent-child relationships such that each parent encompasses the 
concepts of each of its descendants, i.e. child MeSH terms are narrower in scope than their broader-
scoped parents. For example, as seen in Figure 2.1, “Ductal, Carcinoma, Breast” has one immediate 
parent from two branches: “Breast Neoplasms”. “Carcinoma, Ductal, Breast” is a narrower concept than 
its parent and other ancestors in the tree. MeSH terms cover topics across all the articles within PubMed, 
but the most relevant topics to the work presented here are those on diseases, symptoms, processes, 
and related biological and chemical entities, which are well-represented in MeSH terms. These MeSH 
terms need to be linked with gene identifiers, which requires some additional consideration as gene 







Figure 2.1: MeSH tree branches for “Carcinoma, Ductal, Breast” 
Shown are two branches for the MeSH term “Carcinoma, Ductal, Breast”. These branches have two root 
MeSH terms: “Neoplasms” and “Skin and Connective Tissue Diseases”. Preceding MeSH terms (i.e. 
traversal towards a root MeSH term) are ancestors, where descendants are the MeSH following (i.e. 
traversal away from a root MeSH term). The depth of a MeSH term corresponds to the number of 
ancestors it has with depth increasing with traversal away from the root MeSH term. 
Although some genes can be specifically identified by MeSH terms, not all genes are 
represented, especially since gene identifiers are species-specific. Systematic approaches for tagging 
genes that use strategies like named entity recognition (NER) have been implemented(98). However, 
despite the most successful efforts(99), no global approach exists where all genes can be systematically 
identified across all articles in PubMed. In lieu of a global systematic approach, we can rely on numerous 
manual curation efforts with publicly available resources that tag articles with relevant unique gene 
identifiers (GeneID). Although manual curation efforts are low throughput, the quality of mappings is 
higher, especially in resources built based on their manual curation efforts, including CTD and Universal 
Protein Resource (UniProt/SwissProt)(132). These manually curated resources offer valuable information 
alone, but also have great potential for discovery if tied together into one larger resource that also 
includes CTD’s chemical-gene interactions and UniProt’s protein-specific topics.  
Here we describe a novel and transferrable methodology, producing a resource known as the 
Entity MeSH Co-occurrence Network (EMCON), that integrates several resources to develop a network 
connecting genes to MeSH terms. EMCON uses ranked associations between genes and MeSH terms to 
produce ranked gene sets for hypothesis generation and testing. The utility of EMCON was demonstrated 
by evaluating genes putatively linked to breast carcinogenesis, an example highly relevant to public 
health. Given the breadth of ongoing research on chemicals known to increase the frequency of breast 




risk could be uncovered by integrating already existing data housed in resources mentioned above. In this 
example, MeSH terms were selected that represent important processes in carcinogenesis and, more 
specifically, breast carcinogenesis.  These MeSH terms were used to query EMCON and retrieve a 
ranked list of genes. Previously, Silent Spring Institute (SSI) created a list of nearly 300 genes as a 
reference gene set for breast carcinogenesis through expert literature review (ELR)(90). For the purposes 
of this study, that reference gene list was used to measure relevance of the EMCON search results. This 
work demonstrates a novel application of NPMI that critically informs hypothesis generation regarding 
genes that may be involved in breast carcinogenesis. EMCON may be useful in prioritization and 
selection of gene sets for transcriptomic experiments and/or articles to be manually reviewed for 
reference information. The methods described here are transferrable to any disease or AO of interest and 
could be tailored to myriad biomedical or life science research questions.  
 
Methods 
The overall workflow detailed in this paper is represented in Figure 2.2. First, we integrated seven 
resources, including gene2pubmed(102,133), Gene Reference into Function (GeneRIF)(102,134), 
CTD(35,135), UniProt/SwissProt(132,136), Reactome(137,138), Rat Genome Database (RGD)(139,140), 
and Mouse Genome Informatics (MGI)(141,142), to develop a network of naive GeneID-MeSH 
associations. Parent MeSH terms are less specific than their child terms, and as such, associations with 
parent MeSH terms may give less specific insight into the AO (see Figure 2.1); these parent MeSH terms 
should be mapped to all articles mapped to their child terms to reflect this relationship. Accordingly, we 
normalized the MeSH term frequencies to reflect the hierarchy within the MeSH tree so that broader 
terms appeared in associations more frequently while narrower, more specific terms showed up less 
often. This resulted in the less specific parent MeSH terms being mapped more promiscuously. Lastly, the 
GeneID-MeSH associations were ranked using an association measure called normalized pointwise 
mutual information (NPMI) (143). NPMI is commonly used in text mining for collocation extraction to 
identify words that co-occur together more than expected by random chance; the NPMI for any given 
association is a continuous value between -1 and 1. An NPMI greater than zero indicates a co-occurrence 




approaches 1. A positive NPMI does not indicate the direction of association (positive or negative 
association) between the GeneID and MeSH term. The final resource of ranked GeneID-MeSH 
associations is represented by EMCON: a scalable, queryable resource for retrieval of a ranked list of 
genes for a specific topic covered within MeSH terms. 
 
Integration of biomedical text resources 
To build a network relating genes to MeSH terms, we first identified biomedical databases that 
manually link genes or gene products to relevant articles. These databases included Comparative 
Toxicogenomics Database (CTD) (35,135), gene2pubmed (102,133), Gene Reference into Function 
(generif)( 102,134), Universal Protein Resource/Swiss-Prot (UniProt) (132,136), Reactome (137,138), Rat 
Genome Database (RGD) (139,140), Mouse Genome Informatics (MGI) (141,142). Each of these 
resources provide cross-references to Entrez Gene (GeneID) along with a PubMed Identifier (PMID) that 
uniquely identifies a gene and PubMed article respectively. Entrez Gene is a resource managed by the 
National Center for Biotechnology Information (NCBI) providing unique identifiers for genes and linking 
information to genes (biological function, gene products, sequences, etc.) as this type of information is 
discovered (102). PubMed is also managed by NCBI and is the largest resource of freely accessible 
biomedical text with over 27 million citations from a variety of sources including peer-reviewed, biomedical 
journals. Each of the resources listed above can be integrated into a single resource that links PMIDs with 
GeneIDs (Figure 2.2A). 
Next GeneIDs were linked to concepts across PubMed via Medical Subject Headings (MeSH 
terms;Figure 2.2A). Articles within PubMed are both manually and automatically tagged with MeSH terms, 
which is a controlled vocabulary of over 27,000 keywords structured in hierarchical trees used to 
categorize the concepts covered in an article(131). For example a publication titled “Estrogen receptor 
variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines“ (144) has 
been tagged with MeSH term “Breast Neoplasms”, “Receptors, Estrogen”, “RNA, Messenger”, and others. 
This is exemplified in Figure 2.3, which shows how GeneIDs are mapped to MeSH terms.  This article has 
also been manually tagged with the gene estrogen receptor alpha (ESR1). Combined with another 




now has two articles that support a relationship to the MeSH term “Molecular Sequence Data”, “Amino 
Acid Sequence”, “Receptors, Estrogen”, “RNA, Messenger”, and “Tumor Cells, Cultured” (Figure 2.3). As 
more articles are added to the network, the number of supporting articles for a GeneID-MeSH association 




Figure 2.2: Workflow for building Entity MeSH Co-occurrence Network (EMCON) 
EMCON is created by (A) integration of biomedical resources, specifically manually annotated datasets of 
GeneID-PMID mappings. These data are combined with PMID-MeSH mappings to create a naive GeneID-
MeSH network. (B) Next, the naive GeneID-MeSH network is expanded by mapping orthologous genes 
followed by MeSH term frequency normalization. The GeneID-MeSH associations are then ranked to 
generate the final EMCON resource. (C) EMCON can be queried with specific use cases where experts 
identify MeSH terms important to a topic of interest. Those selected MeSH terms are expanded to include 
descendants, which is the full set of MeSH terms used to query EMCON. The final output is a ranked list of 





Figure 2.3: Example of the naive GeneID-MeSH network 
The naive GeneID-MeSH network consists of GeneIDs that have been manually tagged to articles within 
PubMed, which are connected to MeSH terms. 
 
Cross-species gene orthologs 
Several of the resources above do not exclusively contain information on human genes, but for 
this work, we are only concerned with human genes. To maximize the number of articles and avoid 
excluding those that do not have human genes from the network altogether, we identified human 
orthologous genes. We assumed that the topics from an article about non-human orthologs are relevant 
to humans. We utilized UniProt Reference Clusters (UniRef), specifically UniRef50, to identify non-human 
proteins that have a human reference protein with a similar sequence(104). Proteins were mapped back 
to the naive GeneID-MeSH network via GeneID cross-references from UniProt/SwissProt. Then all 
articles tagged with the non-human GeneIDs were mapped back to the reference human GeneID from 





Medical Subject Heading (MeSH term) Frequency Normalization 
At the top of the MeSH hierarchical structure are sixteen root MeSH terms, such as “Anatomy”, 
“Diseases”, “Chemicals and Drugs”, and “Phenomena and Processes”. These broader terms maintain 
parent-child relationships in that each parent MeSH term branches into more specific "child" MeSH terms 
that fall under the umbrella of the broader “parent.” MeSH terms are not limited to any one branch, which 
means that MeSH terms can have multiple parents. For example, “Breast Neoplasms” has the parent 
“Neoplasms by Site” as well as “Breast Diseases” (Figure 2.4A). To reflect this hierarchical structure so 
that broader MeSH terms are mapped more promiscuously to articles than narrower MeSH terms, we 
normalized the frequency of MeSH terms (Figure 2.2B) by mapping the ancestors of a MeSH term back to 
articles of the descendants (Figure 2.4B). This ensures that broader, parent MeSH terms are mapped at 
higher or comparable frequencies than their narrower, more specific descendants. This same type of 
normalization can be seen in gene sets for hierarchical pathway datasets like that of Reactome(137,138). 
This normalization prevents skewing of results towards broader MeSH terms, which may have been 
inconsistently mapped to articles, and enables identification of more specific associations with child terms 
within the MeSH tree, which cuts down on the overall noise to identify the most relevant associations. 
This normalization is defined in equations !(#′)	and '(#′) in Table 2.1.  
 
Figure 2.4: Example of MeSH term frequency normalization 
(A) Shown are the same branches from Figure 2.1. The MeSH term “Breast Neoplasms” has a total of five 
ancestors with two root MeSH Terms: “Neoplasms” and “Skin and Connective Tissue Diseases.” (B) All the 
ancestors for a given a MeSH term are subsequently tagged to each article of a specific MeSH term. The 
original mapped associations are indicated by solid arrows and inferred associations as part of our MeSH 
term normalization are indicated by dashed arrows. 







( = {+,, … +/	} a set of co-occurrences, where c is a GeneID-MeSH term co-occurrence that is unique by PMID and 1 is the 
total number of co-occurrences 
2(3) the number of co-occurrences of ( that contain gene, 3 
!(#) the number of co-occurrences of ( that contain MeSH 
term, # 
!(#′) the number of co-occurrences of ( that contain # and 
all the descendants of # 
T(3;#) the subset of C that contains co-occurrences with both 
3 and # 
'(3) = 	 |2(3)|1  the probability of 3 occurring 
'(#) = 	 |!(#)|1  the probability of # occurring based on frequencies before MeSH term frequency normalization 
'(#′) = 	 |!(#′)|1  
the probability of # and all the descendants of # 
occurring based on frequencies after MeSH term 
frequency normalization 
'(3;#) = 	 |6(3;#)|1  the probability of 3 and # co-occurring 
'#7(3;#) 	= 	893(	 '(3;#)'(3)'(#′)) pointwise mutual information for a given 3 and # 
1'#7(3;#) 	= 	 '#7(3;#)−893('(3,#)) normalized pointwise mutual information for a given 3 and # 




Ranking Gene-MeSH co-occurrences 
The naive GeneID-MeSH network only contains associations between a gene and a MeSH term 
based on the frequency with which those two entities occur together in an article. To extract meaningful 
co-occurrences of a GeneID and a MeSH term, we calculated a rank measure called normalized 
pointwise mutual information (NPMI), which is the normalized variant of pointwise mutual information 
(PMI) (Table 2.1). PMI is a rank measure commonly used in text mining for collocation extraction, i.e., 
identifying words that co-occur together more than random indicating a shared meaning like “hot tea” and 
“crystal clear”. Because PMI is a rank measure, there is no level of significance or accepted cutoff to use 
for co-occurring terms; however, the normalized variant, NPMI, calculates a continuous value between -1 
and 1 where -1 is interpreted as no co-occurrence, 1 is interpreted as perfect co-occurrence, and 0 is 
interpreted as co-occurrence at random(143). These interpretations can be made about GeneID-MeSH 
co-occurrences because GeneIDs were tagged to articles independent of MeSH terms.  Also, NPMI is 
biased in that low frequency co-occurrences are ranked higher(143). To reduce the potential for spurious 
or less-replicable co-occurrences to drive this bias, GeneID-MeSH associations with less than three 
PubMed articles were excluded from the network. This cutoff was chosen based on assumptions that can 
be made about positive reporting of results due to publication bias(146). We assumed that for a GeneID-
MeSH association with three or more PubMed articles that support the association, it was likely that at 
least two of the articles reported positive results for a relationship between the GeneID and MeSH term.  
Table 2.1 summarizes the equations needed to calculate NPMI. The probability of a MeSH term 
# and all the descendants of # occurring ('(#′)) will increase the denominator of PMI resulting in an 
overall lower NPMI for broader terms since frequency is increased for a given MeSH term based on its 
descendants. This adjustment decreases the overall ranks of MeSH terms with many descendants 
whereas more specific MeSH terms ranked higher. The final network was filtered to include only GeneID-
MeSH associations with NPMI > 0, which indicates that each association present exceeds the 
associations expected from random chance (Figure 2.2B).  
 
MeSH Terms for breast carcinogenesis 




query EMCON and retrieve a ranked list of relevant genes. As described in Grashow et al.(90), experts 
selected seventeen MeSH terms that encompassed concepts from seminal papers on 
carcinogenesis(88,147,148)  and breast carcinogenesis(118), including: Neovascularization, pathologic; 
Neovascularization, physiologic; Apoptosis; Cell cycle; Epigenomics; DNA damage; DNA repair; Growth 
hormone; Cell survival; Immune system; Inflammation; Breast; Breast Diseases; Oxidative stress; Cell 
proliferation; Gonadal steroid hormones; and Xenobiotics. These seventeen MeSH terms alone do not 
necessarily reflect the full scope of the concept they represent, therefore the full query also includes all 
descendants of these MeSH terms for a total of 214 MeSH terms to represent breast carcinogenesis. 
Clearly, some of these concepts may be related to cancer phenotypes more broadly, and some may be 
more specific for breast carcinogenesis. 
 
Relevance of retrieved gene list 
For the topic of breast carcinogenesis, a reference gene set of 287 genes was compiled through 
expert literature review (ELR) by Silent Spring Institute as described in Grashow et al.(90) , including: (1) 
gene targets for quantitative nuclease protection assays in ToxCast Phase I; (2) genes responsive to 
nuclear receptors of interest (estrogen, progesterone, androgen, and aryl hydrocarbon receptors); (3) 
genes included in Qiagen microarray panels designed to probe pathways relevant to breast cancer 
(estrogen receptor signaling, breast cancer, DNA repair, DNA damage, growth factors, cellular stress 
response); (4) important genes in breast cancer based on key literature reports(113,149–151); (5) genes 
listed as related to breast cancer in curated databases (OMIM, CTD); and, (6) genes listed by partners at 
NCATS Chemical Genomics Center (NCGC) as important in cytotoxicity response (Figure 2.2C). Potential 
housekeeping genes were chosen from previous reports in MCF-7 cells(152–154). This ELR gene set 
was used as a reference gene set to measure the relevance of the retrieved gene list from EMCON to the 
topic of breast carcinogenesis. 
The EMCON search was conducted 214 times to generate one gene list for each MeSH term in 
the search query. The final gene list was obtained by averaging the NPMI rank per gene in the set of 214 
iterations. Relevance to breast carcinogenesis of the final gene list from EMCON was measured by 




generated gene sets of the same length as the ELR gene set of 287 genes. The retrieved gene list was 
considered relevant to breast carcinogenesis if the mean rank for the ELR gene set is higher than the 
distribution of mean ranks for randomly generated gene sets yielding an empirical p-value < 0.01. We 
used an empirical p-value because the comparison dataset is simulated, i.e. it was not derived using 
reference gene sets from other disorders. We felt that the best comparison would be against random 
gene sets rather than make inferences about how similar or dissimilar disorders may be based on 
respective genes. Recall was calculated as the fraction of ELR genes retrieved in the final list produced 
by EMCON, where the ELR gene set was considered a standard to evaluate the gene list produced by 
EMCON. Precision scores were calculated based on expert assessment of relevance of the top five 
genes for each of the seventeen selected MeSH terms. This expert assessment involved manual review 
of the literature that resulted in the GeneID-MeSH association to classify the association as true positive 
or false positive. 
 
Comparison to a similar tool 
EMCON’s performance was compared to Génie, another literature-based gene prioritization 
approach(155). Génie uses a naive linear Bayesian classifier in conjunction with a Fisher’s exact test to 
produce a list of genes ranked by false discovery rate (FDR). We compared our method with that of Génie 
by using a Spearman rank correlation of the ELR gene set from the EMCON search results with search 
results from Génie. Two gene sets were obtained from Génie: one using only the MeSH term “Breast 
Neoplasms” and another using all 214 MeSH terms used to query EMCON. 
 
Computational and statistical analyses 
All data were downloaded as flat files from their respective sources (Table 2.2). Python 3.6+(156) 
was used to parse the files and import into MongoDB 3.4+(157). All methods were implemented using 
MongoDB’s aggregate pipeline or python packages pandas 0.20+(158), numpy(159), and numba(160). 






Entity MeSH co-occurrence network (EMCON) 
Seven resources that manually tag PubMed articles with GeneIDs were identified (Table 2.2) and 
integrated into a single resource containing GeneID-PMID associations. Subsequently, MeSH terms were 
incorporated to generate a naive GeneID-MeSH network. Most of the genes in the naive GeneID-MeSH 
network are not human, but many produce proteins with high similarity to human protein orthologs, such 
that the information from non-human genes may be relevant to human-related research questions. To 
boost the number of articles mapped to human genes, UniRef50 clusters were used to identify human 
orthologous genes to increase the human relevant articles from around 500,000 to nearly 900,000. Next, 
the MeSH term frequency was normalized by mapping MeSH term ancestors back to articles to which 
their descendants were already mapped. Finally, GeneID-MeSH were ranked using NPMI to create a final 
network called Entity MeSH Co-occurrence Network (EMCON). EMCON is comprised of nearly 14 million 
associations, and, when filtered to require an article count > 2, the associations were dramatically 
reduced with 3.56 million remaining associations. The GeneID-MeSH associations in EMCON have article 
counts ranging from three to 10,276. The NPMI scores range from -0.5 to 0.7 with a mean of 0.025 















gene2pubmed (133) 1,062,713 5,565,651  12,782 
Gene Reference into Function (GeneRIF) (134) 
705,441 90,329  1,913 
Comparative Toxicogenomics Database (CTD) 
(135) 58,180 43,298  76 
Universal Protein Resource (UniProt/Swiss-Prot) 
(136) 950,989 5,156,248  12,555 
Reactome (137) 38 15,650 11,110  9 
Rat Genome Database (RGD) (139) 40 834,585 87,874  7 
Mouse Genome Informatics (MGI) (141) 181,519 42,020  1 
Total Unique 1,238,879 7,074,406  14,126 
Table 2.2:  Manually curated resources used to construct EMCON 
A total of seven resources that manually tag GeneID’s to articles within PubMed were integrated to serve 
as the initial dataset for building EMCON. Over 1.2 million articles make up the naive GeneID-MeSH 






Figure 2.5: EMCON NPMI distribution. 
 
MeSH term frequency normalization 
The MeSH term frequency normalization (represented as p(m’); See Methods) increased the 
promiscuity of MeSH tree terms based on descendants within the hierarchical trees, via mapping MeSH 
terms back to the articles of their descendants. The probability of a given MeSH term occurring in the 
naive GeneID-MeSH network (p(m)) increased with the number of descendants present in the network. 
This increase in promiscuity for broader MeSH terms corresponds to decreased NPMI for associated 
genes. Figure 2.6 demonstrates the probability of a MeSH term occurring before (p(m)) and after (p(m’)) 
frequency normalization; the probability of the MeSH term co-occurring with the gene of interest (p(g,m)); 
and the associated NPMI scores for the GeneID-MeSH co-occurrences for two MeSH branches, “Cell 





Figure 2.6: MeSH frequency normalization for two branches 
Two branches from the MeSH hierarchical tree were used to demonstrate how the annotation bias 
correction alters the probability of a MeSH term occurring (p(m)) along with the resulting NPMI with a 
relevant gene. These values correspond with the depth of a given MeSH term in the hierarchical tree. 
 
First, p(m) and p(m’) were compared for MeSH terms in the “Cell Cycle” and “Skin Diseases” 
branches (Figure 2.5A). p(m) did not inversely decrease with the depth of the MeSH hierarchical tree for 
“Cell Cycle” or “Skin Diseases.” This relationship implied that “Breast Neoplasms” was broader than “Skin 
Diseases” because the p(m) for “Breast Neoplasms” (p(m)=0.001) was greater than the p(m) for “Skin 
Diseases” (p(m)=2.3e-5). However, after MeSH term frequency normalization, p(m’) decreased as the 
depth increased for a given branch. For example, the p(m’) for “M Phase Cycle Checkpoints,” a term 
representing increased depth within the “Cell Cycle” branch, was less than the p(m’) values associated 
with its ancestors. Figure 2.6A also shows that despite p(m’) decreasing as depth increased within the 
“Cell Cycle” branch, the MeSH term “Cell Nucleus Division” was nearly absent from the network 
altogether with a p(m’)=2e-6. Similarly, following frequency normalization, the probability of the MeSH 
term “Skin Diseases” occurring in the gene-curated literature was greater than the probability of observing 
“Triple Negative Breast Neoplasms.”  
Increases in p(m’) correlated with decreases in NPMI, as illustrated in Figure 2.6B. In other 
words, for more promiscuous MeSH terms, the GeneID-MeSH term co-occurrence for that term was less 
likely to be specifically relevant for the specific topic of interest. When looking at the association between 
the MeSH branch, “Skin Diseases,” with epidermal growth factor receptor (EGFR), we see that the 




that these MeSH terms were less relevant specifically to breast carcinogenesis. The NPMI scores for the 
MeSH terms “Breast Neoplasms” and “Triple Negative Breast Neoplasms” co-occurring with EGFR 
remained at 0.1 and 0.21, respectively, because the p(m’) remained relatively similar to p(m). The NPMI 
decreased for most MeSH terms with MAD2L1 where “Cell Division” and “Cell Nucleus Division” drop 
below zero, which are excluded from EMCON. However, the NPMI scores for “Mitosis” and “M Phase Cell 
Cycle Checkpoints” remained above 0, therefore these associations were preserved. Despite the 
decreased NMPI for “Cell Cycle” and MAD2L1, these associations remained above 0 and were also 
preserved.  
 By normalizing the MeSH term frequency, we reduced the noise introduced into the network to 
retrieve more specific and useful GeneID-MeSH co-occurrences. This network cleaning approach 
assured that broader terms would not be ranked higher than more specific terms. The net impact is that 
less-specific MeSH terms will have lower NPMIs; many articles relate to “Skin Diseases” or “Breast 
Neoplasms,” but these articles may have little association with “Triple Negative Breast Neoplasms.” 
MeSH terms more closely associated with the pathological finding of interest such as“Triple Negative 
Breast Neoplasms,” will have a greater NPMI due to closer association. For all gene ID-MeSH co-
occurences for a given branch, the NPMI will increase with depth; i.e., the lowest descendant MeSH term-
gene co-occurrence will have the greatest NPMI. Thus, the most salient associations will be quantitatively 
identified. 
 
Relevance of search results to breast cancer 
 Genes related to the topic of breast carcinogenesis were retrieved from EMCON using seventeen 
expert-selected MeSH terms that represent concepts from seminal papers on the topic of specifically 
breast carcinogenesis(118) and carcinogenesis in general(88,147,148). These seventeen MeSH terms 
were expanded to include all descendants in the MeSH trees to ensure the full scope is represented 
within the selection. The final list of MeSH terms totals 214, which were used to query EMCON and 
retrieve a final list of 14,811 genes.  
Relevance of the EMCON-returned genes to breast cancer was evaluated by comparing the 




(Figure 2.6). The random gene sets were generated by randomly selecting 287 genes, which is the length 
of the ELR gene set. The average rank of the ELR gene set was clearly distinguished from the random 
gene set distribution (empirical p-value << 0.01). Using the ELR gene set, recall from EMCON search 
results was 0.983. Precision was calculated by manually assessing the relevance of the top five genes 
with the corresponding MeSH term. The average precision across the seventeen selected MeSH terms 
was 0.87 (Table 2.3). We then looked at the top MeSH terms related to well-studied, breast cancer 
genes: BRCA1, BRCA2, ESR1, ESR2, and PGR (Table 2.4). The MeSH terms retrieved are all specific to 
breast cancer or molecules linked to breast cancer like “Progesterone” and “Estradiol”. 
 
Figure 2.7: Comparison of mean rank of ELR, breast cancer-specific gene set to random gene sets 
within EMCON search results 
The ELR gene set is, on average, ranked higher than any of the mean ranks for randomly generated gene 
sets of the same length. Shown are 300 representative random gene sets from a total of 1000. The mean 





MeSH name Top five genes (gene symbol) Precision 
Neovascularization, Pathologic VEGFA, KDR, ANGPT2, ANGPT4, 
VASH1 
1 
Neovascularization, Physiologic KDR, FLT1, TEK, ANGPT1, EPHB4 1 
Apoptosis CASP3, BAX, CASP9, BCL2, CASP8 1 
Cell Cycle CDK2, CDK1, CCNE1, CCNA2, CDKN1B 1 
Epigenomics PARP12, DNMT3A, TET3, GREB1, KAT8 0.6 
DNA Damage ATR, CHEK1, ATM, MDC1, DDB2 1 
DNA Repair RAD51, XRCC1, XPC, ERCC2, XPA 1 
Growth Hormone CSHL1, GH1, GH2, GHR, CSH1 1 
Cell Survival ARIH2OS, CASP3, BAD, BCL2, BCL2L1 0.8 
Immune System LAT2, CLEC4E, ARL4C, CLEC6A, NAV1 0.6 
Inflammation NLRP3, CRP, PYDC1, SPATA31E1, 
NLRP13 
0.8 
Breast SCGB3A1, WISP3, PTK6, SCGB2A1, 
SCGB2A2 
1 
Breast Diseases TBX3, IGFBP3, TP63, TP73, IGF1 1 
Oxidative Stress CAT, GSR, NFE2L2, SOD2, GPX1 1 
Cell Proliferation CCND1, FOXM1, CDKN1B, YAP1, 
CDKN1A 
1 
Gonadal Steroid Hormones SEMG2, ACRV1, HSD17B1, SEMG1, 
HSD17B3 
1 





Table 2.3: Manual Precision for 17 selected MeSH terms 
Relevance of the five top ranked genes for each of the seventeen selected MeSH terms relevant to breast 
carcinogenesis was evaluated by performing a literature search of through Entrez Gene. Gene symbols in 








672 BRCA1 Breast Neoplasms 
Triple Negative Breast Neoplasms 
Breast Neoplasms, Male 
Hereditary Breast and Ovarian Cancer Syndrome 
Carcinoma, Ductal, Breast 
675 BRCA2 Breast Neoplasms, Male 
Hereditary Breast and Ovarian Cancer Syndrome 
Breast Neoplasms 
Triple Negative Breast Neoplasms 
2099 ESR1 Estradiol 
Fibrocystic Breast Disease 
Estrogens, Conjugated (USP) 
Breast Neoplasms 
2100 ESR2 Estradiol 
Estrogens, Conjugated (USP) 
5241 PGR Progesterone 
Table 2.4: Top MeSH terms for genes BRCA1, BRCA2, ESR1, ESR2, and PGR from EMCON 
Five breast cancer-related genes were used to search EMCON. Shown are the top-ranking co-occurring 
MeSH terms. 
 
Comparison to Génie 
We searched Génie with two different queries to obtain breast cancer-related genes to compare 
to EMCON results. The Spearman rank correlation for the results from the query with all 214 MeSH terms 
is 0.561 (Figure 2.7) with a recall for the ELR gene set of 0.718. When using only the MeSH term “Breast 
Neoplasms” to retrieve breast cancer-related genes, the Spearman rank correlation drops to 0.451 





Figure 2.8: The rank comparison of the ELR gene set from EMCON and Génie 
We obtained the two Génie gene sets by searching with 214 breast cancer-related MeSH terms and with 
only “Breast Neoplasms”. The correlation of the rank comparisons was similar across the two queries. 
 
Discussion 
We have developed an accessible and scalable resource called EMCON that is comprised of 
ranked associations between genes and MeSH terms. This novel tool is a needed public health and 
toxicology resource that enables connection of an AO of concern with hypothetical MIE or KE information, 
thus improving development of putative AOPs and providing an empirical approach to hypothesis 
generation. EMCON was developed via integration of multiple data sources and subsequent computation 
of the rank of specific associations. In the example herein, a ranked list of genes putatively related to 
breast carcinogenesis was defined using EMCON for use in hypothesis testing. The performance of 
EMCON in this example was evaluated in three ways: (1) comparison of the mean rank of the ELR gene 
set compared to randomly generated gene sets from the EMCON search results using the expert-
selected MeSH terms related to breast carcinogenesis; (2) evaluation of the recall and precision of the 




the 214 breast carcinogenesis-related MeSH terms from an existing tool, Génie. These three evaluations 
demonstrated that EMCON performed well for the use case of defining genes linked to MeSH terms. 
Within the EMCON search results, the ELR gene set for breast carcinogenesis ranked, on average, 
higher than any randomly generated gene set based on NPMI. Further, EMCON demonstrated excellent 
manually assessed precision (0.87) and recall (0.983) using the ELR gene set, and the EMCON results 
correlated with results from Génie, with some differences noted based on different methodological 
choices. Overall, the results presented herein suggest this is a valuable tool for hypothesis generation, 
providing critical support for the building of AOPs and AOP networks in addition to advancing research in 
biological and biomedical fields. 
EMCON was constructed to better utilize existing information in systematic information extraction 
of information used in hypothesis generation. EMCON was built by first integrating heterogeneous 
resources that map genes to articles containing information across a multitude of topics from PubMed. 
Then protein similarity clusters from UniRef50 were used to identify articles with similar, non-human 
genes to be mapped to the corresponding human gene. MeSH term frequency was normalized by 
mapping MeSH term ancestors back to articles of their descendants so that MeSH frequencies 
correspond to the depth of the MeSH tree. Lastly, GeneID-MeSH associations were ranked using NPMI. 
For construction of EMCON, we utilized several resources that manually curate PubMed articles with 
genes relevant to the content of the article. Each curation effort prioritizes articles based on specific areas 
of interest: pathways (Reactome), proteins (UniProt), chemical-gene/gene product interactions (CTD), etc.  
The total number of articles from all the resources totals to almost 1 million out of 27 million articles within 
PubMed.  Without the development of systematic information extraction or tagging efforts like NER [30], 
researchers are forced to rely on manual approaches. The mappings from manual efforts may be higher 
quality than those derived from potential systematic approaches, but the throughput is low. Also, each 
resource is biased towards a specific topic, so specific topics of interest may not be well represented in 
EMCON.  
An ongoing limitation of any data mining approach using manually curated information from 
PubMed is that curation efforts are not standardized, as demonstrated by curation of certain GWAS and 




an explanation of whether it was all genes included in the panels, only variants identified, or only those 
with differential expression. This lack of standardization or clarification introduces noise into the network. 
However, the article count cutoff used in this approach (see Methods) filtered out much of this noise, 
reducing the total set of associations by 75%. Noise in the set of GeneID-MeSH associations was also 
reduced through MeSH term frequency normalization, which is similar to approaches used in 
overrepresentation analysis like gene set enrichment analysis (GSEA)(91). The Reactome gene set 
available for GSEA or similar pathway analysis methods is normalized in the same manner, i.e., genes 
from the child pathways are all annotated to the parent pathways as well(137).  A further limitation of only 
using manually curated information is applicability to certain use cases. In this work, we explored breast 
cancer, which has a lot of literature in the curated space, but other diseases or outcomes may not be 
associated with any curated data. In moving forward with this work, systematic approaches can be 
developed to extract relevant information from articles to fill in gaps in knowledge. Although a particular 
disease or outcome may have limited information, EMCON could be used if more broad MeSH terms 
could be connected to these topics. 
The universe of possible human-relevant GeneID-MeSH associations was expanded by using 
UniProt Reference 50 (UniRef50) clusters to map non-human genes to corresponding human orthologs. 
Human genes are overrepresented in the curated PubMed literature accounting for nearly 50% of the 
articles with thousands of other species accounted for the remaining articles. However, genes from other 
research conducted in model species may be relevant to human pathogenesis, at least at the level of 
hypothesis generation.  UniRef50 was used because the protein clusters included the cross-species 
orthologs whereas UniRef90 and UniRef100 are typically clusters of same-species protein isoforms. 
Homologene is a resource that also clusters cross-species gene orthologs together(162) and is used by 
similar methods in literature-based gene prioritization(155). However, Homologene has not been updated 
since the last release in 2014. UniRef50 is regularly updated and supports many other efforts in 
proteomics work, and thus presented a clear choice for use in EMCON. It is possible that by expanding 
the network to include human orthologs, we introduced noise by including genes that may not be relevant 




these articles on the human orthologs can be easily identified and then removed if deemed irrelevant. 
This type of noise would not necessarily detract from the utility of EMCON for hypothesis generation. 
Normalized pointwise mutual information or NPMI was chosen as the association measure 
because of the defined threshold of NPMI>0.0 is interpreted as having dependent co-occurrence. Similar 
measures exist like Fisher’s exact, log-likelihood ratio, and Pearson’s chi-square (163), but despite their 
similar use in ranking, do not have defined thresholds to distinguish between independent and dependent 
co-occurrence. Similar co-occurrence measures to identify GeneID-MeSH associations are implemented 
in Gene2MeSH(164) and MeSHOPs(165). However, Gene2MeSH does not normalize the MeSH term 
frequency, and both lack cross species similarity mappings and use Fisher’s exact test to identify and 
rank MeSH terms associated with a gene. There is currently no consensus on which association measure 
works best because each measure can outperform the other depending the dataset(163,166). For the 
purposes of this paper, NPMI was chosen because a continuous rank measure could be more easily 
incorporated into other methods like the gene prioritization workflow implemented in Grashow et al.(90). It 
is possible that the best use of an association measure with this dataset may be a combination of the 
previously listed measures. However, this work demonstrated the utility of NPMI for this problem where 
previous work has only focused on use of Fisher’s exact(164,165) or more complex machine learning 
methods(155).   
The utility of EMCON was demonstrated within the scope of breast carcinogenesis. Breast 
carcinogenesis was chosen as a use case because of the large amount of information available on the 
topic due to major public health interest. Seventeen MeSH terms were selected by experts that, along 
with their descendants, represented important characteristics of breast carcinogenesis. A total of 214 
MeSH terms were used to query EMCON and retrieve ranked lists of genes where the NPMI was 
averaged across all MeSH terms for a final ranked list of genes. The MeSH tree was not considered when 
MeSH terms were selected, so the depth of each MeSH term varies. Due to the inclusion of descendants 
with MeSH terms at varying depths, MeSH terms like “Immune System” are overrepresented with 69 
descendants, while MeSH terms like “Epigenomics” are underrepresented with 0 descendants. This over- 
and underrepresentation introduces bias in the results for breast cancer. It is possible the MeSH term 




approach. The MeSH term selection could also be improved by consideration of the parent-child 
relationships in the MeSH tree and the MeSH-MeSH association from common publications(167). 
Comprehensive gene sets for complex disorders are typically comprised of variants derived from 
genome-wide association studies (GWAS). However, for this work, we wished to include a more 
heterogeneous set of genes that may be related to processes seen in carcinogenesis. A breast cancer-
specific gene set compiled through ELR was used to evaluate the relevance of the retrieved gene list to 
the topic of breast carcinogenesis. Using the ELR gene set as a standard, the final breast cancer gene list 
from EMCON had a recall of 0.983, and the ELR gene set ranked well above randomly generated gene 
sets of the same length (empirical p<<0.01) indicating that the higher-ranking genes from EMCON are 
likely relevant to breast carcinogenesis. This was further demonstrated by manually assessing precision 
of the top five genes for the seventeen selected MeSH terms (average precision=0.87). The MeSH terms 
that did not have a precision of 1 had either very few descendants (“Cell Survival” and “Epigenomics”) or 
had many descendants (“Immune System” and “Inflammation”; Figure 2.9). MeSH terms with few 
descendants could represent newer topics with fewer relevant articles or could represent cases wherein 
few genes have been specifically annotated to the topic, e.g., “Epigenomics”. MeSH terms with many 
descendants could have genes promiscuously mapped to them because of the large number of varied 
topics within the descendants. In both cases, the genes that were not explicitly related to the 
corresponding MeSH term were not well annotated, demonstrated low article count relative to the other 
top-ranked genes, or may have resulted from promiscuous mapping of geneID to MeSH. This type of 
false positive is an artifact of using NPMI since rare co-occurrences (GeneID-MeSH associations with low 
article counts) are artificially ranked higher. The article count cutoff could be raised to a more 
conservative number to remove these types of associations and tune EMCON to the specific research 
application based on the level of specificity required. When evaluating MeSH terms related to well-known 
breast cancer-related genes (BRCA1, BRCA2, ESR1, ESR2, and PGR), the topics were all specific to 






Figure 2.9: Number of genes retrieved for the 17 selected MeSH terms 
The number of genes reflects the genes mapped to select MeSH term along with those genes also 
mapped to the descendants.  
 
EMCON’s performance was compared to results from Génie(155). The Spearman rank 
correlations indicate that EMCON has a strong positive correlation with a more complicated method. The 
recall values for the ELR gene set in both result sets from Génie were much lower than EMCON; Génie 
did not retrieve all genes identified as breast cancer-relevant through expert review. The differences in 
recall between the two tools may be due to some key differences in the function of Génie; unlike EMCON, 
Génie relies on gene2pubmed and GeneRIF rather than all available sources of curated GeneID-PMID 
mappings and does not correct for MeSH term tagging frequency. EMCON is further distinguished from 
Génie as a standalone, easily searchable resource that is scalable to include updates from any of the 
included resources.  
Other previous efforts in data mining to link genes to disease have included a variety of 
implementations, including GeneDistiller(168), Endeavor(169), and many more further outlined in Moreau 
and Tranchevent(170). However, many of these resources have not been updated or maintained, are 
commercial products, or have limited accessibility for further customized integration. Further 
distinguishing EMCON from these resources is the use of MeSH term frequency normalization, 




compatible with previous efforts at putative AOP development, but clearly different in its approach. 
Putative AOPs have been developed using frequent itemset mining(34) based on shared chemicals in 
ToxCast and CTD, in an effort to identify MIEs and KEs that may be relevant. In contrast, EMCON works 
in the opposite direction, i.e. starting with the AO and its associated MeSH terms, with the goal of finding 
possible targets for an MIE or KE related to an AO of interest. 
EMCON has been used as one of several data streams for a gene prioritization project to identify 
breast cancer gene sets for investigating the molecular mechanisms of mammary carcinogens(90). Other 
potential applications of EMCON include defining reference gene sets for high throughput transcriptomics 
chemical screening efforts(128,129). It can be used alongside traditional pathway analysis, as it provides 
a means of linking differentially expressed genes to perturbations at higher levels of biological 
organization (tissue, organ, body, etc.). Also, due to the scalability of EMCON, other data can easily be 
incorporated from chemical and toxicity resources like PubChem(171), the Toxicity Reference 
Database(28), and ToxCast. These additional resources would provide associations between chemicals 
and biological entities (genes, pathways, in vitro and in vivo toxicity endpoints), further expanding the 
utility of EMCON for hypothesis generation, chemical hazard identification and prioritization, and putative 
AOP development. Ultimately, EMCON provides a scalable, comprehensive resource to strengthen 
empirical experimental design and systematic literature review via prioritization of hypotheses based on 
GeneID-MeSH associations. EMCON is a bioinformatic tool for public health and biomedical sciences that 
leverages the existing body of information on putative gene-outcome relationships to support research 
and improve health outcomes. 
 
Summary 
Entity MeSH Co-occurrence network (EMCON) was created using a novel data integration 
pipeline and available information on genes extracted from research articles. The resulting resource, 
EMCON, can be queried to retrieve a ranked list of genes linked to any topic that is captured in literature. 
To demonstrate the utility of EMCON, genes linked to breast cancer were retrieved and success was 
measured by comparing the average rank of a list of known breast cancer genes to randomly generated 




list of random genes indicating the results returned from EMCON are, in fact, relevant to breast cancer. 
The resource can be extended for any topic of interest that is covered within biomedical literature. This 
work demonstrates resources that support interoperability i.e., curating information to exposure points of 






With an increasing need for rapid screening and prioritization of chemicals for hazard and risk 
evaluations, researchers are developing new strategies for predicting chemical toxicity. In accordance 
with these efforts, the Toxicity Forecaster (ToxCast) research program (11) has been developed by the 
U.S. Environmental Protection Agency (EPA) to assist in the realization of the National Research 
Council’s (NRC) vision for improving rapid assessment of the hazard potential of many chemicals for 
human, animal, and environmental health (5,172). These efforts served as an impetus to develop the 
Toxicity Reference Database (ToxRefDB), a digital resource of in vivo toxicity study results. ToxRefDB 
comprises information from over fifty years of in vivo toxicity data, largely from summaries of studies 
performed in accordance with US EPA Office of Chemical Safety and Pollution Prevention (OCSPP) 870 
series health effects test guidelines. The database includes information for over 1,000 chemicals, and is 
being used as a primary source of validation for continued efforts of the ToxCast program(28,29), as well 
as for numerous predictive and retrospective analyses(25,27,173,174). The utility of ToxRefDB to 
predictive toxicology is clear; it has been used as the basis for validation of new approach methods 
(NAMs) to identify specific adverse outcomes of interest(24,26,175,176), as a retrospective benchmark 
for predictive performance of NAMs (27,173,177,178), and in evaluation of the reproducibility and 
interpretation of observed in vivo outcomes(179,180). ToxRefDB has been used for a wide variety of 
applications across industry, government, and academia, with 41 other publications citing either Martin et 
al. (2009) (28) or Martin et al. (2009) (29) in PubMed (APPENDIX 1) as of October 2018. Using 
ToxRefDB to develop an understanding of the reproducibility and variability in in vivo toxicity testing 
                                                   
 
2 This chapter has been submitted to the journal Reproductive Toxicology for publication in 2019. Watford, S., Pham, L., Wignall, J., 
Shin, R., Martin, M., Paul-Friedman, K. (2019). ToxRefDB version 2.0: Improved Utility for Predictive and Retrospective Toxicology 
Analyses.. 
CHAPTER 3: TOXREFDB VERSION 2.0: IMPROVED UTILITY FOR PREDICTIVE AND 




clearly supports development of baseline expectations for NAMs that promise to assist with rapid 
prioritization and screening level assessments(181–185). Thus, ToxRefDB represents a seminal resource 
for predictive toxicology applications, and lessons learned from the initial implementation have been 
addressed in a major re-development that we describe herein as ToxRefDB version 2.0. 
To understand this re-development, it is necessary to further describe previous development and the 
evolution of ToxRefDB. The first version of ToxRefDB (ToxRefDB v1) initially captured basic study design, 
dosing, qualitative information for effects, and point of departures (PODs) from summaries of roughly 400 
chemicals tested in over 4,000 registrant-submitted toxicity studies, known as data evaluation records 
(DERs), from the U.S. EPA’s Office of Pesticide Programs (OPP). These studies adhered to Office of 
Chemical Safety and Pollution Prevention (OCSPP) 870 series Health Effects testing guidelines. As this 
resource was intended to serve as training information in understanding the utility of NAMs like those 
employed in ToxCast(9,125), the chemical selection for ToxRefDB was originally prioritized to maximize 
the overlap with ToxCast phase 1 chemicals (ToxCast ph1v1)(1), which were compiled based on 
commercial availability, solubility in dimethyl sulfoxide, chemical structural features suggesting diversity, 
and the availability of in vivo data, with the result that pesticide active ingredients comprised a high 
percentage of the ToxRefDB and ToxCast ph1v1 libraries. Expanded efforts in data collection and 
curation, driven by an attempt to cover as much of the primary ToxCast chemical library as possible, 
increased the chemical and biological coverage of ToxRefDB v1.3 to over 5,900 in vivo toxicity studies 
from additional sources, including the National Toxicology Program (NTP), peer-reviewed primary 
research articles, and pharmaceutical preclinical toxicity studies, among others, for a total of over 1,000 
chemicals. As an update to ToxRefDB v1, ToxRefDB v1.3 was released in 2014 to the public as three 
spreadsheets that consolidated information on adverse effects from the database as well as study 
citations(186,187). 
Though ToxRefDB is unique in its public availability, level of curation, and coverage of chemicals and 
study types, since the initial release of ToxRefDB v1 in 2009 and through subsequent updates, 
challenges have surfaced surrounding the extraction, storage, and maintenance of heterogeneous in vivo 
toxicity information. Several stakeholders commented on challenges in using ToxRefDB with respect to 




“non-neoplastic,”(188), as well as the need to be able to integrate the data from ToxRefDB with other 
public databases(189). Further concerns about the need for negatives, i.e. chemicals tested and shown to 
be negative for a specific endpoint or effect, to form balanced datasets for predictive 
modeling(24,25,180,190) strongly relate to the need for an updated vocabulary and determination of 
which effects are measured in a given study. The desire for more quantitative dose-response information 
is obvious, given that benchmark dose modeling(191) may provide POD estimates less dependent on 
specific dose selection. Developmental and reproductive effects, involving complex study designs with 
multiple generations, also appeared to require a more complex database structure to distinguish effect 
levels between generations(175). A more nebulous problem that is common to all databases that seek to 
make legacy information computationally accessible is minimizing data entry error rate. While error rates 
never reach zero, they could be improved through standardized form-based data extraction with 
additional layers of quality assurance (QA)(192). 
In this work, we further describe the challenges realized through the use and release of ToxRefDB v1, 
and how these challenges have been addressed to date with development of ToxRefDB v2, including a 
detailed description of the new content in ToxRefDB v2. The goal of ToxRefDB v2 is to provide a public 
database that better supports the needs of predictive toxicology by increasing the qualitative and 
quantitative information available and by facilitating the interoperability of legacy in vivo hazard 
information with other tools and databases. Recognizing that predictive toxicology will require iterative 
efforts to build computational resources like ToxRefDB, work to generate ToxRefDB v2 has been 
conducted primarily in three main areas: 
• Aggregation of complex and heterogeneous study designs; 
• Controlled vocabulary for accurate data extraction, aggregation, and integration; and, 
• Quantitative data extraction, including quality assurance and efforts to reduce error rate. 
This work represents a significant advancement in increasing the richness of information available for 




Meeting Challenges in ToxRefDB 2.0 
ToxRefDB Overview 
Like ToxRefDB v1, ToxRefDB v2 contains summary information for over 5,900 studies labeled 
“acceptable” for data extraction purposes only, i.e. source document was readable and study design was 
clear, from six main subsources: DERs from the US EPA OPP (OPP DER), a subset of available NTP 
study reports (NTP), the open literature (OpenLit), donated pharmaceutical industry studies (pharma), 
and other (Other; including unpublished submissions and unknown sources) (Figure 3.1A). The study 
types included in ToxRefDB v2 cover the same study designs as ToxRefDB v1: chronic (CHR; 1-2 year 
exposures depending on species and study design) bioassays conducted predominantly in rats, mice, 
and dogs; subchronic (SUB; 90 day exposures) bioassays conducted predominantly in rats, mice, and 
dogs; subacute (SAC; 14-28 day exposures depending on the source and guideline) bioassays 
conducted predominantly in rats, mice, and dogs; developmental toxicity studies (DEV) conducted 
predominantly in rats and rabbits; multigeneration reproductive toxicity studies (MGR) conducted 
predominantly in rats; reproductive (REP) toxicity studies conducted largely in rats; developmental 
neurotoxicity (DNT) studies conducted predominantly in rats; and a small number of studies with designs 
characterized as acute (ACU), neurological (NEU), or “other” (OTH) (Figure 3.1B). Though ToxRefDB v2 
contains summary data from roughly the same number of studies and chemicals as ToxRefDB v1, 





Figure 3.1: Number of studies by study type and species in ToxRefDB v2 
(A) ToxRefDB contains over 5,900 animal toxicity studies from a variety of sources include Office of 
Pesticides Programs Data Evaluation Records (OPP DER), National Toxicology Program study reports 
(NTP), pharmaceutical preclinical testing (pharma), open literature (OpenLit), and others (Other). (B) The 
study designs include chronic (CHR), sub-chronic (SUB), developmental (DEV), subacute (SAC), 
multigeneration reproductive (MGR), developmental neurotoxicity (DNT), reproductive (REP), neurotoxicity 
(NEU), acute (ACU), and other (OTH) for numerous species, but mostly for rat, mouse, rabbit, and dog.  
 
Aggregation of complex and heterogeneous study designs 
Animal studies are designed to address specific hypotheses, with flexibility in study design required to 
potentially reduce cost, time, and the number of animals needed(193). However, this flexibility presents 
challenges in structuring the study-related information, so when designing a database to capture both 
study design and adverse effect-related information, a structure that allows for that flexibility is necessary. 
An example of the needed flexibility in terms of archiving information on many treatment groups becomes 
apparent in consideration of the MGR study in rats(194) (Figure 3.2). The addition of quantitative data 
required a reorganization and expansion of the previous database. Thus, the number of tables and their 




heterogeneous study designs that also may have additions or deletions of treatment groups or doses 
needed to thoroughly investigate toxicity and complete a study (Figure 3.3). 
 
 
Figure 3.2: Three generation MGR example 
This example demonstrates that within the MGR study design, there could be 14 treatment groups, which 
would then need to be multiplied by the number of doses used in the study. Many of the study designs in 
ToxRefDB have the potential for the addition of interim, recovery, and satellite groups in order to 
investigate findings of interest. Even though the guidance in the associated MGR guideline (194) does not 
require an F3 generation, many studies will report findings from at least a “first mating” treatment group of 






Figure 3.3: ToxRefDB general schema with changes made from ToxRefDB v1 to ToxRefDB v2 
Highlighted in blue are the additions to the generic schema to accommodate the updates and additional 
features for ToxRefDB v2. These include tables to capture the dose-response, quantitative data; guideline 
profiles for the inference workflow to determine negative endpoints and effects; UMLS cross-references; 
and effect groupings for systematically calculating PODs and associated effect levels. 
 
Controlled effect vocabulary for accurate data extraction, aggregation, and integration 
Controlled effect vocabulary 
A controlled effect vocabulary is critical for any resource aggregating information across a diverse 
set of sources for efficient retrieval and to enforce semantics, especially within biology (195). ToxRefDB 
exemplifies this need as it is used for modeling efforts and retrospective analysis. One of the most 
significant challenges in extracting and/or integrating in vivo toxicity studies is the lack of adherence to 
controlled vocabularies. Inconsistencies in vocabulary arise both as advancements are made to better 
understand adverse effects in the fields of pathology and toxicology and through preferential terminology 
in reporting due to differences among experts (196). These inconsistencies can also be seen across 
studies adhering to the same guideline but conducted years apart. Without adherence to a standard 
vocabulary that is actively updated and maintained, these studies can only be manually integrated in a 
way that is unreliably subjective (197). The current landscape of pathology terminology appears to be 




Toxicologic Pathology (STP) as part of the International Harmonization of Nomenclature and Diagnostic 
Criteria (INHAND) project (198). Perhaps most evolved and ready for current use are solutions in the 
medical science field that can be seen through the adoption of electronic medical records and electronic 
health records for reporting adverse events, including data reporting from clinical trials for 
pharmaceuticals and medical devices (199,200). In fact, current efforts are underway to develop 
international standards for capturing data from clinical trials, which includes non-clinical data. These 
efforts are led by the Clinical Data Interchange Standards Consortium (CDISC), where collaboration 
between international regulatory agencies and their stakeholders is fostered to develop standards for 
digital submission of clinical trial data (201,202). 
Originally, ToxRefDB vocabulary for endpoints distinguished between non-neoplastic and 
neoplastic lesions, which conformed to the vocabulary used by NTP (79). Improving the controlled 
endpoint vocabulary for ToxRefDB was a particular challenge because the terminology found in OCSPP 
guidelines or NTP study specifications may not necessarily match the reported pathology, clinical 
chemistry, and toxicology study results, where terminology is sometimes more specific. Guideline 
language needs to be flexible and lasting, rather than overly prescriptive, but this needed flexibility also 
leads to potential mismatching of information across studies. One demonstrative example is provided by 
the terminology of the guideline requirement for OCSPP 870.4100, “full histopathology on the organs and 
tissues…of all rodents and nonrodents in the control and high-dose groups, and all rodents and 
nonrodents that died or were killed during the study” (203), which doesn’t distinguish between non-
neoplastic and neoplastic lesion types nor detail all possible histological findings that could be observed, 
e.g., hypertrophy, adenoma, fatty changes. In ToxRefDB v1, the effect vocabulary was generally 
standardized and hierarchically structured into broader categories called endpoints (Figure 3.4 and further 
described below). Effects were grouped into categories like carcinogenic, neoplastic, and non-neoplastic 
pathology, organ weight, etc. This categorization was maintained for ToxRefDB v2, however, as 
mentioned before, the terminology for endpoints reported in the studies did not match the terminology in 
the corresponding guidelines and specifications. This was problematic for two primary reasons: (1) 
identifying the correct endpoint within a guideline is required to determine whether or not it was negative 




neoplastic or neoplastic process rather than allowing the user to define what effects might be related to 
cancer phenotypes or other adverse outcomes. 
 
Figure 3.4: Example of the controlled effect terminology in ToxRefDB v2 
An example of the terminology hierarchy is demonstrated for an effect described as “intrahepatic bile duct 
hyperplasia”. The finding is recorded as the “effect description free”, which is the wording used in the 
study report. The remaining fields are part of the ToxRefDB controlled terminology. The endpoint 
category is systemic, the endpoint type is pathology microscopic, the endpoint target is the liver, the effect 
description is hyperplasia, and the specific observation of “intrahepatic bile duct hyperplasia” was made in 
the adult life-stage at the specific target site, the bile duct. 
 
The terminology for both endpoints and effects was standardized to better reflect the terminology 
used in both the OCSPP guidelines as well as what was reported in the summaries in DERs. The primary 
change made in ToxRefDB v2 is that for the endpoint category “systemic,” the tissue pathology endpoint 
types are now “pathology microscopic” and “pathology gross,” with no a priori suggestion of whether the 
observation relates to specific cancer or non-cancer related adverse outcomes. Further, duplicative 
endpoints were standardized, reducing the number of endpoints from approximately 500 to 400. The 
number of effects remained the same as they were re-binned into the most relevant endpoint. Though the 
endpoint and effect terminology in ToxRefDBv2 is not comprehensive for all in vivo toxicity studies, it 
captures the observations from the studies and study types currently within ToxRefDB. Each effect can 
be further qualified to include life stage, direction of effect (increase, decrease, neutral), target site, and 
exact terms from the source document used to capture the effect (a field called “effect description free”) 
(Figure 3.4).  
The endpoint category “neurological” was not updated and has been left out of the release of 
ToxRefDB v2. The corresponding effects for that endpoint are associated with 18 NEU and 185 DNT 
studies. However, the study design, dosing, and treatment group information is still available for these 




development, with the intention to extend the controlled terminology and extract this information to be 
available in future updates.  
 
Enabling semantic interoperability 
Adopting a controlled terminology for ToxRefDB is beneficial for data extraction and data 
retrieval, but we can also extend the use to enable semantic interoperability across similar resources 
archiving in vivo toxicology data. This will allow interoperability with other sources that also capture in vivo 
toxicology data like Chemical Effects of Biological Systems (CEBS) (61), International Uniform Chemical 
Information Database (IUCLID) (83), and eTox (80).  We identified resources like CDISC that actively 
maintain and update controlled vocabularies for all aspects of nonclinical studies. Specifically, we were 
interested in the terminology developed in Standards for Exchange of Nonclinical Data (CDSIC-SEND) 
and Study Data Tabulation Model (CDISC-SDTM). These vocabularies are maintained by National 
Cancer Institute Thesaurus (NCIt), which is a subset of the National Library of Medicine’s (NLM) Unified 
Medical Language System (UMLS) (78). UMLS is a semantic network linking over 150 terminology 
resources (CDISC being one of those resources) within the biomedical domain. A UMLS concept is 
uniquely identified by a concept code. These concept codes were mapped to the controlled terminology 
defined in ToxRefDB on a manual basis, using the UMLS Terminology Services and NCI Thesaurus 
browsers. Figure 3.5 describes the completeness of the mapping for endpoints and effects and the 
coverage from CDISC-SEND and CDISC-SDTM. By cross-referencing ToxRefDB terminology with 
UMLS, a crosswalk to any other resources that adhere to any of the terminology resources maintained 





Figure 3.5: Terminology sources and membership of UMLS concept codes cross-referenced to 
ToxRefDB endpoints and effects 
Over 1,800 UMLS concept codes were mapped to endpoints and effects in ToxRefDB. Only 500 of those 
concept codes are a part of the CDISC-SEND terminology. All of the concept codes are a part of 
vocabularies within both National Cancer Institute Thesaurus (NCIt) as well as UMLS. 
 
Quantitative data extraction, quality assurance, and efforts to reduce error rate 
Study extraction process 
Initially, studies available in ToxRefDB v1 lacked quantitative, dose response information; the 
quantitative information and its application is described in the next section in more detail but served as a 
strong impetus to motivate re-extraction of the studies in ToxRefDB. This task initially proceeded using an 




after uploading study extractions to the ToxRefDB MySQL database, including: inconsistent comments, 
different number of animals for the same treatment group, and added effects outside of the controlled 
terminology. Thus, following initial attempts with Excel-based extraction, an Access database file was 
generated from the MySQL database for each study (Figure 3.6). The Access database files featured 
several improvements, including: standardized options for more consistent reporting in some fields, such 
as the units on time and dose, dose-treatment group, and effect information; checkbox reporting for 
observation status on each endpoint and effect; and a log for tracking changes and facilitating QA. Nearly 
32% of the studies were extracted using Excel-based approach, with the remaining studies extracted 
using the Access database approach. Switching to Access database files significantly reduced errors and 
increased standardization of reporting. 
 
Figure 3.6: Data extraction and review workflow 
Access databases are generated for each study and batched to data extractors with the corresponding 
source files. The data in the Access databases are curated with additional data extracted from the source 
files with up to three levels of review. The Access databases are batched back and the data is imported 





Guidance for data extraction was stratified first according to study type (e.g., CHR, SUB, DEV, 
MGR) then by study source (e.g., OPP DER and NTP) because of the differences in both study design 
and adverse effects required for reporting as stated in guidelines. The process used to extract study 
information was also an important aspect of QA efforts for ToxRefDB v2. First, a primary reviewer 
extracted study, dose, treatment group, effect, and endpoint observation information, per standard 
operating procedures provided to the reviewer. The instructions detailed how to review the toxicological 
data and extract it from the original data sources consistently across reviewers using the Access 
database. This was reviewed by a second, senior reviewer, who was asked to review all extracted 
information as if they were extracting it again and, also, to review the comment log from the primary 
reviewer. Finally, if either the primary or secondary reviewer noted that it was necessary, an additional 
senior toxicologist reviewed the comment logs, extracted information, and resolved any conflicts or 
questions prior to finalization of the extraction. The final, tertiary review occurred for approximately 10% of 
the studies. All reviewers were trained in the procedures prior to reviewing studies. For release of 
ToxRefDBv2, the full quantitative data extraction for all CHR and SUB studies were completed, with 
quantitative data extraction completed for many other study types and sources as well (additional 
quantitative data will be added in updates to the version 2 release). Table 3.1 lists the current number of 





A Study type Study source Number of studies 
extracted 
CHR NTP 347 
CHR OPP DER 1,079 
CHR OpenLit 9 
DEV NTP 10 
DEV OPP DER 958 
DEV OpenLit  1 
DEV  Other 6 
MGR OPP DER 345 
MGR OpenLit  1 
MGR Other 20 
SAC NTP 59 
SAC OPP DER 25 
SUB NTP 247 
SUB OPP DER 769 
SUB OpenLit  6 
Total 3,882 
 











Total chemicals 1142 
Table 3.1: Extraction progress as of ToxRefDB v2 release 
Over 65% of the studies have been curated with dose-response, quantitative data extracted. Priority was 
given to chronic (CHR) and sub-chronic (SUB) OPP DERs and NTP study reports, which are completed. 
The remaining studies are predominantly from OpenLit and pharma.  A) The number of studies per 
source by study type. B) The number of chemicals per study type. 
 
Critical Effect Determination 
ToxRefDB v1 and v2 have several effect levels stored; treatment-related effects define lowest effect 
levels (LELs) and no effect levels (NELs), whereas critical effect designations define the lowest 
observable adverse effect and no observable adverse effect levels (LOAELs, NOAELs). A critical effect 
level is defined as the dose at which a treatment-related effect is deemed to have toxicological 
significance. Critical effects are typically used to define the study-level POD for regulatory toxicology 
applications. Not all studies within ToxRefDB v1 had been assessed for critical effects, or the critical 




from the source document as previously identified by toxicologists who had reviewed the original study 
file. If for a given source document, particularly those from sources other than OPP DER files, critical 
effect information was lacking, senior toxicologists trained to extract information for ToxRefDB reviewed 
the study and determined the critical effects and critical effect levels. For each study, the reviewers 
determined the critical effect and lowest observed adverse effect level(s) (LOAEL) using a weight-of-
evidence (WoE) approach (204), like the approach used to evaluate registrant-submitted studies for 
generation of DERs. Using this approach, the identification of potential critical effects from a given study 
was determined based on statistical significance, considerations of biological relevance, and consistency 
across multiple endpoints (in the presence or absence of statistical significance) to select the appropriate 
LOAEL value(s) and the overall study LOAEL. The WoE evaluation included review of all pertinent 
information so that the full impact of biological plausibility and coherence was adequately considered. 
This approach involves weighing individual lines of evidence and combining the entire body of evidence 
to make an informed judgment. Judgment about the WoE involved considerations of the quality and 
adequacy of data, and consistency of responses induced by the agent in question. The WoE judgment 
required combined input of relevant disciplines. Generally, no single factor determined the overall weight; 
all potential factors were judged in combination. The results of these reviews were recorded along with 
appropriate rationales and can be found in ToxRefDB v2.  
Quality assurance and quality control efforts to reduce error rate 
Error rate is an inherent problem for legacy databases as much of the source information was 
entered manually, so human errors resulting from transcription are impossible to completely avoid (192). 
However, as part of the ToxRefDB v2 effort, increased QA measures to promote greater fidelity of the 
information captured, which included numerous quality control (QC) checks to ensure data integrity were 
implemented. First, studies were extracted utilizing a defined QA process, with multiple levels of review 
and Access form-based entry (described previously) to prevent extraction errors as described above. 
Upon upload into ToxRefDB v2, these extractions were required to pass QC measures because, although 
the Access database files enforce the MySQL database constraints as well as use of the controlled 
terminology to minimize data entry error, logical errors can persist. We checked a series of potential 




defining a series of tests up front that must resolve to a particular answer. Below are some of the logical 
errors that were flagged using a QC check following import of the Access database files to the MySQL 
database: 
• Dose level numbering did not correspond to the total number of doses; 
• Duplication of concentration/dose values, including two control doses; 
• No concentration and no dose adjusted value for a reported effect (possible extraction error or 
possibly that the effect was qualitatively reported); 
• The critical effect level is at a dose below where treatment-related effects were observed; and/or, 
• The control was incorrectly identified as a critical effect level. 
Any of these issues that could not be resolved systematically were flagged to undergo a second 
round of extraction and QA to correct. Though QC is an ongoing and evolving process, these QC checks 
are serving as an improvement to the overall database and database development process. 
An additional ongoing problem for reporting quantitative data from clinical or related laboratory 
findings is unit standardization (205,206). No guidance is provided on how to report findings in the 
OCSPP guidelines nor from any other sources, so units were extracted exactly as they were presented in 
the reports. The units were standardized by eliminating duplicate entries for the same units that were 
originally entered differently or with typographical errors. Units were only standardized, so no conversions 
were made. Further work must be undertaken to further standardize units and define conversions that can 
be systematically automated.  
In order to understand how increased quality assurance and quality control may have affected 
quantitative information in ToxRefDB, a comparison of study level LEL and LOAEL values for 3,446 
studies between ToxRefDB v1.3 and v2 was conducted. This evaluation showed ~95% concordance for 
the LELs and ~90% for LOAELs between ToxRefDB v1.3 and ToxRefDB v2. Though the values in v1.3 
and v2 were largely concordant, addition of critical effect review for studies that previously lacked a 
critical effect and/or error correction account for the minute differences. The magnitude of the differences 
ranged from 0.1 log10-mg/kg/day to 2.4 log10-mg/kg/day, with an average difference of 0.52 log10-




Distinctions between negative effects and not tested effects 
Many study sources only report information on the adverse effects, and data extracted in ToxRefDB 
v1 reflected this (i.e. only contained data for positive or treatment-related effects). These values were 
reported as lowest effect levels (LELs) or lowest observable adverse effect levels (LOAELs), with no 
effect and no observable adverse effect levels (NELs, NOAELs) inferred as the next lowest dose, 
respectively. A positives-only database presented a major challenge for predictive modeling applications 
that require balanced training sets of positive and negative findings: the user was left to infer negatives 
from the database without the guidance of what was tested and reported for the study based on its 
adherence (or non-adherence) to a guideline. Finding a solution to systematic and accurate inference of 
negatives involved leveraging the new controlled effect terminology to match the OCSPP guidelines 
(described above) and annotating endpoints as required, triggered, or recommended. Required endpoints 
are always tested according to the guidelines, whereas triggered endpoints are required under specific 
circumstances, e.g. if a chemical is known to perturb a specific system based on information from 
previous studies. A recommended endpoint is not always tested but are mentioned as important in the 
guidelines. All other endpoints not explicitly mentioned in the guidelines were assumed to be not required. 
The collections of endpoint annotations for guidelines are referred to as guideline profiles.  
These guideline profiles enable assumptions about whether an endpoint was tested for a given study 
based on which guideline the study followed. A majority of the studies (58%) described in ToxRefDB are 
based on OPP DERs, which summarize registrant-submitted data in accordance with OCSPP series 870 
Health Effects Testing Guidelines as seen in Table 3.2. Additionally, though not strictly referred to as 
guidelines, study specifications for SAC, SUB, and CHR studies from NTP (207) were also reviewed and 
developed into guideline profiles to allow for their inclusion in determination of negatives. Developmental 
and reproductive studies from the NTP were not included in guideline profile development at this time due 
to the assumption that these studies may have been highly customized based on the experimental need, 
and as such inference of negatives may not lead to accurate conclusions (personal communication, John 
Bucher and Paul Foster). Because the studies included in ToxRefDB span decades, we also included 
guideline profiles for updated guidelines. For example, since testing requirements were added to the 




profiles: one for studies conducted before 1998 and another for studies conducted in 1998 and later. All of 
the guideline profiles were reviewed by an independent senior toxicologist familiar with the guideline and 
guidance documents. 
Observations were recorded and confirmed in the data extraction process for each to reflect 
concordance with guideline profiles, deviations, endpoints that were measured following a trigger, etc. An 
observation is defined as the testing and reporting status of a given endpoint in the study. Extractors 
made decisions about testing and reporting status as described in Table 3.3, where for example 
endpoints that were reported as tested can be differentiated from endpoints that are assumed to be 
tested based on the guideline profile. The important result of the development of these guideline profiles 
is that missing or not tested data can now be distinguished from negative (tested with no effect seen) for 
a large fraction of the studies described in ToxRefDB v2. The inference workflow to determine negative 
effects based on observations and guideline profiles is described in Figure 3.7. 
Guideline number Guideline name Study Type in ToxRefDB 
870.3100 90-day Oral Toxicity in Rodents SUB 
870.3150 90-day Oral Toxicity in Nonrodents SUB 
870.3250 90-day Dermal Toxicity SUB 
870.3465 90-Day Inhalation Toxicity SUB 
870.3550 Reproduction/Development Toxicity Screening 
Test 
REP 
870.3700 Prenatal Developmental Toxicity Study DEV 
870.3800 Reproduction and Fertility Effects MGR 
870.4100 Chronic Toxicity CHR 
870.4200 Carcinogenicity CHR 
870.4300 Combined Chronic Toxicity/Carcinogenicity CHR 
870.6200 Neurotoxicity Screening Battery NEU 
870.6300 Developmental Neurotoxicity Study DNT 
870.3050 28-day Oral Toxicity in Rodents SAC 












Tested status Reported status Example 
Tested Reported The endpoint was SPECIFICALLY written in the text of 
the study source indicating that data was collected 
(default if required by the guideline for that study type) 
Not tested Reported The endpoint was SPECIFICALLY written in the text of 
the study source indicating that data was NOT collected, 
even if required by the guideline 
Tested Not reported The endpoint was NOT specifically written in the text of 
the study source, however other evidence indicates it 
can be deduced that it was tested (or was required by 
the guideline to be tested) 
Not tested Not reported The endpoint was NOT specifically written in the text of 
the study source and is not required by the guideline, so 
we assume that the endpoint was not collected in this 
study 
Table 3.3: Observations for guideline profiles 
The tested status indicates if the endpoint was evaluated or not by the given study.  The reported status 
indicates if the testing status was reported in the given study. Combining the tested and reported status 
yields the observation status for the specific endpoint of interest on a study-by-study basis. 
 
 
Figure 3.7: Inference workflow to determine negative effects 
Four steps are taken to systematically infer true positives and negatives: (1) study extracted completely; 
(2) application of the observation status; (3) determination of the effect seen (yes/no) on the basis of 
statistically significant findings; (4) conclusion, with true positive (green), true negative (red), not tested 
(orange), and inconclusive (gray) as possible outcomes. 
 
Study Reliability (ToxRTool) 
A majority of the studies referenced within ToxRefDB were extracted via summaries from OPP 
DERs, and these studies typically follow OCSPP 870 series Health Effects Testing Guidelines; however, 
as ToxRefDB was expanded, other studies were summarized from various sources, including: NTP, 




guideline or specification that these studies resembled could be identified, but OpenLit studies were not 
assumed to conform to any guideline. Therefore, all open literature studies were assessed for reliability 
and guideline adherence. The Toxicological Data Reliability Assessment Tool (ToxRTool) was adapted 
for this assessment(208). ToxRTool is an Excel application that includes questions across 5 criteria with 
numerical responses that are summed to lead to a Klimisch score: a score ranging from 1-4 that captures 
an overall assessment of reliability(209). The ToxRTool was adapted specifically in the following ways for 
this project: 
• Added Guideline Adherence Score (an initial question for the reviewer regarding the study’s 
adherence to or consistency with OCSPP guidelines with a five-point rating scale) further 
described in Table 3.4.   
• Added “Context of Tool and Rationale/Intent for Study” field (an open-text field to insert the 
purpose of the study quality review to address the concern raised by Segal et al. (2015) (210) 
that the intended purpose of the ToxRTool-facilitated review could influence evaluations).  
• Added additional scoring notes (to help the reviewers assign scores consistently). 
• Added option for “0.5” rating for selected criteria (for some questions considered more subjective 
than others, if the reviewer concluded the question was partially fulfilled).  
A total of 522 OpenLit studies were assessed with the ToxRTool with scores ranging from 8 to 23 with 23 
being the highest score. The majority of the studies reviewed for ToxRefDB v2 corresponded to Klimisch 
quality scores of 1 (ToxRTool score of ≥ 18) or 2 (ToxRTool score of 13-18). The ToxRTool scores could 
be used as a quality flag both to qualify and prioritize studies for the extraction process, or by users who 












5 Adheres to modern* OECD/EPA guideline for repeat-dose toxicity studies (explicitly stated by 
authors; broad endpoint coverage and ability to assess dose-response) 
4 Adheres to an existing or previous guideline (explicitly stated by authors; previous version of 
OECD/EPA guidelines or FDA guidelines) 
3 Not stated to adhere to guideline but guideline-like in terms of endpoint coverage and ability to 
assess dose-response (e.g., NTP). Please see Quick Guide to EPA Guidelines for Chronic and 
Subchronic studies.  In this table, you can easily assess whether the study was guideline-like 
in terms of the animals used (species, sex, age, number), dosing requirements, and reporting 
recommendations. 
2 Unacceptable adherence to guideline (intended to adhere to guideline but had major 
deficiencies) 
1 Unacceptable (no intention to be run as a guideline study, purely open literature or specialized 
study) 
Table 3.4: Guideline adherence scoring added to ToxRTool 
Note that many of the studies extracted, particularly from sources like the NTP and open literature, were 
never intended to adhere to a guideline and as such “unacceptable” in this case only refers to their 
guideline adherence and not the study design itself. 
*A study is considered as adhering to “modern” OECD/EPA guidelines if it was published after 1998, 
which is the date that many Health Effect 870 series guidelines were re-published.  
 
Extensions of ToxRefDB v2 updates for research applications 
Systematic calculation of point of departures (PODs) and related effect levels 
Related to the new ToxRefDB v2 controlled effect terminology is the application of this 
terminology for calculation of PODs and related effect levels for various modeling and retrospective 
analyses in the predictive toxicology realm. For purposes of predictive toxicology, PODs can be computed 
per chemical (i.e., lowest dose that produced effects or adverse effects across all study types included in 
the database) or per study (i.e., lowest dose that produced effects or adverse effects in a given study of 
interest). PODs computed by chemical could be broken down into a POD for some combination of effects 
in a POD “category,” e.g., the lowest dose that produced effects or adverse effects on developmental or 
reproductive effects as a group. Acknowledging that the specific application may define the appropriate 
aggregation of the effect data in ToxRefDB for calculation of PODs, ToxRefDB v2 (Figure 3.3) enables 
definition of the list of effects to be grouped together, followed by storage of the PODs calculated based 
on that list. A collection of effect groupings is referred to as an effect profile. An initial set of effect profiles 
were created to define custom grouping of effects from the study, treatment groups, and effects. For 
example, all developmental effects, across studies, could be combined to give a POD, or minimum 
LOAEL or LEL value, for developmental effects. The NEL and NOAEL are designated as the next lowest 




necessarily of toxicological significance and may not correspond to the critical effect level as reviewed by 
toxicologists. In the case that no effects of toxicological significance were observed for a given category 
of effects, or by study, the LOAEL is greater than the highest dose tested and the NOAEL is greater than 
or equal to the highest dose tested for that effect (i.e., a “free-standing NOAEL”). For all POD types, 
including NEL, NOAEL, LEL, and LOAEL, a qualifer (<, >, or =) is provided to assist with quantitative 
interpretation of these values.  
The effect profiles are an important feature addition and address problems previously 
highlighted(189); essentially, the endpoints and effects in ToxRefDB can be grouped a number of ways, 
which may lead to differing interpretations. However, there is no single way to create POD values via 
grouping of effects, as differing interpretations may be equally valid for divergent applications of the data. 
The two effect profiles currently available in ToxRefDB v2 are summarized in Table 3.5 for clarity, with the 
expectation that as use of the database grows, additional effect profiles can be added. It should be noted 
that these effect profiles, and the POD values generated in using them, are for research purposes and do 
not necessarily reflect POD values that may be used in chemical safety evaluations. 
First, effect level data were grouped by study type, endpoint category, and life stage. This first 
effect profile produced POD values for each study type, life stage, and endpoint category combination. 
This first effect profile was used to calculate effect levels for the CompTox Dashboard (17).  
A second effect profile was also employed, where PODs were calculated for each endpoint 
category-endpoint type pairing, except in the case of the systemic endpoint category, where PODs were 
reported for each endpoint targets (i.e., organs). This second effect profile produced POD values for 
cholinesterase, developmental, and reproductive endpoint categories; hematology, in-life observation, 
and urinalysis endpoint types; and organ-specific endpoint targets (e.g., liver). Either of these effect 
groupings and associated effect levels may be useful for research purposes as a meaningful way of 




Effect profile id 
Description 
Example output 
1 Endpoints are grouped by study type, life stage, and endpoint category to produce a POD. NEL, LEL, NOAEL, and LOAEL 












• SUB  














2 Endpoints are grouped according to endpoint category, endpoint type, or endpoint target. The 
endpoint target is used for systemic pathology endpoints, i.e. if the effects are organ-level, the POD 
is reported for the organ system. 
NEL, LEL, NOAEL, and LOAEL 













For the systemic endpoint category, either the endpoint type or organ are used 
Endpoint Type: 
• Clinical chemistry 
• Hematology 
• In life observation 
For pathology microscopic and gross, and organ weights, the organ name is used, e.g.: liver, kidney, 
heart 
Table 3.5: Effect profiles in ToxRefDB v2 for POD computation 









Benchmark Dose (BMD) Modeling for ToxRefDB  
Quantitative dose-response modeling yields PODs for research applications that are less 
dependent on the doses selected for a given study, and ensures that dose values selected correspond to 
similar levels of effects across studies (211). Though there are many possible approaches to curve-
fitting(16,212), the US EPA Benchmark Dose Modeling Software (BMDS)(213–215) has become the 
canonical tool for use in toxicology regulatory and research applications(212,216–218). Using BMDS to fit 
the quantitative response data in ToxRefDB provides modeled values, e.g., benchmark dose (BMD) 
values, using the default recommendations from the BMDS guidance(191).  In ToxRefDB v2, we report 
the results from the largest use of batch processing with BMDS v2.7 employed to date, using a Python 
package(219) (Pham et al). The objectives in reporting this demonstration within the database are (1) to 
promote the use of BMD values in development of predictive toxicology solutions for regulatory 
applications; and (2) to demonstrate the feasibility of large-scale BMDS analysis of legacy toxicology 
information. The BMD values reported are in no way intended to reflect any regulatory decision-making 
on a single chemical basis. 
Over 92,000 quantitative dose-response datasets, i.e. data from chemical-effect pairs, from 
complete study extractions with at least 3 non-control dose levels in ToxRefDB v2 were filtered to yield 
datasets amenable to modeling using BMDS. For each dose group of a study, BMDS analysis requires 
the dose, N, and dichotomous incidence or the continuous effect level mean and variance. In large part 
due to inconsistent or incomplete reporting of variance for continuous responses, only about one-third of 
the total datasets were available for BMDS modeling (nearly 28,000). For each modeled dose-response, 
the data were grouped according to the response type, i.e., continuous response, continuous response 
for organ and body weights, dichotomous response, or dichotomous cancer response. The response type 
guided selection of the models and benchmark response (BMR) used in the automated analysis, as 
shown in Table 3.6, as recommended by the BMDS guidance(191). The effect terminology corresponding 
to cancer is available in APPENDIX 2.  
The current BMD table in ToxRefDB v2 holds results for nearly 28,000 datasets. This includes 
BMD models with 1 standard deviation for continuous data, 10% relative deviation for organ/body weight, 
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and 5 and 10% BMR for dichotomous data. Almost 90% of the datasets were successfully modeled and 
have at least one recommended model and therefore a BMD value (Figure 3.8).  Currently, there are 627 
unique chemicals (as indicated by CAS registry number) with at least one modeled BMD value. The lower 
95% confidence limit on the BMD value estimate, known as the BMDL, is also stored in the database. 
However, some recommended models are associated with cautions for using the BMD and BMDL values 
that were auto-generated by BMDS (v2.7). For example, there may be warnings to indicate a large 
distance between the BMD and BMDL, or that a computed BMDL is likely imprecise because the model 
has not converged. All warnings related to model recommendations are stored in the “logic cautions” 
column of the “bmd” table in the database and should be considered by the end user of the data. The 
rates at which recommended models were achieved for each data type and BMD model type are 
illustrated in Figure 3.9.   
One hypothesis in modeling these dose-response data is that BMDL values will tend to be lower 
than the discrete NOAEL or NEL values for a given study-level effect. Indeed, most of the recommended 
BMDL values are less than the stored NOAEL and NEL values for that effect. For datasets (continuous 
and dichotomous) successfully modeled using a BMR of 5% extra risk (dichotomous) or 5% increase 
relative to control mean estimate (continuous), 98% of the BMDL values were less than the 
corresponding NOAEL values, and 66.4% of the BMDL values were less than the corresponding NEL 
values. For the datasets with a BMR of 10% extra risk (dichotomous) or 10% increase relative to control 
mean estimate (continuous), 95.7% of the BMDL values were lower than the NOAEL values, and 48.5% 
of the BMDLs were lower than the corresponding NEL values. This is mostly consistent with previous 
works showing that modeled BMDLs are a more conservative estimation of PODs than the statistically 
derived NOAELs(220,221). Similarly, we also compared BMD values to LEL and LOAEL values. For the 
datasets that used a BMR of 5% extra risk (dichotomous) or 5% increase relative to control mean 
estimate (continuous), BMD values were less than their corresponding LEL or LOAEL values 
approximately 89% of the time. For the datasets that used a BMR of 10% extra risk (dichotomous) or 10% 
increase relative to control mean estimate (continuous), the BMD values were less than the 




All study type and BMDS-amenable data were used for this exercise to model the largest dataset 
possible. Some caution needs to be taken when evaluating the BMD models, particularly for studies 
where multiple generations are evaluated. Ideally, for MGR and DEV studies, a nested model should be 
used to calculate BMDs for the litters and, if needed, a correction for the degree of variability or sample 
size adjustment. However, due to the availability of information from source files, and the data structure in 
ToxRefDB v2, information from individuals in each litter were not available. Therefore, the summary data 














BMD Model / 
Total 
Cancer 1 170 
5% 1 101 243 / 247 
10% 1 107 246 / 247 
Non-cancer 
dichotomous 17 318 
5% 16 059 609 / 612 












3 006 284 / 300 
Table 3.6: Number of datasets in ToxRefDB v2 for BMDS modeling 
Each dataset consists of all doses, number of test animals, effect values, and variance information if 
available. The table shows the number of modeled datasets, the BMR used, the number of recommended 
models, and number of chemicals with a recommended BMD model by type of data.  The  chemical 
counts are by data type, as the same chemical can have data in multiple data types. The “total” number of 





Figure 3.8: Proportion of effects in ToxRefDB that can be modeled 
(A) Of the 92,646 quantitative dose response datasets, approximately one third met data quality filters for 
BMDS. (B) There were 27,756 datasets that met data quality filters for using BMDS. Of the ~28k 
datasets, 87% produced a recommended model result. The percentage of the data corresponding to each 





Figure 3.9: The number and type of models for each dataset 
The stacked bars for each model indicates the number of models that were or were not recommended.  
For each dataset type, the BMR was also indicated with their label. A 10 % relative deviation was used as 
the BMR for the continuous datasets for the body weight and organ weights.  All other continuous 
datasets used a BMR of 1 standard deviation.  The dichotomous datasets used a 5 and a 10% BMR. 
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Data Integration  
It is increasingly apparent that many toxicology research questions will require the integration of 
public data resources, both with those containing the same types of information, as well as with other 
databases to connect different kinds of information. For example, with increasing global interest in finding 
rapid chemical screening alternatives like the use of ToxCast to build predictive models, the need for 
linking in vitro effects to outcomes observed in vivo is essential(222). To connect the ToxRefDB endpoint 
and effect terminology with other resources, the ToxRefDB terminology was standardized and cross-
referenced to the United Medical Language System (UMLS). UMLS cross-references enable mapping of 
in vivo pathological effects from ToxRefDB to PubMed (via Medical Subject Headings or MeSH terms) 
that may be relevant for toxicological research and systematic review. This enables linkage to any 
resource that is also connected to PubMed or indexed with MeSH. For example, Entity MeSH Co-
occurrence Network (EMCON)(32), a resource to retrieve ranked lists of genes for a given topic, can be 
used to identify genes related to adverse effects observed in ToxRefDB. Subsequently, ToxCast can be 
integrated since the intended targets are mapped to Entrez gene IDs. The result of updating the 
terminology in ToxRefDB v2 and linking to the UMLS concepts is that ToxRefDB may be used to better 
anchor or compare to in vitro data like ToxCast data, or to other in vivo databases of toxicological 
information, like those available from eChemPortal(223), e-TOX(80), or others. Integration of these data 
resources is a major hurdle toward to evaluating the reproducibility and biological meaning of both 
traditional, legacy toxicity information and the data from NAMs. 
 
Conclusions 
ToxRefDB has served as a seminal resource for in vivo toxicity studies with broad applications in 
predictive modeling, retrospective analysis, and validation of in vitro chemical screening results. Although 
robust in scope for capturing effect information, early versions of ToxRefDB only contained data for 
positive findings and thus were limited by a lack of distinction between tested and not tested effects. 
Additionally, the terminology concerning endpoints did not adhere to a standardized classification system. 
Moreover, specific effect information and quantitative, dose-response information were needed to support 
predictive toxicology questions. To address these issues, ToxRefDB has undergone extensive updates 
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that include extraction of additional information (quantitative data as well as observations about tested 
endpoints), data standardization, and quality assurance measures to maintain data integrity. With these 
updates, the utility of ToxRefDB can be extended to myriad applications, and our process can serve as a 
reference for other resources aggregating similar information. The features added in this release of 
ToxRefDB v2 support ongoing efforts to use these data to train predictive models and also to evaluate the 
reproducibility and variability in existing animal-based approaches for safety testing used for model 
training and performance evaluation. The MySQL database and all associated summary flat files are 
available at ftp://newftp.epa.gov/comptox/High_Throughput_Screening_Data/Animal_Tox_Data/current/. 
Further documentation, code, and examples are available at https://github.com/USEPA/CompTox-
ToxRefDB. 
Summary 
Toxicity Reference Database (ToxRefDB) underwent significant updates to extract more 
information from animal toxicity studies, ensure quality, and support interoperability. Of the updates, the 
most relevant to the overall theme of this dissertation is the establishment of a controlled vocabulary (CV) 
for reporting of adverse events as well as mapping the CV to Unified Medical Language Systems (UMLS), 
a semantic network comprised of over 150 biomedical vocabularies. The mappings support 
interoperability by exposing a point of integration with any resource that also maps to UMLS; e.g., 
outcomes related to cancer can be rapidly identified and connected to other information related to those 
outcomes, such as articles in PubMed labeled with relevant Medical Subject Heading terms (MeSH). 
ToxRefDB can now be included in data integration pipelines to make use of animal toxicity studies in new 






With increasing global interest in utilizing new approach methodologies (NAMs) (6,7,224)  for 
rapid screening and prioritization of chemicals for safety applications(37), agencies including the US 
Environmental Protection Agency (USEPA), the US Food and Drug Administration (FDA), the National 
Intitules of Environmental Health Sciences (NIEHS), Health Canada, the European Chemicals Agency 
(ECHA), the European Food Safety Authority (EFSA), and many others (225) are actively generating and 
aggregating data to support the development of computational models to predict adverse outcomes 
(AOs). Among these efforts are USEPA’s Toxicity Forecaster (ToxCast) program (8,11) that has produced 
in vitro toxicity information on over 3,000 chemicals and 400 gene targets. The resulting information from 
these efforts has been used to develop a number of computational models. However, adoption by 
regulators has been slow with questions about the relevance of mechanistic data within the context of 
human-related AOs like cancer both due to lack of clear links between mechanisms and AOs as well as 
relevant biological coverage. The work in this publication seeks to address the questions on the biological 
coverage of ToxCast assay information for specific AOs using a computational approach, rather than an 
expert-driven approach, to better understand the challenges in using the information for chemical safety 
applications. The result is a demonstration of a new computational approach that is relatable to any AO.   
Currently, only the ToxCast estrogen receptor model (23) has been adopted for regulatory 
applications; However, an androgen receptor model (21) and steroidogenesis model (22) are also being 
considered for use in screening chemicals as part of the Endocrine Disruptor Screening Program (EDSP). 
Chemical-mediated endocrine disruption has been well-characterized mechanistically with clear links 
between exposures and human-relevant AOs (226,227). For example, exposure to diethylstilbestrol 
(DES), which is a xenoestrogen, has been linked to breast cancer as well a number of other AOs from in 
CHAPTER 4: EVALUATING THE CANCER- RELATED BIOLOGICAL COVERAGE OF 
TOXICITY FORECASTER (TOXCAST): IDENTIFICATION OF KNOWLEDGE GAPS AND 
IMPLICATIONS FOR CHEMICAL SCREENING 
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utero exposure (114). However, other human-relevant AOs are complex without clear links between 
chemical exposures and a resulting phenotype as is the case for many types of cancer (228) and 
metabolic disorders (229). Also, many environmental chemicals do not have well defined targets (12), so 
establishing clear links between exposure and outcome can be difficult. Both promiscuous bioactivity of 
chemicals and lack of concordant responses between in vitro and in vivo studies is evident in attempts at 
building computational models for complex AOs like reproductive (173) or developmental (27) toxicity, 
hepatotoxicity (24), and even cancer (25). From these models, despite being considered successful, 
questions remain about why some in vitro targets would be predictive for the corresponding AO. 
Findings from both Cox et al. (2016) (85) and Becker et al. (2017) (89) echo these concerns and 
propose that a “more rigorous mode-of-action pathway-based framework to organize, evaluate, and 
integrate mechanistic evidence with animal toxicity”(89) is needed. This approach aligns with the Adverse 
Outcome Pathway (AOP) framework that can be used to organize relevant biological events across levels 
of biological organization(70). The typical structure of an AOP begins with an upstream molecular 
initiating event (MIE), in which a chemical interacts with a biological molecule. An MIE is then connected 
to a series of downstream key events (KE) by key event relationships (KER) that contains evidence 
showing a progression from one KE to the next. Finally, the AOP ends with an adverse outcome (AO), 
which is a phenotype that is of toxicological importance.  
The interest in establishing AOPs for regulatory use is to not only organize existing toxicity data 
but also to serve as a screening and prioritization approach. For example, if evidence links a data-poor 
chemical (i.e. no animal toxicity data is available) to early KEs within an established AOP, then 
assumptions can be made about the hazard potential based on the evidence along an already 
established AOP. The major challenge in developing AOPs is identifying and filling gaps of information. 
Current approaches in toxicity testing capture information at either end of the AOP, (i.e. MIE to early KE 
or only the AO). For example, ToxCast provides information about chemical-biological interactions 
predominantly within the cell. The next steps would be to extrapolate from those bioactivities to tissue 
level effects like hypertrophy or some other lesion that would be measurable in vivo. However, this is 
difficult since current approaches to capture toxicity information at higher levels of biological organization 
are low throughput and costly. Assays targeting this level of organization are rapidly under 
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development(49), but still remain medium to low throughput with applications as a validation component 
in a tiered screening approach rather than data generation as is the case for high throughput approaches. 
Toxicity data generated at the AO are from animal toxicity studies, which are low throughput, but a 
massive amount of animal toxicity data exists within publications and regulatory documents. Thus, 
USEPA’s Toxicity Reference Database (ToxRefDB)(13) serves to aggregate animal toxicity data into a 
digital repository to support development of computational models.  
ToxRefDB aggregates animal toxicity information for over 1,000 chemicals that are mostly 
pesticides. The information is primarily from registrant submitted studies to USEPA’s Office of Pesticides 
Programs (OPP) and has been extracted from the summary reports called data evaluation records 
(DERs). The information available in ToxRefDB are effects measured in vivo that would be considered 
complex AOs within the context of an AOP.  
The previous attempts to link in vitro and in vivo effects using ToxCast and ToxRefDB 
respectively have primarily consisted of identifying activities for the same chemical across these two 
domains(25), yet we understand the limitations of such an analysis: it is unclear if observed concordance 
is due to the same mechanism(s) operating in vitro and in vivo, and conversely, it is unclear if lack of 
observed concordance is due to lack of biological or mechanistic coverage, e.g. aspects of absorption, 
distribution, metabolism, and excretion, or other aspects of the in vitro screening approach. Additionally, 
there are known factors that contribute to uncertainty in interpretation of the in vitro and in vivo data and 
increase the chances for discordant results, including: compensatory mechanisms in vivo akin to the 
“tipping points” investigated for in vitro effects(50), high-throughput screening assay technology domains 
of applicability(1,23,67,230,231), and in vivo study-level design features like strain used, dose selection, 
etc.(178,232). Thus, a biological connection between the in vitro and in vivo resources is needed to 
understand if more assays or screening information would improve predictions for complex AOs (86,89).  
The complex AO we focus on in this work is cancer. Cancer is a multifactorial adverse outcome 
where susceptibility is influenced by lifestyle, genetic variants, and chemical exposures. Identification of 
chemical carcinogens is predominantly based on available human and animal data that associates 
exposure of a chemical with cancer (233). Human and animal data can be stronger when chemical 
modes of action (MOA) tie the link between exposure and outcome together as is the case for DNA 
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adduct formation in nasal mucosa from inhaled formaldehyde that leads to increased risk of 
nasopharyngeal cancer(234). However, associations are not always so clear as exemplified with 
formaldehyde exposures and links to leukemia. Despite being classified as carcinogenic to humans 
(Group 1) by International Agency for Research on Cancer (IARC)(228), links between formaldehyde 
exposure and leukemia are abundant from epidemiological studies(235), but mechanistic links are still 
being investigated. Currently mechanistic data is being used to more rapidly identify carcinogenicity of a 
chemical by binning ToxCast assays into Ten Key Characteristics of Carcinogens (TKCC) (86–88) and 
subsequently evaluating total bioactivity observed in each of those assays for a given chemical. However, 
this use of chemical-centric data serves to identify carcinogens with more direct links between exposure 
and outcome and not those with an unknown number of chained events that culminate in a measurable in 
vivo effect(5,236). With the example of formaldehyde exposures and leukemia, if critical events leading to 
leukemia can be identified, indirect links between the known formaldehyde mechanisms and leukemia 
could be made. Here we present a data integration approach to evaluate the biological coverage of 
ToxCast for cancer by identifying putative upstream KEs from cancer thus bridging the gap between in 
vitro and in vivo data. In evaluating the biological coverage of ToxCast for cancer, we can further identify 
the potential utility of this data in further building predictive models. 
The work presented here extends previous work from Watford et al. (32) and Grashow et al. (90) 
where a putative gene set for breast cancer was retrieved from a resource called Entity MeSH Co-
occurrence Network (EMCON). EMCON is built using biomedical literature and contains links between 
Entrez gene identifiers (GeneIDs)(102) and Medical Subject Headings (MeSH terms) (131). MeSH terms 
are keywords used to index articles within PubMed, the largest publicly available resource of biomedical 
literature. The genes retrieved from searching EMCON serve as a point of integration to link in vitro 
targets either directly to a corresponding search concept or indirectly through other concepts like 
pathways. We construct two search strategies to build queries to retrieve gene sets from EMCON. The 
first strategy is similar to that described in Watford et al. (32) where cancer concepts (CCs) like evading 
apoptosis were identified from seminal publications (88,118,147,148). A second search strategy is used 
in this approach that directly utilizes the cross-referenced observed toxicity effects from ToxRefDB. The 
observed toxicity effects were cross-referenced to Unified Medical Language System (UMLS), which is a 
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semantic network of over 150 biomedical terminologies(78). MeSH is one of those terminologies thus we 
can identify MeSH terms for each ToxRefDB observed toxicity effect. We identify the cancer-related 
effects and corresponding MeSH terms from ToxRefDB stratified by organ (i.e. liver cancer effects) that 
serve as queries for EMCON. The resulting gene sets are validated using an online tool called Enrichr(95) 
that performs gene set enrichment analysis (GSEA) (91). GSEA identifies topics from reference libraries 
that have significantly overlapping gene sets. Four reference libraries were chosen to validate the cancer-
related gene sets retrieved in this work: Gene Ontology (GO) biological process(237,238), GO molecular 
function(237,238), Reactome(138,239), and Kyoto Encyclopedia of Genes and Genomes (KEGG)(105–
107). With gene sets retrieved and validated for CCs, we can elucidate ToxCast coverage across CCs as 
well as highlight gaps in the coverage by quantifying the gene overlap (direct association) as well the 
topic overlap (indirect association) from the four reference libraries.  
Our analysis aims to estimate the biological coverage of ToxCast for cancer, addressing 
limitations in current knowledge about indirect links between chemical mechanisms and in vivo adverse 
outcomes. Some of the key conclusions of this research include a greater understanding of why ToxCast 
may currently be inadequate for unsupervised prediction of cancer on the basis of biological coverage, 
and the identification of gene sets for specific cancer-related effects observed in a rich database that may 
have forward utility in feature selection for models that use transcriptomic data to predict cancer. 
Ultimately, this work suggests that a combination of unsupervised and expert approaches may be needed 
to use the current data resource for prediction of possible cancer-related outcomes. 
 
Methods 
Overview of approach 
In this work, gene sets linked to cancer concepts (CCs) are retrieved from Entity MeSH Co-
occurrence Network (EMCON) through two search strategies (Figure 4.1A): one using an expert driven 
approach to identify CCs and a second using cancer-related observed effects from ToxRefDB. The 
resulting gene sets are validated (Figure 4.1B) and subsequently used to estimate the biological coverage 
of ToxCast for cancer (Figure 4.1C). 
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For search strategy #1 CCs are identified by experts along with corresponding seed MeSH terms. 
This approach is similar to that described in Watford et al(32) for identification of a breast cancer-related 
gene set, but instead of using the MeSH tree for expanding the MeSH term selection, a MeSH co-
occurrence network is used. A MeSH co-occurrence is any two MeSH terms that have been tagged to the 
same article(167,240). Figure 4.2 shows the workflow for building the MeSH co-occurrence network and 
is further described in the following section. The seed MeSH terms are used to query the MeSH co-
occurrence network and retrieve all other relevant MeSH terms for a CC. For search strategy #2, cancer-
related observed effects were identified from Toxicity Reference Database (ToxRefDB). The effects in 
ToxRefDB are cross-referenced to Unified Medical Language System (UMLS) concepts from which 
relevant MeSH terms can also be identified(13). This initial MeSH term selection was not expanded in this 
strategy because the effects were grouped together at the organ level. For example, effects like 
“hepatocelluar carcinoma” and “hepatocellular adenoma” are grouped together under “liver cancer”. Next, 
for both search strategies, the full set of MeSH terms are used to query EMCON and retrieve a single 
gene set per concept (e.g. “Angiogenesis” or “Liver cancer”). Each search strategy applies a separate set 
of filters (further described in following sections) to identify only the relevant genes. Next the gene sets 
were validated (Figure 4.1B) by manually assessing the relevance of enriched topics for a corresponding 
CC using a gene set enrichment tool called Enrichr (95). Finally, the cancer-related biological coverage of 
ToxCast was evaluated by quantifying the ToxCast assay endpoint gene target overlap with five different 
datasets (Figure 4.1C): CC gene sets, Reactome pathways, KEGG pathways, GO biological processes, 




Figure 4.1: Overall approach for identifying cancer-related gene sets to estimate biological 
coverage of ToxCast for cancer 
(A) First, two search strategies are used to identify cancer concepts (CCs) used to query EMCON. Search 
strategy #1 employs an expert-driven approach to identify seed MeSH terms that correspond to CCs and 
then undergo MeSH term expansion using a MeSH co-occurrence network. Search strategy #2 uses the 
organ-level, cancer-related observed effects identified from ToxRefDB where corresponding MeSH terms 
were retrieved from the UMLS metathesaurus. The queries from both search strategies comprise MeSH 
terms that are used to retrieve a gene set for each CC from EMCON. (B) Next, the resulting gene sets are 
validated using an online tool called Enrichr that was used to perform GSEA with four reference libraries. 
(C) Finally, ToxCast biological coverage was quantified as percent overlap with the CC-derived gene sets 
as well as with the enriched topics for each CC from Enrichr. 
 
Building the MeSH co-occurrence network 
A previous limitation of identifying gene sets using EMCON was expanding the MeSH term 
selection using the MeSH tree (32). Although the MeSH tree implies a relationship between parent and 
child MeSH terms, that relationship is not necessarily reflected in the article tagging. For example, the 
MeSH term “Diabetes Mellitus, Type 2” is closely related to the MeSH term “Insulin resistance” because 
insulin resistance is a key phenotype in type 2 diabetes (241), yet many “Insulin resistance” and 
“Diabetes Mellitus Type 2” do not belong to any of the same branches within the MeSH hierarchical tree. 
To account for this limitation, a MeSH co-occurrence network was built and used to expand the MeSH 
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term selection. A MeSH co-occurrence is any two MeSH terms that are tagged to the same article 
(167,242). The MeSH co-occurrence network was built using the 2017 Medline Baseline Repository 
(MBR) raw data files, specifically the file named “MH_items” (243). This file provides a snapshot of MeSH 
term to PMID mappings (Figure 4.2) from 2016 and is updated annually. This distribution is used because 
it provides only the identifiers we need to build the MeSH co-occurrence network. Next, MeSH term 
frequencies were normalized according to the MeSH tree by tagging all ancestors to articles that are 
tagged with their descendants (Figure 4.2). This ensures that the tagging frequency increases while 
traversing the MeSH tree towards a root MeSH term and that broader MeSH terms have higher 
frequencies than their more specific descendants. This normalization was previously described in Watford 
et al. (32). Next, each co-occurrence is identified by taking every two combinations of MeSH terms for an 
article and keeping only the MeSH co-occurrences that have more than 2 articles to support the 
association. Finally, the MeSH co-occurrences are ranked using normalized pointwise mutual information 
(NPMI), which is the normalized variant of pointwise mutual information that ranks association on a -1 to 1 
scale(143). NPMI values of zero or less indicate an association that may have occurred by chance, and 
NPMI values of greater than zero indicate increasing strength of the association as NPMI approaches 1. 






Figure 4.2: Building the MeSH co-occurrence network 
The MeSH co-occurrence network was built by first normalizing the MeSH term frequency so that the 
frequency of each MeSH term is proportional to the number of descendants the MeSH term has 
according to the MeSH term tree. Next MeSH co-occurrences were identified. A MeSH term co-
occurrence is any two MeSH terms that have been annotated to the same article. Finally, MeSH term co-
occurrences were ranked using normalized pointwise mutual information (NPMI). Any MeSH term co-
occurrences with NPMI < 0 were excluded from the final network. 
 
Selecting carcinogenesis concepts and corresponding MeSH terms 
Cancer concepts (CCs) and the corresponding MeSH terms were identified from previous work to 
identify a breast cancer gene set(90). CCs are defined as critical processes that characterize the 
pathogenesis of cancer and were identified from seminal publications that investigate cancer 
(88,118,147,148). For this work, the topic of mammary tissue was excluded as the CCs of interest are not 
limited to specific breast cancer-related mechanisms. MeSH terms are needed to retrieve gene sets from 
EMCON, so corresponding MeSH terms were selected that best represent each CC (Table 4.1). These 
MeSH terms alone do not fully represent the CC, but rather serves as a seed MeSH term to retrieve all 
closely-associated MeSH terms. The MeSH co-occurrence network was queried with the seed MeSH 
terms to retrieve a comprehensive set of MeSH terms that characterize the CC. Finally, only MeSH terms 





Carcinogenesis Concept MeSH term (DUI, i.e. unique identifier) 
Angiogenesis Neovascularization, Pathologic (D009389) 
Neovascularization, Physiologic (D018919) 
Apoptosis Apoptosis (D017209) 
Cell cycle Cell cycle (D002453) 
Epigenetics Epigenomics (D057890) 
Genotoxicity DNA damage (D004249) 
DNA repair (D004260) 
Growth hormones Growth hormone (D013006) 
Immortalization Cell survival (D002470) 
Immunomodulation Immune system (D007107) 
Inflammation Inflammation (D007249) 
Oxidative stress Oxidative stress (D018384) 
Proliferation Cell proliferation (D049109) 
Steroid hormones Gonadal steroid hormones (D012739) 
Xenobiotic metabolism Xenobiotics (D015262) 
Table 4.1: Carcinogenesis concepts and the corresponding MeSH term(s) 
 
ToxRefDB cancer-related effects and corresponding MeSH terms 
Toxicity Reference Database (ToxRefDB) is a digital resource of results from animal toxicity 
studies [25]. ToxRefDB reporting of observations from in vivo studies is structured as a hierarchy, with 
endpoints as a parent category for effects. For example, the endpoint “systemic pathology microscopic 
liver” is the parent for the effect “liver hyperplasia.” Each endpoint and effect has been cross-referenced 
with Unified Medical Language System (UMLS), which is a semantic network of over 150 biomedical 
vocabularies(78). One of the vocabularies maintained in the semantic network is the MeSH vocabulary. 
The MeSH terms for the subset of cancer-related effects and corresponding endpoints were retrieved 
using the UMLS representational state transfer (REST) application programming interface (API)(244). 
Each effect can link to multiple UMLS concept codes, and multiple effects may link to a single endpoint, 
so each endpoint has multiple MeSH terms mapped to it. For example, MeSH terms “Liver”, “Adenoma”, 
“Carcinoma, Hepatocellular”, and others are mapped to the endpoint “systemic microscopic pathology 
liver”. These MeSH terms are used to retrieve gene sets relevant to the endpoint. The cancer-related 
effects and endpoints are available in APPENDIX 2.  
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Gene set retrieval  
To identify putative gene sets for CCs, Entity MeSH Co-occurrence Network (EMCON) was 
queried with the expanded MeSH term selections that were derived from the methods described above. 
EMCON is a co-occurrence network of GeneID-MeSH associations derived from curated biomedical 
literature resources and ranked using NPMI(143). Like the MeSH co-occurrence network, EMCON only 
retains co-occurrences with NPMI > 0. The MeSH term selections were used to query EMCON and 
retrieve associated genes where only the GeneID-MeSH co-occurrences within the 95th percentile of the 
NPMI distribution for the corresponding MeSH term set were kept.  
Validation of gene sets  
To verify that the gene sets for each CC were, in fact, returning relevant genes, gene set 
enrichment analysis (GSEA)(91) was performed to retrieve enriched topics from four different sources 
called reference libraries: Gene Ontology (GO) biological process, GO molecular function, KEGG, and 
Reactome. GSEA is commonly used to analyze genomic and transcriptomic data to interpret the findings 
of the experimental results. Reference libraries are typically built manually by reviewing literature and 
constructing hierarchical relationships between extracted topics. The four reference libraries that were 
chosen to validate the CC gene sets are widely used and are not confined to a specific topic (i.e. confined 
to a cell line like MCF7). GSEA was performed using Enrichr, which is an online tool that performs 
enrichment analysis for a submitted gene set across over 130 reference libraries. Enrichr produces four 
values that indicates enrichment of a topic for a given gene set and reference library. A p-value is given 
as a result of either Fisher’s Exact or hypergeometric mean. An adjusted p-value is also calculated that 
corrects for multiple hypothesis testing. The z-score is the distance away the observed rank is from the 
expected rank. The converted score is the product of the log of the p-value and z-score. In this work, a 
topic was enriched if the adjusted p-value is < 0.05. Each CC gene set was submitted to Enrichr through 
the RESTful API(245). Finally, the relevance of the top five enriched topics to the corresponding CC was 
manually determined by reviewing literature associated with the enriched topic and either cancer or the 




Linking ToxCast assay endpoint targets to cancer concepts 
ToxCast assay endpoints are uniquely identified by an assay endpoint identifier (aeid)(16) and 
cover a wide range of biological concepts with genes identified as the intended targets for most assays. 
Assays that measure general cytotoxicity or a complex process (i.e. proliferation) are not necessarily 
annotated with an intended gene target. ToxCast assays and corresponding genes were downloaded 
from(246). The intended gene targets are used as a point of integration with each CC via the gene set 
retrieved from EMCON. ToxCast can be linked to a CC either by the gene set retrieved from EMCON or 
by the gene set of an enriched topic from Enrichr. The gene sets from each reference library are made 
available for download from Enrichr(247).  
 
Evaluating cancer-related biological coverage of ToxCast 
With gene sets and enriched topics identified for each CC, the biological coverage of ToxCast 
can be evaluated in two approaches (Figure 4.1C): (1) direct coverage via gene overlap with EMCON 
gene sets and (2) indirect coverage via gene overlap with enriched topics. Indirect coverage was included 
because even though ToxCast may not have a target within the retrieved gene set to assess direct 
coverage, ToxCast genes may play a role in the enriched topics that include pathways and biological 
processes related to the CC, which implies the assay endpoint may still be relevant to a CC. Direct 
coverage was quantified as the percent overlap with the gene set for each CC. Indirect coverage was 
quantified as the percent overlap with the enriched topics for each CC. Because reference libraries 
arrange topics hierarchically, gene sets are either supersets or subsets of each other. For example, the 
pathway “Estrogen-dependent gene expression”(248) has the parent “ESR mediated signaling”(249), so 
the gene set for “Estrogen-dependent gene expression” is a superset of the “ESR mediated signaling” 
gene set because each gene of the child’s gene set is present in the parent’s gene set. The consequence 
of this pattern in quantifying coverage is bias for enriched topics from a single branch because each 
member of the branch would be mapped to the same CC and ToxCast assay endpoint gene targets 
resulting in duplicative associations. To avoid this bias, enriched topics were only kept if the gene set was 
not a superset of any other gene set within their respective reference library. Finally, ToxCast is only 
considered to overlap with an enriched topic if at least five ToxCast intended gene targets overlap with 
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the enriched topic’s gene set. This threshold is called the membership cutoff. The reasoning for the cutoff 
is addressed in the results. 
Results 
MeSH co-occurrence network 
The MeSH co-occurrence network has over 76.5 million unique co-occurrences with 61% having 
more than two articles supporting the co-occurrence and 26% having an NPMI > 0.0. When applying both 
filters, the network is reduced by 83% with 13 million unique MeSH co-occurrences remaining.  
 
Cancer-related gene sets 
For search strategy #1, 13 CCs were identified along with corresponding seed MeSH terms 
(Table 4.2). For search strategy #2, 34 organ-level endpoints were identified to have cancer-related 
effects. However, many of the endpoints had extremely poor coverage with ToxCast. Liver had the most 
coverage and is the only cancer-related endpoint from ToxRefDB in the figures and tables. A summary of 
the remaining 33 organ-level and cancer-related gene sets along with the ToxCast overlap is available in 
APPENDIX 3.  
The number of MeSH terms retrieved from the MeSH co-occurrence network for each CC varied 
widely with a minimum of 2 for “Immunomodulation” to a maximum of 70 for “Oxidative Stress” (Table 
4.2). The number of genes returned for each CC also varied and is not correlated with the number of 
MeSH terms used for the query (rank correlation-coefficient 0.372).  
The NPMI distributions for both the MeSH-MeSH and GeneID-MeSH co-occurrences for all CCs 
are shaped differently. Figure 4.3 shows these distributions for the “Immunomodulation” (Figure 4.3A) and 
“Angiogenesis” (Figure 4.3B) CCs. Only 37 genes are retrieved for the “Immunomodulation” gene set 
(Figure 4.3A) while 313 genes are retrieved for the “Angiogenesis” gene set. Both MeSH-MeSH and 
GeneID-MeSH NPMI distributions for “Angiogenesis” are shifted towards zero which means many of the 
co-occurrences for “Angiogenesis” have less supporting (either as number of articles or promiscuously 







Cancer concept Number of associated 
MeSH terms 
Number of associated 
genes 
#1 Angiogenesis 30 313 
Apoptosis 29 2025 
Cell cycle 7 711 
Epigenetics 11 221 
Genotoxicity 37 907 
Growth hormones 39 195 
Immortalization 7 825 
Immunomodulation 2 37 
Inflammation 20 467 
Oxidative stress 70 2511 
Proliferation 61 3623 
Steroid hormones 41 212 
Xenobiotic metabolism 35 336 
#2 Liver cancer (ToxRefDB) 16 478 
Table 4.2: The number of MeSH terms used to query EMCON and the total number of genes 




Figure 4.3: Filtering gene sets for cancer concepts “Immunomodulation” and “Angiogenesis” 
The GeneID-MeSH NPMI distributions and 95th percentile cutoffs are shown in black, while the MeSH-
MeSH NPMI distributions and 95th percentile cutoffs are shown in red. Each point represents two MeSH 
terms and a GeneID, along with the corresponding NPMI values. The points in blue represent 
associations that are filtered out because they fall below the 95th percentile cutoffs, while the points in 
orange represent associations that are used to identify relevant GeneIDs for a final gene set. (A)  For the 
CC “Immunomodulation”, only 37 GeneIDs are above the cutoffs. (B) For the CC “Angiogenesis”, 313 




Validating gene sets 
  The gene sets were validated by calculating precision for the top five enriched topics from four 
reference libraries: GO biological process, GO Molecular Function, KEGG, and Reactome. The enriched 
topics from each reference library were identified using Enrichr’s REST API(245). The relevance of an 
enriched concept to a CC was determined by reviewing abstracts retrieved from a PubMed or related 
search. For example, for the CC “Epigenetics” and enriched concept from GO biological process 
“chromatin assembly”, PubMed was searched with the query "epigenetics and chromatin assembly" which 
returns nearly 800 articles. Many of these articles not only link the CC and enriched concept, but also link 
both topics to cancer (250,251). The overall precision score is 0.975. “Growth hormones” had the lowest 
precision of any CC at 0.9 (Table 4.3). APPENDIX 4 provides the relevance decisions made for each 
enriched topic. 
 




KEGG Reactome Average 
Precision 
Proliferation 1.0 1.0 1.0 1.0 1.00 
Angiogenesis 1.0 1.0 1.0 1.0 1.00 
Oxidative Stress 1.0 1.0 1.0 1.0 1.00 
Apoptosis 1.0 1.0 1.0 1.0 1.00 
Genotoxicity 1.0 1.0 1.0 0.8 0.95 
Immortalization 1.0 1.0 0.8 1.0 0.95 
Cell Cycle 1.0 1.0 1.0 1.0 1.00 
Xenobiotic Metabolism 1.0 1.0 1.0 1.0 1.00 
Inflammation 1.0 0.8 1.0 1.0 0.95 
Epigenetics 1.0 1.0 1.0 1.0 1.00 
Steroid Hormones 1.0 0.8 1.0 1.0 0.95 
Growth Hormones 1.0 1.0 0.8 0.8 0.90 
Immunomodulation 1.0 1.0 1.0 1.0 1.00 
Liver Cancer (ToxRefDB) 1.0 1.0 1.0 1.0 1.00 
Overall precision 0.975 
Table 4.3: Precision of enriched topics retrieved from each reference library for each CC 
 
Estimating ToxCast biological coverage of cancer 
A gene set was retrieved from EMCON for each CC and validated using Enrichr to retrieve a set 
of enriched topics from four reference libraries. ToxCast biological coverage is quantified as percent 
overlap with the gene set for each CC and the percent enriched topics with overlapping genes greater 
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than the membership cutoff. The membership cutoff of four is approximately the 95th percentile for each 
reference library as indicated by the black dashed line in Figure 4.4A. With a membership cutoff of 0 (at 
least 1 gene is present in the enriched topic’s gene set), the average percent coverage from the four 
reference libraries would be 65% with KEGG having the highest percent coverage of 82%.  
As shown in Figure 4.4B, the gene set overlap alone is low with a mean coverage of 6%, but 
when expanded for enriched topics and at a membership cutoff of 4, the coverage increases to an 
average of 32%. No ToxCast intended gene targets overlap with the “Epigenetics” gene set, but they 
overlap with enriched topics from all four reference libraries. The genes in the “Epigenetics” gene set 
account for protein-coding genes for histone modifications and DNA methylation, which were not 
considered in selection of ToxCast targets. ToxCast targets were selected by both availability of assay 
technologies as well as targeting endocrine disruption and metabolic activity. ToxCast has the highest 
coverage from KEGG for each CC; however, this may be misleading because KEGG has the lowest 
number of topics at 278 as well as the largest gene sets per topic at an average of 80.6 (Table 4.4).  
For this approach, no other aspects are considered like assay technology or cell line, which 
means the average cancer-related biological coverage with a membership cutoff of 4 is 32% is the 
maximum coverage that will only decrease as other parameters are considered. Because of this, the 
biological coverage is considered low and insufficient for the CCs identified which also includes all organ-
level effects from ToxRefDB. The enriched topics with the most overlapping genes from each reference 
library are in Table 4.5. The enriched topic with the highest percent coverage is “Nuclear Receptor 






Figure 4.4: The ToxCast coverage for cancer-related gene sets and enriched topics from four gene 
set reference libraries 
(A) Shown is the average percent coverage across all CCs for each reference library as the membership 
cutoff increases. The black dashed line is the membership cutoff of 4 genes and is approximately the 95th 
percentile for each reference library. (B) Also, shown in this figure is the percent of the ToxCast intended 
gene targets that overlap with the gene sets per CC and the percent of enriched topics identified using 
Enrichr from four reference libraries: GO biological process, GO molecular function, KEGG, and 
Reactome. 
 
Reference library Number of topics Mean gene set length per topic 
GO biological process 3076 23.3 
GO molecular function 697 23.5 
Reactome 699 23.7 
KEGG 278 80.6 





Reference library Enriched topic (identifier) ToxCast genes 
present in 
gene set 
Total number of 
genes in gene set 
KEGG Neuroactive ligand-receptor 
interaction (hsa04080) 
71 277 




GO Molecular Function RNA polymerase II core promoter 
proximal region sequence-specific 
DNA binding (GO:0000978) 
35 263 
Reactome Nuclear Receptor transcription 
pathway (R-HSA-383280) 
47 51 
Table 4.5: Enriched topics with the highest number of ToxCast genes present in gene set 
 
Discussion 
In this work, we presented novel methods 1) to identify gene sets linked to cancer concepts (CCs) 
and specifically to cancer-related animal toxicity endpoints from ToxRefDB and 2) to estimate the cancer-
related biological coverage of ToxCast. The goal was to understand if unsupervised approaches could be 
used to relate ToxCast information to prediction of cancer. Two search strategies were implemented to 
identify cancer-related gene sets. The first approach, search strategy #1, is an expert driven approach 
where seed MeSH terms were selected that best represent a concept of interest (e.g. evading apoptosis). 
Next, the seed MeSH terms were used to query the MeSH co-occurrence network to retrieve closely 
associated MeSH terms that serve as the full query for EMCON and retrieve gene sets relevant to the 
CCs. The second approach, search strategy #2, uses the UMLS cross-references to cancer-related 
animal toxicity endpoints from ToxRefDB to identify relevant MeSH terms to query EMCON and retrieve 
corresponding gene sets. Gene set enrichment analysis (GSEA) was performed on each gene set using 
Enrichr to identify enriched topics from four reference libraries: GO biological process, GO molecular 
function, KEGG, and Reactome. Precision was calculated by manually determining the relevance of the 
top five enriched topics from each reference library and CC. The precision was 0.975 with only seven of 
280 associations not directly relevant. Finally, the biological coverage of ToxCast for each CC was 
estimated directly by ToxCast intended gene target overlap with each CC gene set and indirectly by 
percent enriched topics with at least five ToxCast intended gene targets overlapping with each enriched 
topic’s gene set. The average direct coverage across each CC is only 6% while the average indirect 
coverage across each CC is 32%, which is considered a maximum coverage that will decrease when 
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considering other parameters like membership cutoff. Because of these dependencies, the cancer-related 
biological coverage of ToxCast is consider poor, implying the use of ToxCast for unsupervised prediction 
of cancer is limited. However, the unsupervised approaches here to identify ToxCast data that may be 
relevant to prediction of cancer could be reviewed by experts in support of weight-of-evidence analysis for 
carcinogenesis. 
Co-occurrence networks are used to represent knowledge in datasets whether it’s from social 
media (252), language (253), or biomedical concepts (42,167,254) that can subsequently be used to 
support information retrieval, analytics, and predictive modeling like link prediction for knowledge 
discovery, i.e. identify future associations. In this work, two co-occurrence networks, MeSH co-
occurrences and MeSH-GeneID co-occurrences (EMCON), were used to retrieve cancer-related gene 
sets. Related efforts have been previously used to identify gene sets from co-occurrence networks like 
that from Gene2MeSH (164) and MeSH Overrepresentation Profiles (MeSHOPs) (165), but combining 
this information with MeSH co-occurrences has not been done before. This approach yields a high 
precision of 0.975 of the enriched topics from GSEA indicating that relevant genes to each CC, including 
the cancer-related ToxRefDB observed effects, are retrieved. The success of this approach supports the 
notion that our current methodologies can be improved upon with integrating more data for richer 
datasets, yet complexity in managing and analyzing this information increases exponentially (42,51). One 
of the major challenges in this approach was properly managing numerous external resources (i.e. 
PubMed and resources supporting EMCON) in a single infrastructure to support the analysis. Further 
work could incorporate many other entities (e.g. pathways, chemicals, proteins, and experimental results), 
but, without both a standard data model (255–257) and a modern technology stack to support the 
increased complexity, this approach becomes chaotic. Also, EMCON maintains the limitations previously 
described in Watford et al. (2018) (32): EMCON is built using only manually curated biomedical 
resources. EMCON contains information from nearly 700K PubMed articles, but much more information 
about genes remains in articles that have yet to be curated.  
The number of associated MeSH terms retrieved from the MeSH co-occurrence network was not 
correlated with the number of genes retrieved from EMCON as indicated by the rank correlation 
coefficient of 0.372. Other factors that may contribute to the number of MeSH terms or genes retrieved is 
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the number of descendants a MeSH term has according to the MeSH hierarchical tree. For example, the 
CC with the fewest number of genes is “Immunomodulation” with only 37 genes. The seed term used to 
represent “Immunomodulation” is “Immune System”, which has 69 descendants. Immune system function 
is a broad topic that plays a role is nearly all aspects of biology and is related to many of the other CCs 
used in this approach like “Oxidative stress”, which has only 2 descendants, and “Apoptosis”, which has 
only 3 descendants. Though this approach improved upon the original expert-driven search strategy from 
initial implementation of EMCON for breast cancer research (32,90), limitations remain in selection of the 
MeSH terms that are most relevant. 
Gene set enrichment analysis (GSEA) was performed by Enrichr to validate that the cancer- 
related genes, were, in fact, being identified from EMCON. GSEA relies on reference libraries of gene 
sets that are specific to a topic. Of the four reference libraries used in this approach, only two, Reactome 
and KEGG, arrange the gene sets according to the relationships between genes or provide pathway 
diagrams. Both GO reference libraries are a collection of annotations from GO consortium participants. 
Each reference library varied by the number of topics as well as the average gene set length per topic. 
KEGG varied the most with the lowest number of lowest-level (determined by gene set subsets) topics at 
278 and the highest average gene set length at 80.6. Reference library selection is crucial in interpreting 
GSEA results (258) as exemplified in the contrasting results in Figure 4.4B. Without comparison to other 
reference libraries, we might have concluded that ToxCast cancer-related biological coverage is sufficient 
for building predictive models in cancer from KEGG alone. However, when identifying the KEGG enriched 
topic with the most overlapping ToxCast intended gene targets (Neuroactive ligand-receptor interaction), 
we find that it is a non-specific topic of 277 genes that wouldn’t necessarily be useful in interpreting 
results from a predictive model. Both GO reference libraries show similar results. In contrast, the 
Reactome enriched topic with the most overlapping ToxCast intended gene targets (Nuclear Receptor 
transcription pathway) is well characterized with only 51 genes. However, this includes estrogen receptor 
and androgen receptor activity, which is already the primary use case in building predictive models using 
ToxCast (21,23). These models comprise multiple assays but only account for two genes each (ER model 
(23): ESR1 and ESR2, AR model (21): AR and SRC). All genes except for SRC are present in 
Reactome’s “Nuclear Receptor transcription pathway”, although, SRC-mediated interactions are 
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mentioned in the description of a reaction in the pathway (259). Because ToxCast intended gene targets 
cover many other genes involved with the “Nuclear Receptor transcription pathway”, a more 
comprehensive computational network model combining both existing ER and AR models could be 
developed to include more reactions that are downstream KEs for endocrine disruption AOs. Both KEGG 
and Reactome would be great sources to look further into for applicability of building computational 
network models similar to the AR and ER models because the genes are arranged in a pathway with 
evidence linking each reaction together similar to linking KEs. This would require manual review of the 
enriched topics and expert knowledge on the ToxCast assay technologies to determine relevance, and 
each enriched topic has been linked to cancer with supporting evidence from EMCON. This approach can 
be expanded to include other topics besides cancer.  
Despite possible applications to further utilize ToxCast for building predictive models for cancer 
mentioned above, the overall cancer-related biological coverage of ToxCast is considered poor. This 
conclusion was made primarily on the average percent coverage across each CC and reference libraries, 
which was 32% despite having higher coverage when lowering the membership cutoff (Figure 4.4A). 
Cancer, along with the cancer concepts selected in this work, is a broad topic that involves complex 
biological interactions across nearly all known domains of biology. The ToxCast assays comprise 
chemical bioactivity information on over 350 gene targets, but account for numerous cell types, species, 
and technologies limiting the applicability to few domains. Ongoing efforts to generate a dose-response 
high throughput transcriptomics (HTTr) information(33,128,129) will eliminate some parameters because 
the technology will be consistent as well eliminate questions on relevant biological coverage by evaluating 
the whole genome. However, questions still remain on how to analyze dose-response transcriptomic data 
linking the changes in gene expression to adverse outcomes (i.e. linking genotype to phenotype) (112).  
The approach in this work has myriad applications in computational toxicology including 
information retrieval and organization for systematic review(260), putative linkage of key events (KEs) to 
fill knowledge gaps in existing Adverse Outcome Pathways(261), and analysis of high throughput 
transcriptomics (HTTr) or gene expression profiling results(33,128,129). Identifying gene sets specific to a 
concept allows for linking other topics like pathways to that concept as well. This provides a way to 
organize available information to aid in manual review process like that of annotating ToxCast assays or 
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identifying linked information for a systematic review. Traditional pathway analysis of gene expression 
results relies on GSEA. Finally, the methods presented here allow for retrieval of gene sets relevant to 




Chapter 2 introduced a resource called EMCON created using a data integration pipeline that 
links genes to any topic in literature. Chapter 3 highlights a major update to ToxRefDB that exposes a 
point of integration so that the resource can be included in data integration pipelines. The work presented 
in this chapter utilized work from both chapters to investigate the biological coverage of ToxCast 
specifically for cancer. Two approaches were taken to link ToxCast gene targets to cancer or cancer 
processes. The first queries EMCON to retrieve genes linked to important processes in cancer, which are 
then subsequently linked to the ToxCat genes. The second approach identifies organ-specific cancer 
genes by integrating ToxRefDB. Both direct and indirect methods were used to calculate biological 
coverage. The direct method quantifies the number of ToxCast genes are linked to each cancer process 
or organ-specific cancer observed from ToxRefDB. The indirect method incorporates pathways and 
processes from other resources like Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes 
(KEGG) and Reactome. The indirect biological coverage is calculated as the number of pathways or 
processes that are linked to both ToxCast gene targets and corresponding cancer processes. According 
to direct biological coverage, ToxCast is relevant to most of the cancer processes identified in this work 
except for epigenetics. The indirect coverage shows higher biological coverage indicating that ToxCast 
has relevant biological coverage for all cancer processes. Despite having relevant biological coverage for 
cancer using this method, more work is needed to understand the implications of the links identified in this 
work. Manual curation of ToxCast is needed like that from the International Agency for Research on 
Cancer (IARC), but the data integration strategy here can aid in identifying relevant information to 
manually review. More work to understand etiologies of complex disease and the influence of 
environmental chemical exposures is needed in order to answer questions about the necessary biological 





Interest in the development and use of NAMs for chemical safety evaluation will continue to grow 
as new technologies become available for massive data generation. The employment of this information 
in regulatory applications is still being considered as progress is made in building robust computational 
models. A prominent challenge exists in linking in vitro bioactivities to adverse outcomes (AOs) of interest. 
To understand the current data landscape and identify gaps in knowledge, legacy data as well as newly 
generated data must be able to be integrated. Thus, efforts to support interoperability across different 
information systems must be prioritized. The work outlined in this dissertation described methods for 
increasing data interoperability so resources can be combined in data integration and analysis pipelines 
as a new approach to investigate obstacles in toxicology.  
First, in Chapter 2, a resource called Entity MeSH Co-occurrence Network (EMCON) that links 
genes to any topic in literature was created from information manually extracted from literature. The utility 
of EMCON was demonstrated by identifying genes linked to breast cancer and shown to retrieve relevant 
genes to the topic of interest, namely breast cancer. Second, in Chapter 3, Toxicity Reference Database 
(ToxRefDB) was extensively updated to increase the richness of the data provided and to ensure quality 
and support interoperability. A controlled vocabulary (CV) was established for the reporting of adverse 
events observed in animal toxicity studies. The CV was mapped to Unified Medical Language System 
(UMLS), a semantic network of over 150 biomedical vocabularies that allows for easy integration with 
other resources that are also mapped to UMLS or any of the contained vocabularies. Finally, in Chapter 
4, the work from the previous two chapters was utilized to investigate the biological coverage of ToxCast 
for cancer. ToxCast is comprised of a number of assay endpoints that employ measures of genes 
relevant for all of the cancer processes identified in this work, except for epigenetics. When including 
pathways that contain the genes associated with ToxCast assay endpoints as an indirect measurement of 
biological coverage, the coverage of cancer concepts was higher and also included epigenetics. Despite 
CHAPTER 5: CONCLUSIONS, PERSPECTIVES, AND FUTURE DIRECTIONS 
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having relevant biological coverage for cancer using this method, the use of ToxCast for building robust 
computational models for chemical cancer hazard classification may still not be feasible at this time. 
The data integration workflow presented in Chapter 2 is an extension of other strategies for 
integrating the same information. The workflow and the use of normalized pointwise mutual information 
(NPMI) to identify relevant GeneID-MeSH associations were shown to be successful, supporting the 
assertion that bioinformatic tools like EMCON that bridge gaps in data interoperability will critically inform 
hypothesis generation and further research. However, caveats in this approach remain. The available 
information was limited to curated literature. Of the over 28 million articles in PubMed, less than one 
million were able to be integrated into EMCON. As manual curation and extraction efforts continue, 
there’s a need to develop automatic data extraction pipelines. The rate of publishing will always outpace 
the rate of manual curation, so unless automatic data extraction of relevant information exists, no one 
resource relying on information extracted from literature can be considered comprehensive. 
For legacy information databases like ToxRefDB, manual curation and extraction of data is the 
only solution for many of the documents due to the format of the source files, which are not amenable to 
computational processing. The updates to ToxRefDB exemplify a good approach to ensure data quality 
and completeness. The use of a CV enforced consistency and reduced error rates. Although, manual 
extraction can never accomplish an error rate of zero due to unavoidable human error, quality checks can 
be put into place to identify errors derived from manual entry. Unfortunately, many legacy information 
systems with relevant toxicity data are in need of updates similar to ToxRefDB, and document 
management and an underlying infrastructure to support such updates are not prioritized. Without an 
emphasis on document management and building modern and flexible infrastructures, legacy systems 
will continue to grow in silos. Updating information systems infrastructure and prioritizing interoperability 
are feasible as exemplified by the recent changes to FDA’s data submission standards (262). FDA 
worked closely with an international data standards organization, CDISC, to define data formatting 
standards for global exchange of clinical and nonclinical information. Currently, companies that submit 
information on drugs to the FDA for review must comply with strict data formatting standards. A relevant 
use case in toxicology for the benefits of data formatting standards is the analysis of ToxCast data. 
Chemical dose-response data is collected from several vendors in various formats and may limit insights 
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using established data analysis pipelines (e.g., tcpl). Developing data formatting standards for chemical 
dose-response information could speed up the delivery and analysis of results by enabling easier 
integration into other systems for the development of automated pipelines.  
A significant application of this work is the use in organizing information for automatic binning and 
subsequent manual review for tasks like that of IARC in identifying ToxCast assays relevant to any of the 
TKCC. In Chapter 4, cancer processes were defined by consulting seminal publications in cancer; 
however, IARC only considered the TKCC. The data integration and binning methods from Chapter 4 can 
be updated to focus on TKCC to identify putative links between ToxCast assays and the TKCC. The 
underlying information that supports the associations can then be manually reviewed. The information 
available for review includes PubMed articles that support the links between ToxCast assay gene targets 
and TKCCs, enriched pathways and terms from the indirect biological coverage, and the evidence (i.e. 
research articles) linking genes to each pathway and term. This data organization approach yields a more 
comprehensive review of available information than a literature search alone and can be applied to any 
concept beyond cancer.  
A further application of the work presented in this dissertation is a new route for exploring 
biological information within existing applications like the Comptox Chemicals Dashboard and the AOP 
wiki. Currently within the Comptox Chemicals Dashboard, information about assays is accessible if some 
aspect about the assay is known like the gene target or assay design. However, many users are 
interested in which assays are related to complex diseases, a feature that is not currently available. 
Within the AOP wiki, the information has been incorporated by crowdsourcing. With an underlying 
resource like EMCON, a biological search and subsequent exploration modules can be designed for 
browsing. In the AOP wiki, genes, gene products (e.g. proteins), pathways, and related concepts can be 
putatively added to gaps in existing AOPs for manual review. Also possible is condensing manual 
curation efforts. For example, AOPs for each TKCC or other relevant cancer process can be added 
automatically into the AOP wiki from EMCON. The AOP could then serve as a data curation and 
extraction tool used by IARC to continuously and transparently build evidence linking ToxCast assays to 
relevant cancer processes. Crowdsourcing or internal manual curation can continue to improve quality, 
but, if interoperability is considered when designing the application, information can continuously be 
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incorporated whenever available. Continued development of resources like EMCON is iterative because 
information can be incrementally added by manual review and identifying and integrating other available, 
relevant resources.  
Resources like EMCON can also be used to analyze information from new data streams like high-
throughput transcriptomics. Identifying environmental chemical biological targets from gene expression 
data remains an active field of research as the understanding of genotype-phenotype relationships 
becomes more complex. Instead of traditional methods like GSEA and using reference gene set libraries 
to link pathways or other processes, a graph-based approach like those used to understand genetic 
susceptibility to complex disease (263–266) could be implemented. A network like EMCON could serve 
as a starting point to develop new methods for analyzing the dose-response gene expression profiles 
from high-throughput transcriptomics. As more information is added and curated, the analysis methods 
can iteratively be explored and improved upon. Table 5.1 further presents challenges faced by specific 
user groups or organizations while describing how EMCON can be applied to address their respective 
challenges. An IARC use case is further described in Figure 5.1 depicting how the original workflow can 
be augmented with EMCON incorporating a data-driven approach to identifying assays relevant to 
consider in evaluating carcinogenic potential of chemicals. 
The path forward in the toxicology must include consideration of how data can be integrated and 
used, coinciding with expansion of the methods and approaches used in regulatory toxicology to 
investigate the impact chemical exposures have on human health. As federal agencies begin to prioritize 
good data management and modernize existing infrastructures, new analytical methods will continue to 
become available to explore not just how chemicals affect biological systems, but, also, deepen our 






Challenge EMCON application 
IARC Bin in vitro assays into 
TKCC to evaluate 
mechanistic bioactivity per 
chemical 
IARC has been increasingly relying on 
mechanistic information for identifying 
carcinogenic potential of chemicals for 
subsequent grouping. The ToxCast assays 
have been identified as a source of mechanistic 
data to be used in a weight-of-evidence 
approach by binning assays into TKCC. The 
original workflow relies only on experts to 
manually bin the assays into TKCC, but 
EMCON can be utilized as a data-driven 
approach to bin assays into TKCC while also 
pulling in relevant articles to review.  
 
Experts can select MeSH that represent each 
TKCC to retrieve both gene sets and relevant 
enriched topics from relevant reference libraries 
like Reactome or Gene Ontology. The links 
between the gene or enriched topic and one of 
the TKCC is supported with literature that can 
be reviewed. Expert involvement is still required 
because prior knowledge about the assay 
platform and any targets is needed as well as 
expertise to review literature. Figure 5.1 shows 
where EMCON can be incorporated in the 
existing workflow for using ToxCast as a source 
of mechanistic data to evaluate carcinogenic 




Identify relevant literature 
and related evidence for 
building chemical 
assessments 
The IRIS program is tasked with building 
chemical assessments that include evidence 
supporting links between a given chemical 
exposure and specific health outcomes through 
a process called systematic review. Information 
is initially collected from a broad literature 
search from a number of different databases 
and then iteratively filtered using approaches 
like topic modeling. Manual review of literature 
is required, so maximizing retrieval of only 
relevant articles to minimize time spent 
reviewing irrelevant articles is a goal. EMCON 
can be used as one of the databases to retrieve 
literature as well as pulling in associated meta-
data (e.g. linked pathways or other topics) as 
additional evidence. 
 
For this application, EMCON would be best 
utilized if chemicals were added the network. 
Experts can select MeSH that best account for 
health outcomes of interest pulling out relevant 
links to genes as well as chemicals. All links are 
supported by articles that can be further 
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reviewed and considered as evidence in the 
assessment. 
NTP, EPA/NCCT Analyze dose-response 
transcriptomics data 
streams from S1500+ and 
HTTr projects by linking 
changes in gene 
expression to adverse 
outcomes 
Both S1500+ and HTTr projects aim to generate 
dose-response transcriptomics information. 
Among the benefits of this approach are use of 
a single platform and ability to collect 
information from human cell lines. This 
approach has the potential to generate a 
massive amount of information, yet 
understanding how to analyze this information 
and linking the changes in gene expression to 
relevant adverse outcomes remains a 
challenge. Many of the environmental chemicals 
screened do not have well-defined molecular 
targets and, therefore, a gene expression profile 
may be difficult to extract and subsequently link 
to any adverse outcome. EMCON can be used 
to generate gene sets for any adverse outcome 
of interest. Traditional GSEA can be used, but 
would eliminate the need for manually curated 
reference libraries that may not capture relevant 
information about toxicity pathways.   
 
Experts select MeSH for adverse outcomes of 
interest or select toxicity outcomes from 
ToxRefDB to identify gene sets that serve as a 
reference for GSEA to analyze results from 
S1500+ and HTTr. 




Figure 5.1 Example IARC workflow for using ToxCast to identify carcinogenic potential of 
chemicals 
A) The original workflow relies experts with prior knowledge about the ToxCast assays as well as relevant 
expertise to review literature to bin each of the assays into one or more of the TKCC. EMCON can be 
used to modify this workflow and putatively bin many more assays into the TKCC. Iterative manual review 
is still required to eliminate false positives. B) The remaining original workflow would not have to be 






ToxCast (invitrodb) invitrodb is a database that stores the processed outputs and resulting data from 
the complete analysis pipeline (16) from different high-throughput technologies 
used for screening chemicals. The full MySQL database as well as a number of 
summary files are available from EPA’s ftp website (267). 
ToxVal ToxVal is a database that contains Toxicity Values, or values that may be used 
within regulatory applications, derived from a number of sources (268). 
ToxRefDB Toxicity Reference Database (ToxRefDB) is a publicly available database of 
animal toxicity studies that primarily adhere to guideline studies (13). The recent 
update will include increased accessibility to the resource that includes access to 
the full database, summary files, example code, and a user’s guide. 
CPDat Chemical Products Database (CPDat) stores information on chemicals in various 
products (68,269). The information is accessible through the Comptox Chemistry 
Dashboard (17). 
DSSTox Distributed Structure Searchable Toxicity Database (DSSTox) stores high quality 
chemical information and serves as the primary resource supporting the Comptox 
Chemistry Dashboard.  
httk High-throughput toxicokinetics (httk) is an R software package that implements 
models to calculate the dose a species would have been exposed to given the 
bioactivities in ToxCast (15).  
ACToR Aggregated Computational Toxicology Resource (ACToR) was a web application 
and database providing access to toxicity information across numerous domains. 
As other tools and applications have been developed, the ACToR project’s 
primary focus has been development of a web services API called actorws (65). 
tcpl ToxCast pipeline (tcpl) is an R package used to model dose-response curves 
from ToxCast (16). 
ToxCast 
Dashboard 
The ToxCast Dashboard is a web application that exclusively provides access to 
the chemical and dose-response information for the ToxCast assays (270). 
EDSP21 
Dashboard 
The EDSP21 Dashboard is a web application that provides access to the ToxCast 
data that was used to develop computational models to support the Endocrine 
Disruptor Screening Program (EDSP). The information available in this tool is the 





The Comptox Chemistry Dashboard provides toxicity and chemical information 
from a majority of the resources available within the EPA and many external 
resources. The web application serves as a step towards increasing 
interoperability across all existing resources currently supporting EPA’s 
computational toxicology efforts (17). 





Article title Journal title Publication type(s) 





20056575 Integrating omic technologies into 
aquatic ecological risk assessment 
and environmental monitoring: 





Support, Non-U.S. Gov't 
20368123 In vitro screening of 
environmental chemicals for 






Support, U.S. Gov't, 
Non-P.H.S. 
20421935 Simulating microdosimetry in a 





Support, U.S. Gov't, 
Non-P.H.S. 
20483702 Computational toxicology: 
realizing the promise of the 




20572635 Trust, but verify: on the 
importance of chemical structure 
curation in cheminformatics and 
QSAR modeling research. 







Support, U.S. Gov't, 
Non-P.H.S. 
20702588 A novel framework for predicting 
in vivo toxicities from in vitro data 
using optimal methods for dense 
and sparse matrix reordering and 
logistic regression. 
Toxicological sciences 
: an official journal of 






Support, U.S. Gov't, 
Non-P.H.S. 
20826373 Endocrine profiling and 
prioritization of environmental 





Support, U.S. Gov't, 
Non-P.H.S. 
21339822 Using nuclear receptor activity to 
stratify hepatocarcinogens. 
PloS one Journal Article 
21538556 Genetic toxicology in the 21st 






21556171 Combined toxic exposures and 
human health: biomarkers of 
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21666745 Evaluation of 309 environmental 
chemicals using a mouse 
embryonic stem cell adherent cell 
differentiation and cytotoxicity 
assay. 
PloS one Journal 
Article;Research 
Support, U.S. Gov't, 
Non-P.H.S. 
21745399 Simulating quantitative cellular 
responses using asynchronous 
threshold Boolean network 
ensembles. 
BMC systems biology Journal Article 
21788198 Environmental impact on vascular 







Support, U.S. Gov't, 
Non-P.H.S. 
22387746 Predictive modeling of chemical 
hazard by integrating numerical 
descriptors of chemical structures 
and short-term toxicity assay data. 
Toxicological sciences 
: an official journal of 






Support, U.S. Gov't, 
Non-P.H.S. 
22405527 Toxic environmental chemicals: 
the role of reproductive health 
professionals in preventing 
harmful exposures. 







Support, Non-U.S. Gov't 
22408426 Aggregating data for 
computational toxicology 
applications: The U.S. 
Environmental Protection Agency 
(EPA) Aggregated Computational 
Toxicology Resource (ACToR) 
System. 
International journal 
of molecular sciences 
Journal 
Article;Research 
Support, U.S. Gov't, 
Non-P.H.S.;Review 
23056181 Integrating constitutive gene 
expression and chemoactivity: 
mining the NCI60 anticancer 
screen. 
PloS one Journal Article 










23603051 A C. elegans screening platform 
for the rapid assessment of 








Support, Non-U.S. Gov't 
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23603828 Improving the human hazard 







23844697 Advancing human health risk 
assessment: integrating recent 
advisory committee 
recommendations. 
Critical reviews in 
toxicology 
Journal Article;Review 
23958734 Incorporating new technologies 
into toxicity testing and risk 
assessment: moving from 21st 
century vision to a data-driven 
framework. 
Toxicological sciences 
: an official journal of 




Support, Non-U.S. Gov't 
24415822 THE INTERACTIVE DECISION 
COMMITTEE FOR CHEMICAL 
TOXICITY ANALYSIS. 
Journal of statistical 
research 
Journal Article 
24950175 Profiling animal toxicants by 
automatically mining public 
bioassay data: a big data approach 
for computational toxicology. 




Support, Non-U.S. Gov't 
24972337 Multigenerational exposure to 
dietary zearalenone (ZEA), an 
estrogenic mycotoxin, affects 









25326588 Identification of Environmental 
Chemicals Associated with the 
Development of Toxicant-
associated Fatty Liver Disease in 
Rodents. 




25821157 Models of germ cell development 











25836969 Predicting the future: 
opportunities and challenges for 
the chemical industry to apply 
21st-century toxicity testing. 
Journal of the 
American Association 
for Laboratory 
Animal Science : 
JAALAS 
Journal Article 
25984295 Reproductive toxicity and meiotic 
dysfunction following exposure to 
the pesticides Maneb, Diazinon 
and Fenarimol. 
Toxicology research Journal Article 
26106137 Assessing the carcinogenic 





chemical mixtures in the 
environment: focus on the cancer 





26496690 Developmental Effects of the 
ToxCast™ Phase I and Phase II 
Chemicals in Caenorhabditis 
elegans and Corresponding 












26506572 Health effects of toxicants: Online 
knowledge support. 




26662846 Systems Toxicology of Male 
Reproductive Development: 
Profiling 774 Chemicals for 





26863090 Global analysis of publicly 
available safety data for 9,801 
substances registered under 





Support, Non-U.S. Gov't 
27884602 A data-driven weighting scheme 
for multivariate phenotypic 






28531190 Real-time cell toxicity profiling of 
Tox21 10K compounds reveals 
cytotoxicity dependent toxicity 
pathway linkage. 
PloS one Journal Article 
29075892 Predicting in vivo effect levels for 
repeat-dose systemic toxicity 
using chemical, biological, kinetic 




29155963 Generating Modeling Data From 
Repeat-Dose Toxicity Reports. 
Toxicological sciences 
: an official journal of 
the Society of 
Toxicology 
Journal Article 
30090397 Improving the prediction of 
organism-level toxicity through 
integration of chemical, protein 
target and cytotoxicity qHTS data. 
Toxicology research Journal Article 
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30090410 QSAR modeling for predicting 
reproductive toxicity of chemicals 
in rats for regulatory purposes. 





Endpoint type Endpoint target Effect description 
systemic pathology microscopic bone marrow lymphoma malignant 
systemic pathology gross full gross 
necropsy 
lipoma 
systemic pathology microscopic thyroid gland adenocarcinoma 
systemic pathology microscopic epididymis mesothelioma nos 
systemic pathology microscopic uterus interstitial stromal tumor 
systemic pathology microscopic clitoral gland adenoma 
systemic pathology microscopic testes adenoma 
systemic pathology microscopic ovary granulosa cell tumor 
systemic pathology microscopic liver hepatocholangiocarcinoma 
systemic pathology microscopic epididymis sarcoma 
systemic pathology microscopic uterus polyp adenomatous 
systemic pathology microscopic kidney neoplasm nos 
systemic pathology microscopic zymbal's gland squamous cell carcinoma 
systemic pathology microscopic stomach hemangiosarcoma 
systemic pathology microscopic skin fibrous histiocytoma 
systemic pathology microscopic preputial gland neoplasm nos 
systemic pathology microscopic stomach adenoma 
systemic pathology microscopic intestine large adenoma/carcinoma 
combined 
systemic pathology microscopic liver sarcoma 
systemic pathology microscopic lymph node leukemia 
systemic pathology microscopic pancreas hemangiosarcoma 
systemic pathology gross full gross 
necropsy 
mesothelioma malignant 
systemic pathology microscopic bone osteosarcoma 
systemic pathology microscopic uterus histiocytic sarcoma 
systemic pathology microscopic seminal vesicle adenoma 
systemic pathology microscopic skin subcutaneous mass 
systemic pathology microscopic lung histiocytic sarcoma 
systemic pathology gross full gross 
necropsy 
neoplasm nos 
systemic pathology microscopic skin adenocarcinoma 
systemic pathology microscopic ovary hemangiosarcoma 
systemic pathology microscopic mammary gland fibroadenoma 
systemic pathology microscopic skin papilloma 
systemic pathology microscopic skin lipoma 
systemic pathology microscopic blood leukemia mononuclear 
APPENDIX 3: SUBSET OF TOXREFDB ENDPOINTS AND EFFECTS CONSIDERED CANCER-
RELATED FOR RESEARCH PURPOSES 
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systemic pathology microscopic skin adenoma 
systemic pathology microscopic thymus lymphoma nos 
systemic pathology microscopic lung carcinoma nos 
systemic pathology microscopic brain glioma nos 
systemic pathology microscopic mammary gland adenoacanthoma 
systemic pathology microscopic lymph node lymphoma malignant 
systemic pathology microscopic skin basal cell carcinoma 
systemic pathology microscopic stomach fibrosarcoma 
systemic pathology microscopic harderian gland adenocarcinoma 
systemic pathology microscopic ovary sex cord stromal tumor, 
benign 
systemic pathology gross full gross 
necropsy 
lymphoma nos 
systemic pathology microscopic lung adenoma/carcinoma 
combined 
systemic pathology microscopic zymbal's gland carcinoma 
systemic pathology microscopic intestine large carcinoma 
systemic pathology microscopic spleen leukemia lymphocytic 
systemic pathology microscopic kidney lymphoma malignant 
systemic pathology microscopic pituitary gland acidophil adenoma 
systemic pathology microscopic liver cholangioma 
systemic pathology microscopic testes mesothelioma nos 
systemic pathology microscopic mammary gland adenocarcinoma 
systemic pathology microscopic adrenal gland pheochromocytoma 
malignant 
systemic pathology microscopic skin trichoepithelioma 
systemic pathology microscopic skin carcinoma 
systemic pathology microscopic parathyroid 
gland 
adenoma 
systemic pathology microscopic bone marrow leukemia 
systemic pathology microscopic skin basal cell adenoma 
systemic pathology microscopic pharynx squamous cell papilloma 
systemic pathology microscopic nose squamous cell carcinoma 
systemic pathology microscopic intestine small carcinoma 
systemic pathology microscopic liver adenoma/carcinoma 
combined 
systemic pathology microscopic liver hemangiosarcoma 
systemic pathology microscopic urinary bladder papilloma 
systemic pathology microscopic mammary gland adenoma/carcinoma 
combined 
systemic pathology microscopic mesentery mesothelioma nos 





systemic pathology microscopic lung alveolar/bronchiolar 
adenoma 
systemic pathology microscopic kidney sarcoma 
systemic pathology microscopic mammary gland mixed tumor nos 
systemic pathology microscopic stomach neoplasm nos 
systemic pathology microscopic brain astrocytoma malignant 
systemic pathology microscopic skin fibroma 
systemic pathology microscopic uterus deciduoma nos 
systemic pathology microscopic spleen fibroma 
systemic pathology microscopic zymbal's gland adenoma 
systemic pathology microscopic stomach leiomyosarcoma 
systemic pathology microscopic adrenal gland pheochromocytoma nos 
systemic pathology microscopic spleen hemangiosarcoma 
systemic pathology microscopic liver leukemia lymphocytic 
systemic pathology microscopic adrenal gland hemangiosarcoma 
systemic pathology microscopic blood neoplasm nos 
systemic pathology microscopic liver neoplasm nos 
systemic pathology microscopic nose mixed tumor malignant 
systemic pathology microscopic liver neoplastic nodule 
systemic pathology microscopic testes neoplasm nos 
systemic pathology microscopic skin mesothelioma malignant 
systemic pathology microscopic gallbladder adenoma 
systemic pathology microscopic uterus polyp 
systemic pathology microscopic uterus adenoma/carcinoma 
combined 
systemic pathology microscopic mammary gland carcinoma 
systemic pathology microscopic skin keratoacanthoma 
systemic pathology microscopic ovary granulosa-theca tumor nos 
systemic pathology microscopic peritoneum neoplasm nos 
systemic pathology microscopic thyroid gland neoplasm nos 
systemic pathology microscopic liver mixed tumor nos 
systemic pathology microscopic lacrimal gland lymphoma malignant 
systemic pathology microscopic tongue papilloma 
systemic pathology microscopic skin rhabdomyosarcoma 
systemic pathology microscopic epididymis mesothelioma benign 
systemic pathology microscopic pituitary gland adenoma 
systemic pathology microscopic oral mucosa squamous cell carcinoma 
systemic pathology microscopic nerve sarcoma 
systemic pathology microscopic skin hemangioma 
systemic pathology microscopic nose neoplasm nos 
systemic pathology microscopic urinary bladder lymphoma nos 
systemic pathology microscopic liver mixed tumor malignant 
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systemic pathology microscopic preputial gland adenoma/carcinoma 
combined 
systemic pathology microscopic blood lymphoma malignant 
systemic pathology microscopic skin schwannoma nos 
systemic pathology gross full gross 
necropsy 
osteosarcoma 
systemic pathology microscopic intestine small adenoma 
systemic pathology microscopic liver adenocarcinoma 
systemic pathology microscopic liver hepatocellular carcinoma 
systemic pathology microscopic liver hepatoblastoma 
systemic pathology microscopic blood leukemia lymphocytic 
systemic pathology microscopic tongue carcinoma 
systemic pathology microscopic liver adenoma 
systemic pathology microscopic liver cholangiocarcinoma 
systemic pathology microscopic salivary glands lymphoma malignant 
systemic pathology microscopic lung adenocarcinoma 
systemic pathology microscopic heart schwannoma malignant 
systemic pathology microscopic stomach squamous cell carcinoma 
systemic pathology microscopic oral mucosa carcinoma nos 
systemic pathology microscopic uterus adenocarcinoma 
systemic pathology microscopic brain astrocytoma nos 
systemic pathology microscopic intestine large adenoma 
systemic pathology microscopic stomach squamous cell papilloma 
systemic pathology microscopic harderian gland carcinoma 
systemic pathology microscopic intestine large hemangiosarcoma 
systemic pathology microscopic peritoneum mesothelioma benign 
systemic pathology microscopic lymph node hemangioma 
systemic pathology microscopic heart lymphoma malignant 
systemic pathology microscopic nose adenocarcinoma 
systemic pathology microscopic bone adenoma 
systemic pathology microscopic lymph node lymphoma nos 
systemic pathology microscopic kidney adenoma/carcinoma 
combined 
systemic pathology microscopic spleen fibrosarcoma 
systemic pathology microscopic blood lymphoma malignant 
histiocytic 
systemic pathology microscopic skin squamous cell carcinoma 
systemic pathology microscopic intestine small neoplasm nos 
systemic pathology microscopic pituitary gland carcinoma 
systemic pathology microscopic ovary mixed tumor benign 
systemic pathology microscopic ureter papilloma 
systemic pathology microscopic thymus thymoma nos 
systemic pathology microscopic thyroid gland cystadenoma 
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systemic pathology microscopic intestine large squamous cell carcinoma 
systemic pathology gross full gross 
necropsy 
rhabdomyosarcoma 
systemic pathology microscopic uterus polyp stromal 
systemic pathology microscopic lung alveolar/bronchiolar 
carcinoma 
systemic pathology microscopic tongue squamous cell papilloma 
systemic pathology microscopic thyroid gland adenoma/carcinoma 
combined 
systemic pathology microscopic esophagus squamous cell papilloma 
systemic pathology microscopic clitoral gland adenoma/carcinoma 
combined 
systemic pathology microscopic preputial gland squamous cell carcinoma 
systemic pathology microscopic spleen sarcoma 
systemic pathology microscopic intestine small polyp adenomatous 
systemic pathology microscopic nose polyp 
systemic pathology microscopic thymus lymphoma malignant 
systemic pathology microscopic skin squamous cell papilloma 
systemic pathology microscopic pituitary gland adenoma/carcinoma 
combined 
systemic pathology gross full gross 
necropsy 
lymphoma malignant 
systemic pathology microscopic skeletal muscle sarcoma 
systemic pathology microscopic thyroid gland mixed tumor nos 
systemic pathology microscopic blood leukemia 
systemic pathology microscopic ovary neoplasm nos 
systemic pathology microscopic blood vessel hemangioma 
systemic pathology gross full gross 
necropsy 
leukemia granulocytic 
systemic pathology microscopic kidney transitional epithelial 
carcinoma 
systemic pathology microscopic lung squamous cell carcinoma 
systemic pathology microscopic spleen neoplasm nos 
systemic pathology microscopic skin fibrous histiocytoma benign 
systemic pathology microscopic adrenal gland adenoma 
systemic pathology microscopic testes interstitial cell tumor benign 
systemic pathology microscopic mesentery hemangiosarcoma 
systemic pathology microscopic kidney papilloma 
systemic pathology microscopic stomach carcinosarcoma 
systemic pathology microscopic uterus mesothelioma malignant 
systemic pathology microscopic intestine small adenoma/carcinoma 
combined 
systemic pathology microscopic lung carcinoma 
systemic pathology microscopic seminal vesicle carcinoma 
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systemic pathology microscopic pancreas adenoma 
systemic pathology microscopic preputial gland adenoma 
systemic pathology microscopic urinary bladder carcinoma 
systemic pathology microscopic pancreas adenoma/carcinoma 
combined 
systemic pathology microscopic liver carcinoma nos 
systemic pathology microscopic uterus carcinoma 
systemic pathology microscopic stomach papilloma 
systemic pathology microscopic uterus sarcoma 
systemic pathology microscopic lung mixed tumor nos 
systemic pathology gross full gross 
necropsy 
adenoma 
systemic pathology microscopic liver hemangioma 
systemic pathology microscopic adrenal gland pheochromocytoma benign 
systemic pathology gross full gross 
necropsy 
hemangiosarcoma 
systemic pathology microscopic urinary bladder squamous cell carcinoma 
systemic pathology microscopic kidney adenocarcinoma 
systemic pathology microscopic skin fibrosarcoma 
systemic pathology microscopic kidney lymphoma nos 
systemic pathology microscopic harderian gland adenoma/carcinoma 
combined 
systemic pathology microscopic seminal vesicle carcinoma nos 
systemic pathology microscopic liver carcinoma 
systemic pathology microscopic liver hepatocholangioma 
systemic pathology microscopic adrenal gland adenoma/carcinoma 
combined 
systemic pathology gross full gross 
necropsy 
hemangioma 
systemic pathology microscopic testes interstitial cell tumor nos 
systemic pathology microscopic ovary lymphoma malignant 
systemic pathology microscopic bone marrow leukemia mononuclear 
systemic pathology microscopic lymph node leukemia granulocytic 
systemic pathology microscopic lung cystic keratinizing 
epithelioma 
systemic pathology microscopic brain adenoma 
systemic pathology microscopic mammary gland mixed tumor malignant 
systemic pathology microscopic liver histiocytic sarcoma 
systemic pathology microscopic liver leukemia mononuclear 
systemic pathology microscopic nose carcinoma 
systemic pathology microscopic adrenal gland pheochromocytoma 
complex 
systemic pathology microscopic ovary adenoma 
systemic pathology microscopic kidney carcinoma 
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systemic pathology microscopic skin hemangiosarcoma 
systemic pathology microscopic preputial gland carcinoma 
systemic pathology microscopic uterus adenoma 
systemic pathology microscopic intestine large polyp adenomatous 
systemic pathology microscopic gallbladder papilloma 
systemic pathology microscopic prostate adenoma 
systemic pathology microscopic thyroid gland adenoma 
systemic pathology microscopic pancreas adenocarcinoma 
systemic pathology microscopic gallbladder hemangioma 
systemic pathology microscopic intestine large lipoma 
systemic pathology microscopic ureter adenoma 
systemic pathology microscopic blood vessel hemangiosarcoma 
systemic pathology microscopic uterus squamous cell carcinoma 
systemic pathology microscopic spinal cord astrocytoma nos 
systemic pathology microscopic eye adenoma 
systemic pathology microscopic stomach carcinoma in situ 
systemic pathology microscopic stomach adenocarcinoma 
systemic pathology microscopic heart hemangiosarcoma 
systemic pathology microscopic ovary tubulostromal adenoma 
systemic pathology microscopic pancreas lymphoma nos 
systemic pathology microscopic ovary interstitial stromal tumor 
systemic pathology microscopic stomach carcinoma 
systemic pathology gross full gross 
necropsy 
histiocytic sarcoma 
systemic pathology microscopic intestine small mixed tumor nos 
systemic pathology microscopic liver hepatocellular adenoma 
systemic pathology microscopic mesentery hemangioma 
systemic pathology microscopic uterus hemangioma 
systemic pathology microscopic oral mucosa squamous cell papilloma 
systemic pathology microscopic urinary bladder leiomyosarcoma 
systemic pathology microscopic pharynx carcinoma 
systemic pathology microscopic zymbal's gland adenoma/carcinoma 
combined 
systemic pathology microscopic spleen leukemia mononuclear 
systemic pathology microscopic intestine large adenocarcinoma 
systemic pathology microscopic intestine small sarcoma 
systemic pathology microscopic nose sarcoma 
systemic pathology microscopic ovary granular cell tumor 
malignant 
systemic pathology microscopic spleen osteosarcoma 
systemic pathology microscopic urinary bladder transitional epithelial 
carcinoma 
systemic pathology microscopic mammary gland fibroma 
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systemic pathology microscopic vagina squamous cell carcinoma 
systemic pathology microscopic intestine small adenocarcinoma 
systemic pathology microscopic thyroid gland carcinoma 
systemic pathology microscopic ear squamous cell papilloma 
systemic pathology microscopic skin sarcoma 
systemic pathology microscopic stomach polyp adenomatous 
systemic pathology microscopic mammary gland adenoma 
systemic pathology microscopic mammary gland carcinosarcoma 
systemic pathology microscopic blood lymphoma nos 
systemic pathology gross full gross 
necropsy 
sarcoma 
systemic pathology microscopic nose papilloma 
systemic pathology microscopic peritoneum sarcoma 
systemic pathology microscopic ovary granular cell tumor benign 
systemic pathology microscopic ovary granulosa cell tumor 
benign 
systemic pathology microscopic clitoral gland carcinoma 
systemic pathology microscopic nose rhabdomyosarcoma 
systemic pathology microscopic ovary luteoma 
systemic pathology microscopic lung adenoma 
systemic pathology microscopic nose adenoma 
systemic pathology microscopic lymph node hemangiosarcoma 
systemic pathology microscopic testes mesothelioma malignant 
systemic pathology microscopic blood histiocytic sarcoma 
systemic pathology gross full gross 
necropsy 
fibrosarcoma 
systemic pathology microscopic lung neoplasm nos 
systemic pathology microscopic kidney adenoma 
systemic pathology gross full gross 
necropsy 
lymp lymphoma malignant 
lymphocytic 
systemic pathology microscopic harderian gland adenoma 
systemic pathology microscopic uterus neoplasm nos 
systemic pathology microscopic ovary cystadenoma 
systemic pathology microscopic ovary carcinoma nos 
systemic pathology microscopic [other] histiocytic sarcoma 
systemic pathology microscopic [other] hemangioma 
systemic pathology microscopic [other] hemangiosarcoma 
systemic pathology microscopic [other] leukemia granulocytic 
systemic pathology microscopic [other] lymphoma malignant 











systemic pathology microscopic prostate 1 9 
systemic pathology microscopic blood vessel 1 2 
systemic pathology microscopic thymus 1 2 
systemic pathology microscopic harderian gland 1 4 
systemic pathology microscopic pancreas 1 1 
systemic pathology microscopic mesentery 1 2 
systemic pathology microscopic oral mucosa 1 4 
systemic pathology microscopic skeletal muscle 1 2 
systemic pathology microscopic adrenal gland 2 2 
systemic pathology microscopic gallbladder 2 9 
systemic pathology microscopic zymbal's gland 2 16 
systemic pathology microscopic seminal vesicle 2 11 
systemic pathology microscopic preputial gland 2 16 
systemic pathology microscopic blood 2 2 
systemic pathology microscopic thyroid gland 2 5 
systemic pathology microscopic spleen 3 8 
systemic pathology microscopic brain 3 4 
systemic pathology microscopic [other] 3 8 
systemic pathology gross full gross necropsy 3 5 
systemic pathology microscopic kidney 4 19 
systemic pathology microscopic bone marrow 4 11 
systemic pathology microscopic stomach 4 12 
systemic pathology microscopic intestine large 4 20 
systemic pathology microscopic lymph node 4 8 
systemic pathology microscopic nose 4 18 
systemic pathology microscopic testes 4 4 
systemic pathology microscopic ovary 5 8 
systemic pathology microscopic vagina 5 25 
systemic pathology microscopic urinary bladder 6 9 
systemic pathology microscopic uterus 7 40 
systemic pathology microscopic lung 7 25 
systemic pathology microscopic mammary gland 8 42 
systemic pathology microscopic skin 10 22 
systemic pathology microscopic liver 31 68 
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regulation of endothelial 
cell chemotaxis to 
fibroblast growth factor 
(GO:2000544) 
1 Angiogenesis GO_Biological_Process_2018 
fibroblast growth factor 
receptor signaling 
pathway (GO:0008543) 
1 Angiogenesis GO_Biological_Process_2018 
Activation of gene 
expression by SREBF 
(SREBP)_Homo 
sapiens_R-HSA-2426168 




1 Angiogenesis GO_Biological_Process_2018 
cellular response to 
fibroblast growth factor 
stimulus (GO:0044344) 
1 Angiogenesis GO_Biological_Process_2018 
activin-activated receptor 
activity (GO:0017002) 
1 Angiogenesis GO_Molecular_Function_2018 
growth factor activity 
(GO:0008083) 
1 Angiogenesis GO_Molecular_Function_2018 
Alcoholism_Homo 
sapiens_hsa05034 
1 Epigenetics KEGG_2016 
fibroblast growth factor 
receptor binding 
(GO:0005104) 















1 Proliferation Reactome_2016 
Ascorbate and aldarate 
metabolism_Homo 
sapiens_hsa00053 
1 Growth_hormones KEGG_2016 
Autodegradation of Cdh1 
by Cdh1:APC/C_Homo 
sapiens_R-HSA-174084 
1 Apoptosis Reactome_2016 
Autodegradation of Cdh1 
by Cdh1:APC/C_Homo 
sapiens_R-HSA-174084 
1 Cell_cycle Reactome_2016 
C3HC4-type RING finger 
domain binding 
(GO:0055131) 
1 Immortalization GO_Molecular_Function_2018 
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CARD domain binding 
(GO:0050700) 
1 Inflammation GO_Molecular_Function_2018 
DEx/H-box helicases 




1 Inflammation Reactome_2016 
DNA biosynthetic process 
(GO:0071897) 
1 Oxidative_stress GO_Biological_Process_2018 
DNA helicase activity 
(GO:0003678) 
1 Epigenetics GO_Molecular_Function_2018 
DNA-dependent ATPase 
activity (GO:0008094) 
1 Apoptosis GO_Molecular_Function_2018 
negative regulation of 
ubiquitin-protein ligase 
activity involved in mitotic 
cell cycle (GO:0051436) 





1 Apoptosis GO_Biological_Process_2018 
cell cycle G2/M phase 
transition (GO:0044839) 
1 Apoptosis GO_Biological_Process_2018 
positive regulation of 
ubiquitin-protein ligase 
activity involved in 
regulation of mitotic cell 
cycle transition 
(GO:0051437) 
1 Apoptosis GO_Biological_Process_2018 
DNA-dependent ATPase 
activity (GO:0008094) 
1 Epigenetics GO_Molecular_Function_2018 
DNA-dependent ATPase 
activity (GO:0008094) 





1 Oxidative_stress GO_Biological_Process_2018 
kinase binding 
(GO:0019900) 
1 Apoptosis GO_Molecular_Function_2018 
damaged DNA binding 
(GO:0003684) 




1 Apoptosis KEGG_2016 
Dual Incision in GG-
NER_Homo sapiens_R-
HSA-5696400 




1 Apoptosis KEGG_2016 
Cell cycle_Homo 
sapiens_hsa04110 
1 Apoptosis KEGG_2016 
Apoptosis_Homo 
sapiens_hsa04210 
1 Apoptosis KEGG_2016 
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Dual incision in TC-
NER_Homo sapiens_R-
HSA-6782135 
1 Oxidative_stress Reactome_2016 
Activation of NF-kappaB 
in B cells_Homo 
sapiens_R-HSA-1169091 
1 Apoptosis Reactome_2016 




1 Apoptosis Reactome_2016 
Energy dependent 
regulation of mTOR by 
LKB1-AMPK_Homo 
sapiens_R-HSA-380972 
1 Immortalization Reactome_2016 
ERCC6 (CSB) and 




1 Epigenetics Reactome_2016 
negative regulation of 
G2/M transition of mitotic 
cell cycle (GO:0010972) 















1 Cell_cycle GO_Biological_Process_2018 
positive regulation of 
ubiquitin-protein ligase 
activity involved in 
regulation of mitotic cell 
cycle transition 
(GO:0051437) 




1 Genotoxicity KEGG_2016 
FGFR2c ligand binding 
and activation_Homo 
sapiens_R-HSA-190375 
1 Angiogenesis Reactome_2016 
kinase binding 
(GO:0019900) 
1 Cell_cycle GO_Molecular_Function_2018 
FGFR4 ligand binding 
and activation_Homo 
sapiens_R-HSA-190322 










1 Immortalization KEGG_2016 
frizzled binding 
(GO:0005109) 
1 Cell_cycle GO_Molecular_Function_2018 
Oocyte meiosis_Homo 
sapiens_hsa04114 




1 Growth_hormones Reactome_2016 
Cell cycle_Homo 
sapiens_hsa04110 
1 Cell_cycle KEGG_2016 
The role of GTSE1 in 
G2/M progression after 
G2 checkpoint_Homo 
sapiens_R-HSA-8852276 
1 Cell_cycle Reactome_2016 
glucuronate metabolic 
process (GO:0019585) 
0 Growth_hormones GO_Biological_Process_2018 
Glucuronidation_Homo 
sapiens_R-HSA-156588 
0 Growth_hormones Reactome_2016 
Hepatitis B_Homo 
sapiens_hsa05161 









1 Epigenetics GO_Biological_Process_2018 
chromatin silencing at 
rDNA (GO:0000183) 
1 Epigenetics GO_Biological_Process_2018 
negative regulation of 
gene expression, 
epigenetic (GO:0045814) 




1 Epigenetics GO_Biological_Process_2018 
chromatin assembly 
(GO:0031497) 
1 Epigenetics GO_Biological_Process_2018 
HTLV-I infection_Homo 
sapiens_hsa05166 
1 Cell_cycle KEGG_2016 
HTLV-I infection_Homo 
sapiens_hsa05166 
1 Proliferation KEGG_2016 
Integrin cell surface 
interactions_Homo 
sapiens_R-HSA-216083 
1 Angiogenesis Reactome_2016 
interstrand cross-link 
repair (GO:0036297) 
1 Oxidative_stress GO_Biological_Process_2018 
nucleosomal DNA 
binding (GO:0031492) 




1 Epigenetics KEGG_2016 
Transcriptional 
misregulation in 








1 Angiogenesis KEGG_2016 
Melanoma_Homo 
sapiens_hsa05218 
1 Angiogenesis KEGG_2016 
microtubule plus-end 
binding (GO:0051010) 




1 Epigenetics Reactome_2016 
mitochondrial electron 
transport, NADH to 
ubiquinone 
(GO:0006120) 
1 Oxidative_stress GO_Biological_Process_2018 
DNA methylation_Homo 
sapiens_R-HSA-5334118 
1 Epigenetics Reactome_2016 
RMTs methylate histone 
arginines_Homo 
sapiens_R-HSA-3214858 
1 Epigenetics Reactome_2016 
PRC2 methylates 
histones and DNA_Homo 
sapiens_R-HSA-212300 
1 Epigenetics Reactome_2016 
interstrand cross-link 
repair (GO:0036297) 
1 Genotoxicity GO_Biological_Process_2018 
non-recombinational 
repair (GO:0000726) 
1 Genotoxicity GO_Biological_Process_2018 
DNA replication 
(GO:0006260) 









1 Genotoxicity GO_Biological_Process_2018 
DNA helicase activity 
(GO:0003678) 




1 Genotoxicity GO_Molecular_Function_2018 
DNA-dependent ATPase 
activity (GO:0008094) 
1 Genotoxicity GO_Molecular_Function_2018 
damaged DNA binding 
(GO:0003684) 
1 Genotoxicity GO_Molecular_Function_2018 
single-stranded DNA 
binding (GO:0003697) 




1 Genotoxicity KEGG_2016 
Alcoholism_Homo 
sapiens_hsa05034 


















1 Genotoxicity Reactome_2016 
Dual incision in TC-
NER_Homo sapiens_R-
HSA-6782135 




1 Apoptosis GO_Molecular_Function_2018 




1 Genotoxicity Reactome_2016 




1 Genotoxicity Reactome_2016 
cAMP-mediated signaling 
(GO:0019933) 
1 Growth_hormones GO_Biological_Process_2018 
JAK-STAT cascade 
involved in growth 
hormone signaling 
pathway (GO:0060397) 
1 Growth_hormones GO_Biological_Process_2018 
negative regulation of 
ubiquitin-protein ligase 
activity involved in mitotic 
cell cycle (GO:0051436) 
1 Cell_cycle GO_Biological_Process_2018 
positive regulation of 
multicellular organism 
growth (GO:0040018) 
1 Growth_hormones GO_Biological_Process_2018 
response to nutrient 
levels (GO:0031667) 
1 Growth_hormones GO_Biological_Process_2018 
insulin receptor binding 
(GO:0005158) 
1 Growth_hormones GO_Molecular_Function_2018 
neuropeptide hormone 
activity (GO:0005184) 
1 Growth_hormones GO_Molecular_Function_2018 
protein-hormone receptor 
activity (GO:0016500) 
1 Growth_hormones GO_Molecular_Function_2018 
insulin-like growth factor 
receptor binding 
(GO:0005159) 
1 Growth_hormones GO_Molecular_Function_2018 
insulin-like growth factor 
II binding (GO:0031995) 
1 Growth_hormones GO_Molecular_Function_2018 
Neuroactive ligand-
receptor 





NF-kappa B signaling 
pathway_Homo 
sapiens_hsa04064 




















1 Growth_hormones Reactome_2016 
Regulation of Insulin-like 
Growth Factor (IGF) 
transport and uptake by 




1 Growth_hormones Reactome_2016 
Growth hormone receptor 
signaling_Homo 
sapiens_R-HSA-982772 
1 Growth_hormones Reactome_2016 
Pentose and glucuronate 
interconversions_Homo 
sapiens_hsa00040 
1 Growth_hormones KEGG_2016 
regulation of autophagy 
(GO:0010506) 
1 Immortalization GO_Biological_Process_2018 
autophagy of nucleus 
(GO:0044804) 




1 Immortalization GO_Biological_Process_2018 
positive regulation of 
autophagy (GO:0010508) 









0 Inflammation GO_Molecular_Function_2018 
death domain binding 
(GO:0070513) 
1 Immortalization GO_Molecular_Function_2018 
kinase binding 
(GO:0019900) 
1 Immortalization GO_Molecular_Function_2018 
cysteine-type 
endopeptidase activity 
1 Immortalization GO_Molecular_Function_2018 
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involved in execution 









1 Oxidative_stress GO_Molecular_Function_2018 
phospholipase activator 
activity (GO:0016004) 









1 Immortalization KEGG_2016 
Apoptosis_Homo 
sapiens_hsa04210 
1 Immortalization KEGG_2016 
















1 Angiogenesis Reactome_2016 
Macroautophagy_Homo 
sapiens_R-HSA-1632852 
1 Immortalization Reactome_2016 
monocyte chemotaxis 
(GO:0002548) 




1 Immunomodulation GO_Biological_Process_2018 
neutrophil chemotaxis 
(GO:0030593) 
1 Immunomodulation GO_Biological_Process_2018 
B cell activation 
(GO:0042113) 
1 Immunomodulation GO_Biological_Process_2018 
B cell receptor signaling 
pathway (GO:0050853) 
1 Immunomodulation GO_Biological_Process_2018 
C-C chemokine binding 
(GO:0019957) 
1 Immunomodulation GO_Molecular_Function_2018 
positive regulation of 
protein kinase B signaling 
(GO:0051897) 
1 Angiogenesis GO_Biological_Process_2018 









1 Immunomodulation GO_Molecular_Function_2018 
CCR chemokine receptor 
binding (GO:0048020) 








1 Immunomodulation KEGG_2016 
B cell receptor signaling 
pathway_Homo 
sapiens_hsa04662 









1 Immunomodulation KEGG_2016 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell_Homo 
sapiens_R-HSA-198933 




1 Immunomodulation Reactome_2016 




1 Immunomodulation Reactome_2016 
CD22 mediated BCR 
regulation_Homo 
sapiens_R-HSA-5690714 




1 Immunomodulation Reactome_2016 
regulation of interleukin-6 
production (GO:0032675) 
1 Inflammation GO_Biological_Process_2018 
positive regulation of 
interleukin-1 beta 
secretion (GO:0050718) 
1 Inflammation GO_Biological_Process_2018 
negative regulation of 
defense response 
(GO:0031348) 
1 Inflammation GO_Biological_Process_2018 
neutrophil degranulation 
(GO:0043312) 




1 Inflammation GO_Biological_Process_2018 
Proteasome_Homo 
sapiens_hsa03050 






1 Cell_cycle GO_Molecular_Function_2018 
interleukin-1 receptor 
binding (GO:0005149) 
1 Inflammation GO_Molecular_Function_2018 
Toll-like receptor binding 
(GO:0035325) 
1 Inflammation GO_Molecular_Function_2018 
chemokine activity 
(GO:0008009) 




1 Inflammation KEGG_2016 
protein homodimerization 
activity (GO:0042803) 
1 Immortalization GO_Molecular_Function_2018 
Pertussis_Homo 
sapiens_hsa05133 
1 Inflammation KEGG_2016 
protein homodimerization 
activity (GO:0042803) 

























1 Inflammation Reactome_2016 
lipid hydroxylation 
(GO:0002933) 
1 Liver_cancer_(ToxRefDB) GO_Biological_Process_2018 
fatty acid beta-oxidation 
using acyl-CoA oxidase 
(GO:0033540) 
1 Liver_cancer_(ToxRefDB) GO_Biological_Process_2018 
omega-hydroxylase P450 
pathway (GO:0097267) 
1 Liver_cancer_(ToxRefDB) GO_Biological_Process_2018 
glucuronate metabolic 
process (GO:0019585) 
1 Liver_cancer_(ToxRefDB) GO_Biological_Process_2018 
epoxygenase P450 
pathway (GO:0019373) 
1 Liver_cancer_(ToxRefDB) GO_Biological_Process_2018 
CoA hydrolase activity 
(GO:0016289) 
1 Liver_cancer_(ToxRefDB) GO_Molecular_Function_2018 
glucuronosyltransferase 
activity (GO:0015020) 
1 Liver_cancer_(ToxRefDB) GO_Molecular_Function_2018 
acyl-CoA oxidase activity 
(GO:0003997) 




acting on paired donors, 
with incorporation or 
reduction of molecular 
oxygen, reduced flavin or 
flavoprotein as one 
donor, and incorporation 
of one atom of oxygen 
(GO:0016712) 
1 Liver_cancer_(ToxRefDB) GO_Molecular_Function_2018 
steroid hydroxylase 
activity (GO:0008395) 

















1 Liver_cancer_(ToxRefDB) KEGG_2016 
Drug metabolism - 
cytochrome P450_Homo 
sapiens_hsa00982 





1 Apoptosis GO_Biological_Process_2018 
CYP2E1 reactions_Homo 
sapiens_R-HSA-211999 
1 Liver_cancer_(ToxRefDB) Reactome_2016 
Recycling of bile acids 
and salts_Homo 
sapiens_R-HSA-159418 
1 Liver_cancer_(ToxRefDB) Reactome_2016 
PPARA activates gene 
expression_Homo 
sapiens_R-HSA-1989781 
1 Liver_cancer_(ToxRefDB) Reactome_2016 
Glucuronidation_Homo 
sapiens_R-HSA-156588 
1 Liver_cancer_(ToxRefDB) Reactome_2016 
Regulation of RAS by 
GAPs_Homo sapiens_R-
HSA-5658442 
1 Angiogenesis Reactome_2016 








1 Liver_cancer_(ToxRefDB) KEGG_2016 
RHO GTPases Activate 
Formins_Homo 
sapiens_R-HSA-5663220 
1 Cell_cycle Reactome_2016 
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cellular response to 
oxidative stress 
(GO:0034599) 
1 Oxidative_stress GO_Biological_Process_2018 
RHO GTPases Activate 
Formins_Homo 
sapiens_R-HSA-5663220 
0 Genotoxicity Reactome_2016 
RNA polymerase II core 
promoter sequence-
specific DNA binding 
(GO:0000979) 
1 Immunomodulation GO_Molecular_Function_2018 
RNA polymerase II distal 
enhancer sequence-
specific DNA binding 
(GO:0000980) 
1 Epigenetics GO_Molecular_Function_2018 
glutathione transferase 
activity (GO:0004364) 
1 Oxidative_stress GO_Molecular_Function_2018 
damaged DNA binding 
(GO:0003684) 





1 Apoptosis Reactome_2016 
Drug metabolism - 
cytochrome P450_Homo 
sapiens_hsa00982 









1 Oxidative_stress KEGG_2016 
Non-alcoholic fatty liver 
disease (NAFLD)_Homo 
sapiens_hsa04932 









1 Liver_cancer_(ToxRefDB) KEGG_2016 
Oxidative Stress Induced 
Senescence_Homo 
sapiens_R-HSA-2559580 




1 Epigenetics KEGG_2016 
transcriptional activator 
activity, RNA polymerase 
II core promoter proximal 
region sequence-specific 
binding (GO:0001077) 
1 Cell_cycle GO_Molecular_Function_2018 
anaphase-promoting 
complex-dependent 





cell cycle G2/M phase 
transition (GO:0044839) 
1 Proliferation GO_Biological_Process_2018 
regulation of stem cell 
differentiation 
(GO:2000736) 





1 Proliferation GO_Biological_Process_2018 




1 Proliferation GO_Biological_Process_2018 
DNA-dependent ATPase 
activity (GO:0008094) 
1 Proliferation GO_Molecular_Function_2018 
RNA polymerase II core 
promoter proximal region 
sequence-specific DNA 
binding (GO:0000978) 
1 Proliferation GO_Molecular_Function_2018 
transcriptional activator 
activity, RNA polymerase 
II core promoter proximal 
region sequence-specific 
binding (GO:0001077) 
1 Proliferation GO_Molecular_Function_2018 
kinase binding 
(GO:0019900) 




1 Proliferation GO_Molecular_Function_2018 
Transcriptional regulation 
of white adipocyte 
differentiation_Homo 
sapiens_R-HSA-381340 
1 Inflammation Reactome_2016 
Focal adhesion_Homo 
sapiens_hsa04510 
1 Proliferation KEGG_2016 
Cell cycle_Homo 
sapiens_hsa04110 
1 Proliferation KEGG_2016 
type II transforming 
growth factor beta 
receptor binding 
(GO:0005114) 




1 Epigenetics KEGG_2016 




1 Proliferation Reactome_2016 
Autodegradation of Cdh1 
by Cdh1:APC/C_Homo 
sapiens_R-HSA-174084 
1 Proliferation Reactome_2016 
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Oxidative Stress Induced 
Senescence_Homo 
sapiens_R-HSA-2559580 









1 Proliferation Reactome_2016 
sodium-independent 
organic anion transport 
(GO:0043252) 
1 Steroid_hormones GO_Biological_Process_2018 
progesterone metabolic 
process (GO:0042448) 




1 Steroid_hormones GO_Biological_Process_2018 
flavonoid glucuronidation 
(GO:0052696) 
1 Steroid_hormones GO_Biological_Process_2018 
glucuronate metabolic 
process (GO:0019585) 
1 Steroid_hormones GO_Biological_Process_2018 
aryl sulfotransferase 
activity (GO:0004062) 








1 Steroid_hormones GO_Molecular_Function_2018 
glucuronosyltransferase 
activity (GO:0015020) 






1 Steroid_hormones GO_Molecular_Function_2018 
Ascorbate and aldarate 
metabolism_Homo 
sapiens_hsa00053 
1 Steroid_hormones KEGG_2016 
Drug metabolism - 
cytochrome P450_Homo 
sapiens_hsa00982 













1 Steroid_hormones KEGG_2016 
Common Pathway of 
Fibrin Clot 








1 Steroid_hormones Reactome_2016 
Transport of organic 
anions_Homo 
sapiens_R-HSA-879518 




1 Steroid_hormones Reactome_2016 
Glucuronidation_Homo 
sapiens_R-HSA-156588 
1 Steroid_hormones Reactome_2016 
flavonoid glucuronidation 
(GO:0052696) 
1 Xenobiotic_metabolism GO_Biological_Process_2018 
glucuronate metabolic 
process (GO:0019585) 




1 Xenobiotic_metabolism GO_Biological_Process_2018 
aminoglycan metabolic 
process (GO:0006022) 
1 Xenobiotic_metabolism GO_Biological_Process_2018 
epoxygenase P450 
pathway (GO:0019373) 
1 Xenobiotic_metabolism GO_Biological_Process_2018 
steroid hydroxylase 
activity (GO:0008395) 
1 Xenobiotic_metabolism GO_Molecular_Function_2018 
aryl sulfotransferase 
activity (GO:0004062) 
1 Xenobiotic_metabolism GO_Molecular_Function_2018 
glucuronosyltransferase 
activity (GO:0015020) 
1 Xenobiotic_metabolism GO_Molecular_Function_2018 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 
reduction of molecular 
oxygen, reduced flavin or 
flavoprotein as one 
donor, and incorporation 
of one atom of oxygen 
(GO:0016712) 
1 Xenobiotic_metabolism GO_Molecular_Function_2018 
glutathione transferase 
activity (GO:0004364) 













1 Xenobiotic_metabolism KEGG_2016 
Drug metabolism - 
cytochrome P450_Homo 
sapiens_hsa00982 






1 Xenobiotic_metabolism KEGG_2016 
CYP2E1 reactions_Homo 
sapiens_R-HSA-211999 




1 Xenobiotic_metabolism Reactome_2016 
Synthesis of Leukotrienes 
(LT) and Eoxins 
(EX)_Homo sapiens_R-
HSA-2142691 
1 Xenobiotic_metabolism Reactome_2016 
Fatty acids_Homo 
sapiens_R-HSA-211935 
1 Xenobiotic_metabolism Reactome_2016 
Glucuronidation_Homo 
sapiens_R-HSA-156588 





1.  Richard AM, Judson RS, Houck KA, Grulke CM, Volarath P, Thillainadarajah I, et al. 
ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology. Chem Res 
Toxicol [Internet]. 2016;29(8):1225–51. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27367298 
2.  Judson R, Richard A, Dix DJ, Houck K, Martin M, Kavlock R, et al. The toxicity data 
landscape for environmental chemicals. Env Heal Perspect [Internet]. 
2009;117(5):685–95. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/19479008 
3.  Egeghy PP, Judson R, Gangwal S, Mosher S, Smith D, Vail J, et al. The exposure data 
landscape for manufactured chemicals. Sci Total Env [Internet]. 2012;414:159–66. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22104386 
4.  Shimkus JM. Frank R. Lautenberg Chemical Safety for the 21st Century Act 
[Internet]. United States Statutes at Large. 2014. p. 448–513. Available from: 
https://www.congress.gov/114/plaws/publ182/PLAW-114publ182.pdf 
5.  National Research Council. Toxicity Testing in the 21st Century: A Vision and a 
Strategy [Internet]. Washington, DC: The National Academies Press; 2007. 216 p. 
Available from: https://www.nap.edu/catalog/11970/toxicity-testing-in-the-21st-
century-a-vision-and-a 




7.  OCSPP U, USEPA. Strategic Plan to Promote the Development and Implementation of 
Alternative Test Methods Within the TSCA Program [Internet]. 2018. Available from: 
https://www.epa.gov/sites/production/files/2018-
06/documents/epa_alt_strat_plan_6-20-18_clean_final.pdf 
8.  Thomas RS, Paules RS, Simeonov A, Fitzpatrick SC, Crofton KM, Casey WM, et al. The 
US Federal Tox21 Program: A strategic and operational plan for continued leadership. 
ALTEX [Internet]. 2018;35(2):163–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29529324 
9.  Tice RR, Austin CP, Kavlock RJ, Bucher JR. Improving the human hazard 
characterization of chemicals: a Tox21 update. Env Heal Perspect [Internet]. 
2013;121(7):756–65. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23603828 
10.  Using 21st Century Science to Improve Risk-Related Evaluations [Internet]. 






11.  Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. The ToxCast 
program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 
[Internet]. 2007;95(1):5–12. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/16963515 
12.  Judson RS, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, Mortensen HM, et al. In 
vitro screening of environmental chemicals for targeted testing prioritization: the 
ToxCast project. Env Heal Perspect [Internet]. 2010;118(4):485–92. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/20368123 
13.  Watford S, Pham L, Wignall J, Shin R, Martin M, Paul-Friedman K. ToxRefDB version 
2.0: Improved utility for predictive and retrospective toxicology analyses. Prep.  
14.  Judson RS, Martin MT, Egeghy P, Gangwal S, Reif DM, Kothiya P, et al. Aggregating 
data for computational toxicology applications: The U.S. Environmental Protection 
Agency (EPA) Aggregated Computational Toxicology Resource (ACToR) System. Int J 
Mol Sci [Internet]. 2012;13(2):1805–31. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/22408426 
15.  Pearce RG, Setzer RW, Strope CL, Wambaugh JF, Sipes NS. httk: R Package for High-
Throughput Toxicokinetics. J Stat Softw [Internet]. 2017;79(4):1–26. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30220889 
16.  Filer DL, Kothiya P, Setzer RW, Judson RS, Martin MT. tcpl: the ToxCast pipeline for 
high-throughput screening data. Bioinformatics [Internet]. 2017;33(4):618–20. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27797781 
17.  Williams AJ, Grulke CM, Edwards J, McEachran AD, Mansouri K, Baker NC, et al. The 
CompTox Chemistry Dashboard: a community data resource for environmental 
chemistry. J Cheminform [Internet]. 2017;9(1):61. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29185060 
18.  Bioplanet [Internet]. [cited 2018 Dec 28]. Available from: 
https://tripod.nih.gov/bioplanet/ 
19.  Tox21 Toolbox [Internet]. Vol. 2018. Available from: 
https://ntp.niehs.nih.gov/results/tox21/tbox/ 
20.  Bell SM, Phillips J, Sedykh A, Tandon A, Sprankle C, Morefield SQ, et al. An Integrated 
Chemical Environment to Support 21st-Century Toxicology. Environ Health Perspect 
[Internet]. National Institute of Environmental Health Science; 2017 [cited 2019 Jan 
15];125(5):054501. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28557712 
21.  Kleinstreuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, et al. Development 
and Validation of a Computational Model for Androgen Receptor Activity. Chem Res 
Toxicol [Internet]. 2017;30(4):946–64. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27933809 
22.  Haggard DE, Karmaus AL, Martin MT, Judson RS, Setzer RW, Paul Friedman K. High-
Throughput H295R Steroidogenesis Assay: Utility as an Alternative and a Statistical 
Approach to Characterize Effects on Steroidogenesis. Toxicol Sci [Internet]. 




23.  Judson RS, Magpantay FM, Chickarmane V, Haskell C, Tania N, Taylor J, et al. 
Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro 
High-Throughput Screening Assays for the Estrogen Receptor. Toxicol Sci [Internet]. 
2015;148(1):137–54. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26272952 
24.  Liu J, Mansouri K, Judson RS, Martin MT, Hong H, Chen M, et al. Predicting 
hepatotoxicity using ToxCast in vitro bioactivity and chemical structure. Chem Res 
Toxicol [Internet]. 2015;28(4):738–51. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25697799 
25.  Kleinstreuer NC, Dix DJ, Houck KA, Kavlock RJ, Knudsen TB, Martin MT, et al. In vitro 
perturbations of targets in cancer hallmark processes predict rodent chemical 
carcinogenesis. Toxicol Sci [Internet]. 2013;131(1):40–55. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23024176 
26.  Kleinstreuer N, Dix D, Rountree M, Baker N, Sipes N, Reif D, et al. A computational 
model predicting disruption of blood vessel development. PLoS Comput Biol 
[Internet]. 2013;9(4):e1002996. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23592958 
27.  Sipes NS, Martin MT, Reif DM, Kleinstreuer NC, Judson RS, Singh A V, et al. Predictive 
models of prenatal developmental toxicity from ToxCast high-throughput screening 
data. Toxicol Sci [Internet]. 2011;124(1):109–27. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21873373 
28.  Martin MT, Mendez E, Corum DG, Judson RS, Kavlock RJ, Rotroff DM, et al. Profiling 
the reproductive toxicity of chemicals from multigeneration studies in the toxicity 
reference database. Toxicol Sci [Internet]. 2009;110(1):181–90. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19363143 
29.  Martin MT, Judson RS, Reif DM, Kavlock RJ, Dix DJ. Profiling chemicals based on 
chronic toxicity results from the U.S. EPA ToxRef Database. Env Heal Perspect 
[Internet]. 2009;117(3):392–9. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19337514 
30.  Pigliucci M. Genotype-phenotype mapping and the end of the “genes as blueprint” 
metaphor. Philos Trans R Soc L B Biol Sci [Internet]. 2010;365(1540):557–66. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20083632 
31.  Lehner B. Genotype to phenotype: lessons from model organisms for human genetics. 
Nat Rev Genet [Internet]. 2013;14(3):168–78. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23358379 
32.  Watford SM, Grashow RG, De La Rosa VY, Rudel RA, Friedman KP, Martin MT. Novel 
application of normalized pointwise mutual information (NPMI) to mine biomedical 
literature for gene sets associated with disease: use case in breast carcinogenesis. 






33.  Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next 
Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 
[Internet]. 2017;171(6):1437–1452 e17. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29195078 
34.  Oki NO, Edwards SW. An integrative data mining approach to identifying adverse 
outcome pathway signatures. Toxicology [Internet]. 2016;350–352:49–61. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/27108252 
35.  Davis AP, Grondin CJ, Johnson RJ, Sciaky D, King BL, McMorran R, et al. The 
Comparative Toxicogenomics Database: update 2017. Nucleic Acids Res [Internet]. 
2017;45(D1):D972–8. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27651457 
36.  Rooney AA, Boyles AL, Wolfe MS, Bucher JR, Thayer KA. Systematic review and 
evidence integration for literature-based environmental health science assessments. 
Env Heal Perspect [Internet]. 2014;122(7):711–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24755067 
37.  Kavlock RJ, Bahadori T, Barton-Maclaren TS, Gwinn MR, Rasenberg M, Thomas RS. 
Accelerating the Pace of Chemical Risk Assessment. Chem Res Toxicol [Internet]. 
2018;31(5):287–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29600706 
38.  Wilkinson MD, Dumontier M, Aalbersberg IjJ, Appleton G, Axton M, Baak A, et al. The 
FAIR Guiding Principles for scientific data management and stewardship. Sci Data 
[Internet]. The Author(s); 2016 Mar 15;3:160018. Available from: 
https://doi.org/10.1038/sdata.2016.18 
39.  Chen M, Mao S, Liu Y. Big Data: A Survey. Mob Networks Appl [Internet]. 
2014;19(2):171–209. Available from: https://doi.org/10.1007/s11036-013-0489-0 
40.  Raja K, Patrick M, Gao Y, Madu D, Yang Y, Tsoi LC. A Review of Recent Advancement 
in Integrating Omics Data with Literature Mining towards Biomedical Discoveries. Int J 
Genomics [Internet]. 2017;2017:6213474. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28331849 
41.  Jagodnik KM, Koplev S, Jenkins SL, Ohno-Machado L, Paten B, Schurer SC, et al. 
Developing a framework for digital objects in the Big Data to Knowledge (BD2K) 
commons: Report from the Commons Framework Pilots workshop. J Biomed Inf 
[Internet]. 2017;71:49–57. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28501646 
42.  Bui AAT, Van Horn JD, Consortium NBKC. Envisioning the future of “big data” 
biomedicine. J Biomed Inf [Internet]. 2017;69:115–7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28366789 
43.  Sagiroglu S, Sinanc D. Big data: A review. In: 2013 International Conference on 
Collaboration Technologies and Systems (CTS). 2013. p. 42–7.  
44.  Begoli E, Horey J. Design Principles for Effective Knowledge Discovery from Big Data. 
In: 2012 Joint Working IEEE/IFIP Conference on Software Architecture and European 
Conference on Software Architecture. 2012. p. 215–8.  
138 
 
45.  Affymetrix Standards Program [Internet]. [cited 2019 Jan 15]. Available from: 
http://www.affymetrix.com/about_affymetrix/outreach/standards_program/standards
-program.affx 
46.  Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression 
and hybridization array data repository. Nucleic Acids Res [Internet]. 2002 Jan 1 
[cited 2019 Feb 6];30(1):207–10. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11752295 
47.  Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI 
GEO: archive for functional genomics data sets—update. Nucleic Acids Res [Internet]. 
2012 Nov 26 [cited 2019 Feb 6];41(D1):D991–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23193258 
48.  Merrick BA, Paules RS, Tice RR. Intersection of toxicogenomics and high throughput 
screening in the Tox21 program: an NIEHS perspective. Int J Biotechnol [Internet]. 
2015;14(1):7–27. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27122658 
49.  Harrill J. Development and Use of a High Content Imaging-Based Phenotypic Profiling 
Assay for Chemical Bioactivity Screening. 2018; Available from: 
https://epa.figshare.com/articles/Development_and_Use_of_a_High_Content_Imagin
g-Based_Phenotypic_Profiling_Assay_for_Chemical_Bioactivity_Screening/7003181 
50.  Shah I, Setzer RW, Jack J, Houck KA, Judson RS, Knudsen TB, et al. Using ToxCastTM 
Data to Reconstruct Dynamic Cell State Trajectories and Estimate Toxicological Points 
of Departure. Environ Health Perspect [Internet]. 2016 Jul [cited 2019 Jan 
16];124(7):910–9. Available from: 
https://ehp.niehs.nih.gov/doi/10.1289/ehp.1409029 
51.  NIH STRATEGIC PLAN FOR DATA SCIENCE. [cited 2019 Jan 15]; Available from: 
http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002195 
52.  Mahony C, Currie R, Daston G, Kleinstreuer N, van de Water B. Highlight report: ‘Big 
data in the 3R’s: outlook and recommendations’, a roundtable summary. Arch Toxicol 
[Internet]. Springer Berlin Heidelberg; 2018 Feb 16 [cited 2019 Jan 24];92(2):1015–
20. Available from: http://link.springer.com/10.1007/s00204-017-2145-0 
53.  Judson RS, Kavlock RJ, Setzer RW, Cohen Hubal EA, Martin MT, Knudsen TB, et al. 
Estimating Toxicity-Related Biological Pathway Altering Doses for High-Throughput 
Chemical Risk Assessment. Chem Res Toxicol [Internet]. 2011 Apr 18 [cited 2019 Jan 
24];24(4):451–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21384849 
54.  Judson R, Houck K, Martin M, Knudsen T, Thomas RS, Sipes N, et al. In vitro and 
modelling approaches to risk assessment from the U.S. Environmental Protection 
Agency ToxCast programme. Basic Clin Pharmacol Toxicol [Internet]. 
2014;115(1):69–76. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/24684691 
55.  Barton-Maclaren T, Gwinn M, Thomas R, Kavlock R, Rasenberg M. INSIGHT: New 
Approaches to Chemical Assessment—a Progress Report [Internet]. 2019 [cited 2019 




56.  Fitzpatrick JM, Patlewicz G. Application of IATA – A case study in evaluating the global 
and local performance of a Bayesian network model for skin sensitization. SAR QSAR 
Environ Res [Internet]. 2017 Apr 3 [cited 2019 Jan 24];28(4):297–310. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/28423913 
57.  Fitzpatrick JM, Roberts DW, Patlewicz G. An evaluation of selected (Q)SARs/expert 
systems for predicting skin sensitisation potential. SAR QSAR Environ Res [Internet]. 
2018 Jun 3 [cited 2019 Jan 24];29(6):439–68. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/29676182 
58.  Roberts DW, Patlewicz G. Non-animal assessment of skin sensitization hazard: Is an 
integrated testing strategy needed, and if so what should be integrated? J Appl 
Toxicol [Internet]. 2018 Jan [cited 2019 Jan 24];38(1):41–50. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28543848 
59.  US EPA O. Integrated Risk Information System. [cited 2019 Jan 24]; Available from: 
https://www.epa.gov/iris 
60.  NCBI. PubMed [Internet]. [cited 2019 Jan 24]. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/ 
61.  Lea IA, Gong H, Paleja A, Rashid A, Fostel J. CEBS: a comprehensive annotated 
database of toxicological data. Nucleic Acids Res [Internet]. 2017;45(D1):D964–71. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/27899660 
62.  eChemPortal - Substance Search [Internet]. [cited 2019 Feb 6]. Available from: 
https://www.echemportal.org/echemportal/substancesearch/substancesearchlink.acti
on 
63.  US EPA O. Provisional Peer-Reviewed Toxicity Values (PPRTVs). [cited 2019 Feb 6]; 
Available from: https://www.epa.gov/pprtv 
64.  The Carcinogenic Potency Project (CPDB) [Internet]. [cited 2019 Feb 6]. Available 
from: https://toxnet.nlm.nih.gov/cpdb/index.html 
65.  ACToR Web Services [Internet]. [cited 2019 Jan 21]. Available from: 
https://actorws.epa.gov/actorws/ 
66.  Reif DM, Martin MT, Tan SW, Houck KA, Judson RS, Richard AM, et al. Endocrine 
Profiling and Prioritization of Environmental Chemicals Using ToxCast Data. Environ 
Health Perspect [Internet]. National Institute of Environmental Health Science; 2010 
Dec [cited 2019 Jan 24];118(12):1714–20. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20826373 
67.  Rusyn I, Sedykh A, Low Y, Guyton KZ, Tropsha A. Predictive modeling of chemical 
hazard by integrating numerical descriptors of chemical structures and short-term 






68.  Dionisio KL, Phillips K, Price PS, Grulke CM, Williams A, Biryol D, et al. The Chemical 
and Products Database, a resource for exposure-relevant data on chemicals in 
consumer products. Sci Data [Internet]. Nature Publishing Group; 2018 Jul 10 [cited 
2019 Jan 24];5:180125. Available from: 
http://www.nature.com/articles/sdata2018125 
69.  Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update: 
improved access to chemical data. Nucleic Acids Res [Internet]. 2019 Jan 8 [cited 
2019 Feb 7];47(D1):D1102–9. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/30371825 
70.  Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. 
Adverse outcome pathways: a conceptual framework to support ecotoxicology 
research and risk assessment. Env Toxicol Chem [Internet]. 2010;29(3):730–41. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/20821501 
71.  Brockmeier EK, Hodges G, Hutchinson TH, Butler E, Hecker M, Tollefsen KE, et al. The 
Role of Omics in the Application of Adverse Outcome Pathways for Chemical Risk 
Assessment. Toxicol Sci [Internet]. Oxford University Press; 2017 [cited 2019 Feb 
7];158(2):252–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28525648 
72.  Kleinstreuer NC, Sullivan K, Allen D, Edwards S, Mendrick DL, Embry M, et al. 
Adverse outcome pathways: From research to regulation scientific workshop report. 
Regul Toxicol Pharmacol [Internet]. Academic Press; 2016 Apr 1 [cited 2019 Feb 
7];76:39–50. Available from: 
https://www.sciencedirect.com/science/article/pii/S0273230016300071?via%3Dihub 
73.  Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, et al. How 
Adverse Outcome Pathways Can Aid the Development and Use of Computational 
Prediction Models for Regulatory Toxicology. Toxicol Sci [Internet]. Oxford University 
Press; 2017 [cited 2019 Feb 7];155(2):326–36. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27994170 
74.  Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, et al. 
Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to 
Testing and Assessment (IATA). Regul Toxicol Pharmacol [Internet]. Academic Press; 
2014 Dec 1 [cited 2019 Feb 7];70(3):629–40. Available from: 
https://www.sciencedirect.com/science/article/pii/S0273230014002141?via%3Dihub 
75.  Juberg DR, Knudsen TB, Sander M, Beck NB, Faustman EM, Mendrick DL, et al. 
FutureTox III: Bridges for Translation. Toxicol Sci [Internet]. Oxford University Press; 
2017 [cited 2019 Feb 7];155(1):22–31. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27780885 
76.  Buesen R, Chorley BN, da Silva Lima B, Daston G, Deferme L, Ebbels T, et al. 
Applying ’omics technologies in chemicals risk assessment: Report of an ECETOC 
workshop. Regul Toxicol Pharmacol [Internet]. Academic Press; 2017 Dec 1 [cited 






77.  Adverse Outcome Pathways, Molecular Screening and Toxicogenomics - OECD 
[Internet]. [cited 2019 Jan 21]. Available from: 
http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-
screening-and-toxicogenomics.htm 
78.  Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical 
terminology. Nucleic Acids Res [Internet]. 2004;32(Database issue):D267-70. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/14681409 
79.  Cesta MF, Malarkey DE, Herbert RA, Brix A, Hamlin  2nd MH, Singletary E, et al. The 
National Toxicology Program Web-based nonneoplastic lesion atlas: a global 
toxicology and pathology resource. Toxicol Pathol [Internet]. 2014;42(2):458–60. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/24488020 
80.  Briggs K, Barber C, Cases M, Marc P, Steger-Hartmann T. Value of shared preclinical 
safety studies - The eTOX database. Toxicol Rep [Internet]. 2015;2:210–21. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/28962354 
81.  Ravagli C, Pognan F, Marc P. OntoBrowser: a collaborative tool for curation of 
ontologies by subject matter experts. Bioinformatics [Internet]. Oxford University 
Press; 2017 Jan 1 [cited 2019 Jan 31];33(1):148–9. Available from: 
https://academic.oup.com/bioinformatics/article-
lookup/doi/10.1093/bioinformatics/btw579 
82.  Shapiro AJ, Antoni S, Guyton KZ, Lunn RM, Loomis D, Rusyn I, et al. Software Tools 
to Facilitate Systematic Review Used for Cancer Hazard Identification. [cited 2019 Jan 
31]; Available from: https://doi.org/10.1289/EHP4224. 
83.  Heidorn CJ, Rasmussen K, Hansen BG, Norager O, Allanou R, Seynaeve R, et al. 
IUCLID: an information management tool for existing chemicals and biocides. J Chem 
Inf Comput Sci [Internet]. 2003;43(3):779–86. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/12767136 
84.  IUCLID format - IUCLID [Internet]. [cited 2019 Jan 31]. Available from: 
https://iuclid6.echa.europa.eu/format 
85.  Anthony Tony Cox L, Popken DA, Kaplan AM, Plunkett LM, Becker RA. How well can in 
vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study. 
Regul Toxicol Pharmacol [Internet]. 2016;77:54–64. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26879462 
86.  Chiu WA, Guyton KZ, Martin MT, Reif DM, Rusyn I. Use of high-throughput in vitro 
toxicity screening data in cancer hazard evaluations by IARC Monograph Working 
Groups. ALTEX [Internet]. 2018;35(1):51–64. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28738424 
87.  Guyton KZ, Rusyn I, Chiu WA, Corpet DE, van den Berg M, Ross MK, et al. Application 
of the key characteristics of carcinogens in cancer hazard identification. 





88.  Smith MT, Guyton KZ, Gibbons CF, Fritz JM, Portier CJ, Rusyn I, et al. Key 
Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of 
Carcinogenesis. Env Heal Perspect [Internet]. 2016;124(6):713–21. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26600562 
89.  Becker RA, Dreier DA, Manibusan MK, Cox LAT, Simon TW, Bus JS. How well can 
carcinogenicity be predicted by high throughput “characteristics of carcinogens” 
mechanistic data? Regul Toxicol Pharmacol [Internet]. 2017;90:185–96. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/28866267 
90.  Grashow RG, De La Rosa VY, Watford SM, Ackerman JM, Rudel RA. BCScreen: A gene 
panel to test for breast carcinogenesis in chemical safety screening. Comput Toxicol 
[Internet]. 2018;5(Supplement C):16–24. Available from: 
http://www.sciencedirect.com/science/article/pii/S2468111317300580 
91.  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. 
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci U S A [Internet]. 2005;102(43):15545–
50. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16199517 
92.  Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 
Molecular signatures database (MSigDB) 3.0. Bioinformatics [Internet]. Oxford 
University Press; 2011 Jun 15 [cited 2019 Jan 24];27(12):1739–40. Available from: 
https://academic.oup.com/bioinformatics/article-
lookup/doi/10.1093/bioinformatics/btr260 
93.  Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The 
Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst [Internet]. 
Cell Press; 2015 Dec 23 [cited 2019 Jan 24];1(6):417–25. Available from: 
https://www.sciencedirect.com/science/article/pii/S2405471215002185 
94.  Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles G V, et al. Enrichr: interactive 
and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 
[Internet]. 2013;14:128. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23586463 
95.  Kuleshov M V, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: 
a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids 
Res [Internet]. 2016;44(W1):W90-7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27141961 
96.  Online Mendelian Inheritance in Man, OMIM® [Internet]. Baltimore, MD: McKusick-
Nathans Institute of Genetic Medicine, Johns Hopkins University; Available from: 
https://omim.org/ 
97.  King BL, Davis AP, Rosenstein MC, Wiegers TC, Mattingly CJ. Ranking transitive 
chemical-disease inferences using local network topology in the comparative 
toxicogenomics database. PLoS One [Internet]. 2012;7(11):e46524. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23144783 
98.  Hirschman L, Yeh A, Blaschke C, Valencia A. Overview of BioCreAtIvE: critical 
assessment of information extraction for biology. BMC Bioinformatics [Internet]. 
2005;6 Suppl 1:S1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15960821 
143 
 
99.  Smith L, Tanabe LK, Ando RJ, Kuo CJ, Chung IF, Hsu CN, et al. Overview of 
BioCreative II gene mention recognition. Genome Biol [Internet]. 2008;9 Suppl 2:S2. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/18834493 
100.  Vempati UD, Przydzial MJ, Chung C, Abeyruwan S, Mir A, Sakurai K, et al. 
Formalization, Annotation and Analysis of Diverse Drug and Probe Screening Assay 
Datasets Using the BioAssay Ontology (BAO). PLoS One [Internet]. Public Library of 
Science; 2012 [cited 2019 Feb 7];7(11):e49198. Available from: 
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049198 
101.  Abeyruwan S, Vempati UD, Küçük-McGinty H, Visser U, Koleti A, Mir A, et al. Evolving 
BioAssay Ontology (BAO): modularization, integration and applications. J Biomed 
Semantics [Internet]. 2014 [cited 2019 Feb 7];5(Suppl 1):S5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25093074 
102.  Brown GR, Hem V, Katz KS, Ovetsky M, Wallin C, Ermolaeva O, et al. Gene: a gene-
centered information resource at NCBI. Nucleic Acids Res [Internet]. 
2015;43(Database issue):D36-42. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25355515 
103.  Pundir S, Martin MJ, O’Donovan C. UniProt Protein Knowledgebase. Methods Mol Biol 
[Internet]. 2017;1558:41–55. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28150232 
104.  Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt C. UniRef clusters: a 
comprehensive and scalable alternative for improving sequence similarity searches. 
Bioinformatics [Internet]. 2015;31(6):926–32. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25398609 
105.  Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids 
Res [Internet]. 2000;28(1):27–30. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/10592173 
106.  Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference 
resource for gene and protein annotation. Nucleic Acids Res [Internet]. 
2016;44(D1):D457-62. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26476454 
107.  Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives 
on genomes, pathways, diseases and drugs. Nucleic Acids Res [Internet]. 
2017;45(D1):D353–61. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27899662 
108.  Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The 
Reactome pathway Knowledgebase. Nucleic Acids Res [Internet]. 2016;44(D1):D481-
7. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26656494 
109.  Online Mendelian Inheritance in Man, OMIM® [Internet]. McKusick-Nathans Institute 
of Genetic Medicine, Johns Hopkins University (Baltimore, MD). [cited 2019 Jan 30]. 




110.  Judson R, Thomas RS, Baker N, Simha A, Howey XM, Marable C, et al. Workflow for 
Defining Reference Chemicals for Assessing Performance of In Vitro Assays. ALTEX 
[Internet]. 2018 Dec 17 [cited 2019 Jan 31]; Available from: 
https://www.altex.org/index.php/altex/article/view/1168 
111.  Fridley BL, Jenkins GD, Biernacka JM. Self-contained gene-set analysis of expression 
data: an evaluation of existing and novel methods. PLoS One [Internet]. 2010;5(9). 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/20862301 
112.  Papatheodorou I, Oellrich A, Smedley D. Linking gene expression to phenotypes via 
pathway information. J Biomed Semant [Internet]. 2015;6:17. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25901272 
113.  Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-
Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. 
Science (80- ) [Internet]. 2013;342(6162):1094–8. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/24288332 
114.  Hoover RN, Hyer M, Pfeiffer RM, Adam E, Bond B, Cheville AL, et al. Adverse health 
outcomes in women exposed in utero to diethylstilbestrol. N Engl J Med [Internet]. 
2011;365(14):1304–14. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/21991952 
115.  Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath  Jr. CW, et al. Alcohol, 
tobacco and breast cancer--collaborative reanalysis of individual data from 53 
epidemiological studies, including 58,515 women with breast cancer and 95,067 
women without the disease. Br J Cancer [Internet]. 2002;87(11):1234–45. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/12439712 
116.  Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. 
Estrogen plus progestin and breast cancer incidence and mortality in the Women’s 
Health Initiative Observational Study. J Natl Cancer Inst [Internet]. 
2013;105(8):526–35. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23543779 
117.  Shioda T, Rosenthal NF, Coser KR, Suto M, Phatak M, Medvedovic M, et al. 
Expressomal approach for comprehensive analysis and visualization of ligand 
sensitivities of xenoestrogen responsive genes. Proc Natl Acad Sci U S A [Internet]. 
2013;110(41):16508–13. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/24062438 
118.  Schwarzman MR, Ackerman JM, Dairkee SH, Fenton SE, Johnson D, Navarro KM, et 
al. Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for 
Chemical Safety Evaluation. Env Heal Perspect [Internet]. 2015;123(12):1255–64. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/26032647 
119.  Pirone JR, D’Arcy M, Stewart DA, Hines WC, Johnson M, Gould MN, et al. Age-
associated gene expression in normal breast tissue mirrors qualitative age-at-
incidence patterns for breast cancer. Cancer Epidemiol Biomarkers Prev [Internet]. 





120.  Parada  Jr. H, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, et al. 
Race-associated biological differences among luminal A and basal-like breast cancers 
in the Carolina Breast Cancer Study. Breast Cancer Res [Internet]. 2017;19(1):131. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/29228969 
121.  Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and 
recent advances in the treatment and prevention. Int J Med Sci [Internet]. 
2014;11(11):1185–200. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25249787 
122.  Gwinn MR, Axelrad DA, Bahadori T, Bussard D, Cascio WE, Deener K, et al. Chemical 
Risk Assessment: Traditional vs Public Health Perspectives. Am J Public Heal 
[Internet]. 2017;107(7):1032–9. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28520487 
123.  Perkins EJ, Antczak P, Burgoon L, Falciani F, Garcia-Reyero N, Gutsell S, et al. 
Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case 
Studies With Different Degrees of Completeness and Scientific Confidence. Toxicol Sci 
[Internet]. 2015;148(1):14–25. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26500288 
124.  IBCERCC. Breast Cancer and the Environment: Prioritizing Prevention. In IBCERCC 
(Interagency Breast Cancer and Environmental Research Coordinating Committee); 
2013. Available from: 
https://www.niehs.nih.gov/about/assets/docs/breast_cancer_and_the_environment_
prioritizing_prevention_508.pdf 
125.  Kavlock R, Chandler K, Houck K, Hunter S, Judson R, Kleinstreuer N, et al. Update on 
EPA’s ToxCast program: providing high throughput decision support tools for chemical 
risk management. Chem Res Toxicol [Internet]. 2012;25(7):1287–302. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/22519603 
126.  Mansouri K, Abdelaziz A, Rybacka A, Roncaglioni A, Tropsha A, Varnek A, et al. 
CERAPP: Collaborative Estrogen Receptor Activity Prediction Project. Env Heal 
Perspect [Internet]. 2016;124(7):1023–33. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26908244 
127.  Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online 
Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and 
genetic disorders. Nucleic Acids Res [Internet]. 2015;43(Database issue):D789-98. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/25428349 
128.  Merrick BA, Paules RS, Tice RR. Intersection of toxicogenomics and high throughput 
screening in the Tox21 program: an NIEHS perspective. Int J Biotechnol [Internet]. 
NIH Public Access; 2015 [cited 2019 Jan 15];14(1):7–27. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27122658 
129.  Mav D, Shah RR, Howard BE, Auerbach SS, Bushel PR, Collins JB, et al. A hybrid gene 
selection approach to create the S1500+ targeted gene sets for use in high-





130.  Coordinators NR. Database resources of the National Center for Biotechnology 
Information. Nucleic Acids Res [Internet]. 2017; Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29140470 
131.  NLM. Chapter 11 Relationships in Medical Subject Headings. 2016.  
132.  The UniProt C. UniProt: the universal protein knowledgebase. Nucleic Acids Res 
[Internet]. 2017;45(D1):D158–69. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27899622 
133.  NLM. Gene [Internet]. 2018 [cited 2018 Jan 5]. Available from: 
ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene2pubmed.gz 
134.  NLM. Gene Reference into Function (GeneRIF) [Internet]. 2017 [cited 2017 Nov 30]. 
Available from: https://www.ncbi.nlm.nih.gov/gene/about-generif 
135.  CTD. CTD downloads [Internet]. 2017 [cited 2017 Nov 30]. Available from: 
http://ctdbase.org/downloads/ 
136.  UniProt. UniProt downloads [Internet]. 2017 [cited 2017 Nov 30]. Available from: 
http://www.uniprot.org/downloads 
137.  Reactome. Reactome downloads [Internet]. 2018 [cited 2018 Jan 5]. Available from: 
https://reactome.org/ 
138.  Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The 
Reactome Pathway Knowledgebase. Nucleic Acids Res [Internet]. 2017;46(D1):D649–
55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29145629 
139.  RGD. RGD downloads [Internet]. 2018 [cited 2018 Nov 30]. Available from: 
ftp://ftp.rgd.mcw.edu/pub/data_release/ 
140.  Shimoyama M, De Pons J, Hayman GT, Laulederkind SJ, Liu W, Nigam R, et al. The 
Rat Genome Database 2015: genomic, phenotypic and environmental variations and 
disease. Nucleic Acids Res [Internet]. 2015;43(Database issue):D743-50. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/25355511 
141.  MGI. MGI download [Internet]. 2017 [cited 2017 Nov 30]. Available from: 
http://www.informatics.jax.org/downloads/reports/index.html 
142.  Eppig JT, Smith CL, Blake JA, Ringwald M, Kadin JA, Richardson JE, et al. Mouse 
Genome Informatics (MGI): Resources for Mining Mouse Genetic, Genomic, and 
Biological Data in Support of Primary and Translational Research. Methods Mol Biol 
[Internet]. 2017;1488:47–73. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27933520 
143.  Bouma G. Normalized (pointwise) mutual information in collocation extraction. Proc 
Int Conf Ger Soc Comput Linguist Lang Technol. 2009;  
144.  Pfeffer U, Fecarotta E, Castagnetta L, Vidali G. Estrogen receptor variant messenger 
RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer 




145.  Kang HY, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human 
prostate coactivator ARA54, a novel protein that associates with the androgen 
receptor. J Biol Chem [Internet]. 1999;274(13):8570–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10085091 
146.  Song F, Parekh-Bhurke S, Hooper L, Loke YK, Ryder JJ, Sutton AJ, et al. Extent of 
publication bias in different categories of research cohorts: a meta-analysis of 
empirical studies. BMC Med Res Methodol [Internet]. 2009;9:79. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19941636 
147.  Goodson 3rd WH, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain 
Salsamendi A, et al. Assessing the carcinogenic potential of low-dose exposures to 
chemical mixtures in the environment: the challenge ahead. Carcinogenesis 
[Internet]. 2015;36 Suppl 1:S254-96. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26106142 
148.  Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell [Internet]. 
2011;144(5):646–74. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/21376230 
149.  Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, et al. 
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical 
molecular markers. BMC Med Genomics [Internet]. 2012;5:44. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23035882 
150.  Cancer Genome Atlas N. Comprehensive molecular portraits of human breast 
tumours. Nature [Internet]. 2012;490(7418):61–70. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23000897 
151.  Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, et al. 
Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc 
Natl Acad Sci U S A [Internet]. 2010;107(50):21725–30. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/21118987 
152.  Chen L, Xiao Z, Meng Y, Zhao Y, Han J, Su G, et al. The enhancement of cancer stem 
cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-
cancer drugs. Biomaterials [Internet]. 2012;33(5):1437–44. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/22078807 
153.  Chua SL, See Too WC, Khoo BY, Few LL. UBC and YWHAZ as suitable reference genes 
for accurate normalisation of gene expression using MCF7, HCT116 and HepG2 cell 
lines. Cytotechnology [Internet]. 2011;63(6):645–54. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/21850463 
154.  Jacob MD, Audas TE, Uniacke J, Trinkle-Mulcahy L, Lee S. Environmental cues induce 
a long noncoding RNA-dependent remodeling of the nucleolus. Mol Biol Cell 
[Internet]. 2013;24(18):2943–53. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/23904269 
155.  Fontaine JF, Priller F, Barbosa-Silva A, Andrade-Navarro MA. Genie: literature-based 
gene prioritization at multi genomic scale. Nucleic Acids Res [Internet]. 2011;39(Web 




156.  Guido. Python tutorial, Technical Report CS-R9526. 1995.  
157.  MongoDB [Internet]. Available from: https://www.mongodb.com/ 
158.  pandas: Python Data Analysis Library [Internet]. 2012. Available from: 
http://pandas.pydata.org/ 
159.  Van Der Walt S, Colbert C, Varoquaux G. The NumPy array: a structure for efficient 
numerical computation. 2011; Available from: http://arxiv.org/abs/1102.1523 
160.  Lam S, Pitrou A, Seibert S. Numba: A LLVM-based Python JIT Compiler. In: 
Proceedings of the Second Workshop on the LLVM Compiler Infrastructure in HPC 
[Internet]. Austin, Texas: ACM; 2015. Available from: 
http://dx.doi.org/10.1145/2833157.2833162 
161.  Pérez F, Granger B. IPython: A System for Interactive Scientific Computing. Comput 
Sci Eng [Internet]. IEEE; 2007;9(3):21–9. Available from: 
http://dx.doi.org/10.1109/mcse.2007.53 
162.  Homologene [Internet]. Vol. 2017. Available from: 
https://www.ncbi.nlm.nih.gov/homologene 
163.  Pecina P. Lexical association measures and collocation extraction. Lang Resour Eval 
[Internet]. 2010;44(1):137–58. Available from: https://doi.org/10.1007/s10579-
009-9101-4 
164.  Ade AS, Wright ZC, States DJ. Gene2MeSH [Internet]. Ann Arbor (MI): National 
Center for Integrative Biomedical Informatics; 2007. Available from: 
http://gene2mesh.ncibi.org 
165.  Cheung WA, Ouellette BFF, Wasserman WW. Quantitative biomedical annotation using 
medical subject heading over-representation profiles (MeSHOPs). BMC Bioinformatics 
[Internet]. 2012;13(1):249. Available from: http://dx.doi.org/10.1186/1471-2105-
13-249 
166.  Pearce D. A Comparative Evaluation of Collocation Extraction Techniques [Internet]. 
International Conference on Language Resources and Evaluation. 2002. p. 1530–6. 
Available from: http://www.lrec-conf.org/proceedings/lrec2002/ 
167.  Kastrin A, Rindflesch TC, Hristovski D. Large-scale structure of a network of co-
occurring MeSH terms: statistical analysis of macroscopic properties. PLoS One 
[Internet]. 2014;9(7):e102188. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25006672 
168.  Seelow D, Schwarz JM, Schuelke M. GeneDistiller--distilling candidate genes from 
linkage intervals. PLoS One [Internet]. 2008;3(12):e3874. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19057649 
169.  Tranchevent LC, Ardeshirdavani A, ElShal S, Alcaide D, Aerts J, Auboeuf D, et al. 
Candidate gene prioritization with Endeavour. Nucleic Acids Res [Internet]. 




170.  Moreau Y, Tranchevent LC. Computational tools for prioritizing candidate genes: 
boosting disease gene discovery. Nat Rev Genet [Internet]. 2012;13(8):523–36. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/22751426 
171.  Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem Substance 
and Compound databases. Nucleic Acids Res [Internet]. 2016;44(D1):D1202-13. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/26400175 
172.  Collins FS, Gray GM, Bucher JR. Toxicology. Transforming environmental health 
protection. Science (80- ) [Internet]. 2008;319(5865):906–7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/18276874 
173.  Martin MT, Knudsen TB, Reif DM, Houck KA, Judson RS, Kavlock RJ, et al. Predictive 
model of rat reproductive toxicity from ToxCast high throughput screening. Biol 
Reprod [Internet]. 2011;85(2):327–39. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/21565999 
174.  Theunissen PT, Beken S, Cappon GD, Chen C, Hoberman AM, van der Laan JW, et al. 
Toward a comparative retrospective analysis of rat and rabbit developmental toxicity 
studies for pharmaceutical compounds. Reprod Toxicol [Internet]. 2014;47:27–32. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/25517003 
175.  Knudsen TB, Martin MT, Kavlock RJ, Judson RS, Dix DJ, Singh A V. Profiling the 
activity of environmental chemicals in prenatal developmental toxicity studies using 
the U.S. EPA’s ToxRefDB. Reprod Toxicol [Internet]. 2009;28(2):209–19. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/19446433 
176.  Thomas RS, Black MB, Li L, Healy E, Chu TM, Bao W, et al. A comprehensive 
statistical analysis of predicting in vivo hazard using high-throughput in vitro 
screening. Toxicol Sci [Internet]. 2012;128(2):398–417. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/22543276 
177.  Novotarskyi S, Abdelaziz A, Sushko Y, Korner R, Vogt J, Tetko I V. ToxCast EPA in 
Vitro to in Vivo Challenge: Insight into the Rank-I Model. Chem Res Toxicol 
[Internet]. 2016;29(5):768–75. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27120770 
178.  Truong L, Ouedraogo G, Pham L, Clouzeau J, Loisel-Joubert S, Blanchet D, et al. 
Predicting in vivo effect levels for repeat-dose systemic toxicity using chemical, 
biological, kinetic and study covariates. Arch Toxicol [Internet]. 2018;92(2):587–600. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/29075892 
179.  Hill  3rd T, Nelms MD, Edwards SW, Martin M, Judson R, Corton JC, et al. Editor’s 
Highlight: Negative Predictors of Carcinogenicity for Environmental Chemicals. Toxicol 
Sci [Internet]. 2017;155(1):157–69. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27679563 
180.  Judson RS, Martin MT, Patlewicz G, Wood CE. Retrospective mining of toxicology data 
to discover multispecies and chemical class effects: Anemia as a case study. Regul 





181.  Casati S, Aschberger K, Barroso J, Casey W, Delgado I, Kim TS, et al. Standardisation 
of defined approaches for skin sensitisation testing to support regulatory use and 
international adoption: position of the International Cooperation on Alternative Test 
Methods. Arch Toxicol [Internet]. 2018;92(2):611–7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29127450 
182.  Covell DG. Integrating constitutive gene expression and chemoactivity: mining the 
NCI60 anticancer screen. PLoS One [Internet]. 2012;7(10):e44631. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23056181 
183.  Fourches D, Muratov E, Tropsha A. Trust, but verify: on the importance of chemical 
structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model 
[Internet]. 2010;50(7):1189–204. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20572635 
184.  Sutton P, Woodruff TJ, Perron J, Stotland N, Conry JA, Miller MD, et al. Toxic 
environmental chemicals: the role of reproductive health professionals in preventing 
harmful exposures. Am J Obs Gynecol [Internet]. 2012;207(3):164–73. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/22405527 
185.  Zhao F, Li R, Xiao S, Diao H, El Zowalaty AE, Ye X. Multigenerational exposure to 
dietary zearalenone (ZEA), an estrogenic mycotoxin, affects puberty and reproduction 
in female mice. Reprod Toxicol [Internet]. 2014;47:81–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/24972337 




187.  NCCT. Animal Toxicity Studies: Effects and Endpoints (Toxicity Reference Database - 
ToxRefDB files) [Internet]. 2018. Available from: 
https://figshare.com/articles/Animal_Toxicity_Studies_Effects_and_Endpoints_Toxicit
y_Reference_Database_-_ToxRefDB_files_/6062545 
188.  Janus E. Concerns of CropLife America Regarding the Application and Use of the U.S. 
EPA’s Toxicity Reference Database. Environ Health Perspect [Internet]. National 
Institute of Environmental Health Sciences; 2009;117(10):A432–A432. Available 
from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897210/ 
189.  Plunkett LM, Kaplan AM, Becker RA. Challenges in using the ToxRefDB as a resource 
for toxicity prediction modeling. Regul Toxicol Pharmacol [Internet]. 2015;72(3):610–
4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26003516 
190.  Liu J, Patlewicz G, Williams AJ, Thomas RS, Shah I. Predicting Organ Toxicity Using in 
Vitro Bioactivity Data and Chemical Structure. Chem Res Toxicol [Internet]. 
2017;30(11):2046–59. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28768096 
191.  USEPA. Benchmark dose technical guidance [Internet]. Washington, DC: U.S. 




192.  Wahi MM, Parks D V, Skeate RC, Goldin SB. Reducing errors from the electronic 
transcription of data collected on paper forms: a research data case study. J Am Med 
Inf Assoc [Internet]. 2008;15(3):386–9. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/18308994 
193.  Majid A, Bae ON, Redgrave J, Teare D, Ali A, Zemke D. The Potential of Adaptive 
Design in Animal Studies. Int J Mol Sci [Internet]. 2015;16(10):24048–58. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/26473839 
194.  USEPA. Health Effects Test Guidelines: OPPTS 870.3800 Reproduction and Fertility 
Effects  [Internet]. 1998. Available from: 
https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0018 
195.  Courtot M, Juty N, Knupfer C, Waltemath D, Zhukova A, Drager A, et al. Controlled 
vocabularies and semantics in systems biology. Mol Syst Biol [Internet]. 2011;7:543. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22027554 
196.  Ward JM, Schofield PN, Sundberg JP. Reproducibility of histopathological findings in 
experimental pathology of the mouse: a sorry tail. Lab Anim (NY) [Internet]. NIH 
Public Access; 2017 Mar 22 [cited 2019 Jan 19];46(4):146–51. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/28328876 
197.  Wolf JC, Maack G. Evaluating the credibility of histopathology data in environmental 
endocrine toxicity studies. Environ Toxicol Chem [Internet]. 2017 Mar [cited 2019 Jan 
19];36(3):601–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27883231 
198.  Society of Toxicologic Pathology. International Harmonization of Nomenclature and 
Diagnostic Criteria (INHAND) [Internet]. Available from: 
https://www.toxpath.org/inhand.asp 
199.  Evans RS. Electronic Health Records: Then, Now, and in the Future. Yearb Med Inf 
[Internet]. 2016;Suppl 1:S48-61. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/27199197 
200.  Moreno-Conde A, Moner D, Cruz WD, Santos MR, Maldonado JA, Robles M, et al. 
Clinical information modeling processes for semantic interoperability of electronic 
health records: systematic review and inductive analysis. J Am Med Inf Assoc 
[Internet]. 2015;22(4):925–34. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25796595 
201.  Kaufman L, Gore K, Zandee JC. Data Standardization, Pharmaceutical Drug 
Development, and the 3Rs. ILAR J [Internet]. 2016;57(2):109–19. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/28053065 
202.  Kuchinke W, Aerts J, Semler SC, Ohmann C. CDISC standard-based electronic 
archiving of clinical trials. Methods Inf Med [Internet]. 2009;48(5):408–13. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/19621114 
203.  USEPA. Health Effects Test Guidelines: OPPTS 870.4100 Chronic Toxicity [Internet]. 





204.  Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, et al. Guidance on 
the use of the weight of evidence approach in scientific assessments. EFSA J 
[Internet]. 15(8):e04971. Available from: 
https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2017.4971 
205.  Simpson D. Units for reporting the results of toxicological measurements. Ann Clin 
Biochem [Internet]. 1980;17(6):328–31. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/7212606 
206.  Zegers I, Schimmel H. To Harmonize and Standardize: Making Measurement Results 
Comparable. Clin Chem [Internet]. 2014;60(7):911. Available from: 
http://clinchem.aaccjnls.org/content/60/7/911.abstract 
207.  NTP. Specifications for the conduct of studies to evaluate the toxic and carcinogenic 
potential of chemical, biological and physical agents in laboratory animals for the 
national toxicology program (NTP) [Internet]. RTP, NC; 2006. Available from: 
http://ntp.niehs.nih.gov/ntp/Test_Info/FinalNTP_ReproSpecsMay2011_508.pdf 
208.  Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-
Ovaskainen A, et al. “ToxRTool”, a new tool to assess the reliability of toxicological 
data. Toxicol Lett [Internet]. 2009;189(2):138–44. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19477248 
209.  Klimisch HJ, Andreae M, Tillmann U. A systematic approach for evaluating the quality 
of experimental toxicological and ecotoxicological data. Regul Toxicol Pharmacol 
[Internet]. 1997;25(1):1–5. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/9056496 
210.  Segal D, Makris SL, Kraft AD, Bale AS, Fox J, Gilbert M, et al. Evaluation of the 
ToxRTool’s ability to rate the reliability of toxicological data for human health hazard 
assessments. Regul Toxicol Pharmacol [Internet]. 2015;72(1):94–101. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/25777839 
211.  Haber LT, Dourson ML, Allen BC, Hertzberg RC, Parker A, Vincent MJ, et al. 
Benchmark dose (BMD) modeling: current practice, issues, and challenges. Crit Rev 
Toxicol [Internet]. 2018;48(5):387–415. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29516780 
212.  Hardy A, Benford D, Halldorsson T, Jeger Michael J, Knutsen Katrine H, More S, et al. 
Update: use of the benchmark dose approach in risk assessment. EFSA J [Internet]. 
Wiley-Blackwell; 2017;15(1):e04658. Available from: 
https://doi.org/10.2903/j.efsa.2017.4658 
213.  Davis JA, Gift JS, Zhao QJ. Introduction to benchmark dose methods and U.S. EPA’s 
benchmark dose software (BMDS) version 2.1.1. Toxicol Appl Pharmacol [Internet]. 
2011;254(2):181–91. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/21034758 
214.  USEPA. Benchmark Dose Software (BMDS) [Internet]. 2.2 R65 [B. Research Triangle 





215.  USEPA. Benchmark Dose Software (BMDS). Version 2.2 [Internet]. 2012. Available 
from: http://www.epa.gov/NCEA/bmds/index.html 
216.  Fournier K, Tebby C, Zeman F, Glorennec P, Zmirou-Navier D, Bonvallot N. Multiple 
exposures to indoor contaminants: Derivation of benchmark doses and relative 
potency factors based on male reprotoxic effects. Regul Toxicol Pharmacol [Internet]. 
2016;74:23–30. Available from: http://dx.doi.org/10.1016/j.yrtph.2015.11.017 
217.  Gephart LA, Salminen WF, Nicolich MJ, Pelekis M. Evaluation of subchronic toxicity 
data using the benchmark dose approach. Regul Toxicol Pharmacol [Internet]. 
2001;33(1):37–59. Available from: https://www.ncbi.nlm.nih.gov/pubmed/11259178 
218.  Wignall JA, Shapiro AJ, Wright FA, Woodruff TJ, Chiu WA, Guyton KZ, et al. 
Standardizing benchmark dose calculations to improve science-based decisions in 
human health assessments. Env Heal Perspect [Internet]. 2014;122(5):499–505. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24569956 
219.  Pham L, Watford S, Paul-Friedman K, Fostel J, Wignall J, Shapiro A. Python BMDS: A 
Python interface library and webserver for the canonical EPA dose-response modeling 
software. Prep.  
220.  Faustman EM, Allen BC, Kavlock RJ, Kimmel CA. Dose-response assessment for 
developmental toxicity. I. Characterization of database and determination of no 
observed adverse effect levels. Fundam Appl Toxicol [Internet]. 1994 Nov [cited 2019 
Jan 19];23(4):478–86. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/7867899 
221.  Filipsson AF, Sand S, Nilsson J, Victorin K. The benchmark dose method--review of 
available models, and recommendations for application in health risk assessment. Crit 
Rev Toxicol [Internet]. 2003 [cited 2019 Jan 19];33(5):505–42. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14594105 
222.  Yoon M, Blaauboer BJ, Clewell HJ. Quantitative in vitro to in vivo extrapolation 
(QIVIVE): An essential element for in vitro-based risk assessment. Toxicology 
[Internet]. 2015;332:1–3. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/25680635 
223.  OECD. The Global Portal to Information on Chemical Substances, eChemPortal 
[Internet]. 2014. Available from: http://www.oecd.org/chemicalsafety/risk-
assessment/echemportalglobalportaltoinformationonchemicalsubstances.htm 
224.  Canada H. Science Approach Document Threshold of Toxicological Concern (TTC)-
based Approach for Certain Substances  [Internet]. 2016. Available from: 
https://www.ec.gc.ca/ese-ees/default.asp?lang=En&n=326E3E17-1 
225.  Casey W, Jacobs A, Maull E, Matheson J, Clarke C, Lowit A. A new path forward: the 
Interagency Coordinating Committee on the Validation of Alternative Methods 
(ICCVAM) and National Toxicology Program’s Interagency Center for the Evaluation of 
Alternative Toxicological Methods (NICEATM). J Am Assoc Lab Anim Sci [Internet]. 




226.  Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et 
al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr 
Rev [Internet]. 2009;30(4):293–342. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19502515 
227.  Tilghman SL, Nierth-Simpson EN, Wallace R, Burow ME, McLachlan JA. Environmental 
hormones: Multiple pathways for response may lead to multiple disease outcomes. 
Steroids [Internet]. 2010;75(8–9):520–3. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/20466011 
228.  IARC. Formaldehyde. In: IARC Monographs on the Evaluation of Carcinogenic Risks to 
Humans [Internet]. 2012. p. 401–35. Available from: https://monographs.iarc.fr/wp-
content/uploads/2018/06/mono100F-29.pdf 
229.  Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, et al. 
Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol [Internet]. 
2017;68:3–33. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27760374 
230.  Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci 
[Internet]. 2009;111(2):233–7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/19617452 
231.  Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability 
domains, and virtual screening. Curr Pharm Des [Internet]. 2007;13(34):3494–504. 
Available from: https://www.ncbi.nlm.nih.gov/pubmed/18220786 
232.  Pham L, Watford S, Pradeep P, Judson R, Grulke C, Setzer R, et al. Estimating the 
limits on alternative model predictivity for system effects by defining variability in in 
vivo toxicity studies in Toxicity Reference Database (ToxRefDB). Prep.  
233.  IARC. Preamble: IARC monographs on the evaluation of carcinogenic risks to humans. 
In Lyon, France; 2006. Available from: https://monographs.iarc.fr/wp-
content/uploads/2018/06/CurrentPreamble.pdf 
234.  Swenberg JA, Moeller BC, Lu K, Rager JE, Fry RC, Starr TB. Formaldehyde 
carcinogenicity research: 30 years and counting for mode of action, epidemiology, 
and cancer risk assessment. Toxicol Pathol [Internet]. 2013;41(2):181–9. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/23160431 
235.  Zhang L, Freeman LE, Nakamura J, Hecht SS, Vandenberg JJ, Smith MT, et al. 
Formaldehyde and leukemia: epidemiology, potential mechanisms, and implications 
for risk assessment. Env Mol Mutagen [Internet]. 2010;51(3):181–91. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/19790261 
236.  Cohen SM, Arnold LL. Chemical carcinogenesis. Toxicol Sci [Internet]. 2011;120 
Suppl:S76-92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21147961 
237.  Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: 
tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 





238.  The Gene Ontology C. Expansion of the Gene Ontology knowledgebase and resources. 
Nucleic Acids Res [Internet]. 2017;45(D1):D331–8. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/27899567 
239.  Fabregat A, Korninger F, Viteri G, Sidiropoulos K, Marin-Garcia P, Ping P, et al. 
Reactome graph database: Efficient access to complex pathway data. PLoS Comput 
Biol [Internet]. 2018;14(1):e1005968. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29377902 
240.  MEDLINE Co-Occurrences (MRCOC) Files [Internet]. 2016. Available from: 
https://ii.nlm.nih.gov/MRCOC.shtml 
241.  Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, et al. Insulin resistance 
and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes 
mellitus. Prospective studies of Pima Indians. N Engl J Med [Internet]. 
1993;329(27):1988–92. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/8247074 
242.  Indexing Initiative [Internet]. MEDLINE Co-Occurrences (MRCOC) Files. US National 
Library of Medicine; Available from: https://ii.nlm.nih.gov/MRCOC.shtml 
243.  Medicine USNL of, editor. MEDLINE Baseline Repository Raw Data Files [Internet]. 
2017. Available from: https://mbr.nlm.nih.gov/Download/RawData/2017/ 
244.  UMLS API Technical Documentation. Available from: 
https://documentation.uts.nlm.nih.gov/rest/home.html 
245.  Enrichr Help Center: API Documentation [Internet]. Available from: 
http://amp.pharm.mssm.edu/Enrichr/help#api 
246.  ToxCast and Tox21 Summary Files. 2018; Available from: 
https://figshare.com/articles/ToxCast_and_Tox21_Summary_Files/6062479 
247.  Enrichr Libraries [Internet]. Available from: 
http://amp.pharm.mssm.edu/Enrichr/#stats 
248.  Estrogen-dependent gene expression [Internet]. Reactome Pathway Knowledgebase; 
Available from: https://reactome.org/content/detail/R-HSA-9018519 
249.  ESR mediated signaling [Internet]. Reactome Pathway Knowledgebase; Available 
from: https://reactome.org/content/detail/R-HSA-8939211 
250.  Shu XS, Li L, Tao Q. Chromatin regulators with tumor suppressor properties and their 
alterations in human cancers. Epigenomics [Internet]. 2012;4(5):537–49. Available 
from: https://www.ncbi.nlm.nih.gov/pubmed/23130835 
251.  Kumar R, Li DQ, Muller S, Knapp S. Epigenomic regulation of oncogenesis by 
chromatin remodeling. Oncogene [Internet]. 2016;35(34):4423–36. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26804164 
252.  Martincic-Ipsic S, Mocibob E, Perc M. Link prediction on Twitter. PLoS One [Internet]. 




253.  Goh WP, Luke K-K, Cheong SA. Functional shortcuts in language co-occurrence 
networks. PLoS One [Internet]. Public Library of Science; 2018;13(9):e0203025. 
Available from: https://doi.org/10.1371/journal.pone.0203025 
254.  Kastrin A, Rindflesch TC, Hristovski D. Link Prediction on a Network of Co-occurring 
MeSH Terms: Towards Literature-based Discovery. Methods Inf Med [Internet]. 
2016;55(4):340–6. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27435341 
255.  Fridsma DB, Evans J, Hastak S, Mead CN. The BRIDG project: a technical report. J 
Am Med Inf Assoc [Internet]. 2008;15(2):130–7. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/18096907 
256.  Pareja-Tobes P, Tobes R, Manrique M, Pareja E, Pareja-Tobes E. Bio4j: a high-
performance cloud-enabled graph-based data platform. bioRxiv [Internet]. 2015; 
Available from: http://biorxiv.org/content/early/2015/03/20/016758.abstract 
257.  Messina A, Pribadi H, Stichbury J, Bucci M, Klarman S, Urso A. BioGrakn: A 
Knowledge Graph-Based Semantic Database for Biomedical Sciences. In: Barolli L, 
Terzo O, editors. Complex, Intelligent, and Software Intensive Systems. Cham: 
Springer International Publishing; 2018. p. 299–309.  
258.  Bateman AR, El-Hachem N, Beck AH, Aerts HJWL, Haibe-Kains B. Importance of 
collection in gene set enrichment analysis of drug response in cancer cell lines. Sci 
Rep [Internet]. The Author(s); 2014;4:4092. Available from: 
https://doi.org/10.1038/srep04092 
259.  Formation of NR-MED1 Coactivator Complex [Internet]. Reactome Pathway 
Knowledgebase; Available from: https://reactome.org/content/detail/R-HSA-376419 
260.  Angrish MM, Allard P, McCullough SD, Druwe IL, Helbling Chadwick L, Hines E, et al. 
Epigenetic Applications in Adverse Outcome Pathways and Environmental Risk 
Evaluation. Env Heal Perspect [Internet]. 2018;126(4):45001. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/29669403 
261.  Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA. Adverse Outcome 
Pathways-Organizing Toxicological Information to Improve Decision Making. J 
Pharmacol Exp Ther [Internet]. 2016;356(1):170–81. Available from: 
https://www.ncbi.nlm.nih.gov/pubmed/26537250 
262.  Study Data Standards - Study Data for Submission to CDER and CBER. [cited 2019 
Feb 2]; Available from: 
https://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/ucm587508.ht
m 
263.  Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. The human disease 
network. Proc Natl Acad Sci [Internet]. National Academy of Sciences; 2007 May 22 
[cited 2019 Feb 3];104(21):8685–90. Available from: 
https://www.pnas.org/content/104/21/8685 
264.  Civelek M, Lusis AJ. Systems genetics approaches to understand complex traits. Nat 
Rev Genet [Internet]. NIH Public Access; 2014 Jan [cited 2019 Feb 3];15(1):34–48. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24296534 
157 
 
265.  Silverman EK, Loscalzo J. Network medicine approaches to the genetics of complex 
diseases. Discov Med [Internet]. NIH Public Access; 2012 Aug [cited 2019 Feb 
3];14(75):143–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22935211 
266.  Emmert-Streib F, Dehmer M, Haibe-Kains B. Gene regulatory networks and their 
applications: understanding biological and medical problems in terms of networks. 
Front cell Dev Biol [Internet]. Frontiers Media SA; 2014 [cited 2019 Feb 3];2:38. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/25364745 
267.  Toxicology ENC for C. ToxCast Database (invitroDB) [Internet]. 2018. Available from: 
https://epa.figshare.com/articles/ToxCast_Database_invitroDB_/6062623 
268.  US EPA O. Chemistry Dashboard Help: Toxicity Values. [cited 2019 Feb 1]; Available 
from: https://www.epa.gov/chemical-research/chemistry-dashboard-help-toxicity-
values 
269.  US EPA O. Chemical and Products Database (CPDat). [cited 2019 Feb 1]; Available 
from: https://www.epa.gov/chemical-research/chemical-and-products-database-
cpdat 
270.  US EPA O. ToxCast Dashboard. [cited 2019 Feb 1]; Available from: 
https://www.epa.gov/chemical-research/toxcast-dashboard 
271.  USEPA. Use of High Throughput Assays and Computational Tools; Endocrine Disruptor 
Screening Program; Notice of Availability and Opportunity for Comment. 2015.  
272.  US EPA OCSPP. Endocrine Disruptor Screening Program (EDSP) in the 21st Century. 
[cited 2019 Feb 1]; Available from: https://www.epa.gov/endocrine-
disruption/endocrine-disruptor-screening-program-edsp-21st-century 
 
